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SUMMARY
This study has investigated the interactions of a number of methyl- 
enedioxyphenyl compounds with hepatic cytochrome P-450.
The administration of isosafrole to rats resuited in the formation of 
an in vivo isosafrole metabolite-cytochrome P-450 complex which caused 
inhibition of the hepatic monooxygenase activities. In the oxidized state 
this in vivo metabolite complex readily dissociated in vitro following the 
addition of certain lipophilic Type I binding compounds, many of which were 
substrates for the monooxygenase. The time-dependent dissociation of the 
in vivo metabolite complex resulted in an apparent increase in the cyto­
chrome P-450-mediated monooxygenase activities. The enzyme activities 
which increased following displacement of the complex were those generally 
associated with induction by 3-methylcholanthrene.
Induction by isosafrole resulted in an increase in the monooxygenase 
activities of hepatic microsomes from both C57BL/10 and DBA/2 mice, 
strains which are respectively "responsive" and "non-responsive" to induction 
by polycyclic aromatic hydrocarbons. The monooxygenase activities which 
showed the largest increases in activity following dissociation of the 
isosafrole metabolite-cytochrome P-450 complex were those which were 
generally increased by 3-methylcholanthrene induction. The induction 
profile of the hepatic microsomes from both C57BL/10 and DBA/2 mice 
was compared by sodium dodecyl sulphate polyacrylamide gel electro­
phoresis. Isosafrole induced a pattern of proteins similar to those induced 
by both phenobarbitone and 3-methylcholanthrene.
Spectral investigations in isolated hepatocytes demonstrated Type I 
and Type II binding spectra but not Type RI spectra. The addition of 
methylenedioxyphenyl compounds to a suspension of isolated hepatocytes in
vitro resulted in the formation of absorption maxima at 427 nm and 460 nm 
although the 460 nm peak was small. However, the rate of formation of the 
427 nm and 455 nm absorption maxima during oxidative metabolism of 
isosafrole in hepatic microsomes was shown to be pH-dependent, with 
formation of the 427 nm maximum favoured at low pH whilst a higher pH 
favoured formation of the 455 nm maximum.
Isosafrole-related material was also found to be apparently irrever­
sibly bound to the cellular components of isolated rat hepatocytes incubated 
14with [w - C] isosafrole in vitro. This binding was increased by prior 
induction of the hepatic monooxygenase with phenobarbitone, 3-methyl­
cholanthrene and isosafrole.
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1.1. CYTOCHROME P-450 AND DRUG METABOLISM
1.1.1. Historical
in vitro metabolism of xenobiotics is commonly investigated 
using a fraction of the liver termed the "microsomes" or the "microsomal 
fraction". The microsomes are a heterogeneous mixture of membrane 
fragments from the endoplasmic reticulum, Golgi bodies, plasma-membrane 
and disrupted mitochondria and are usually obtained as the pellet produced 
by high speed centrifugation (100,000 x g for 1 hr) of the post mitochondrial 
supernatant (Siekevitz, 1965).
The hepatic microsomal fraction was observed by Axelrod (1954) to
mediate the demethylation of sympathomimetic amines and the oxidative
deamination of amphetamine. In a further study, the microsomes were
found to be the most active cell fraction at mediating the hydroxylation of
L-amphetamine (Axelrod, 1955). The first introduction of an absolute
requirement for molecular oxygen was provided by Mason et al. (1955) who
18demonstrated the direct incorporation of heavy oxygen ( O  ^ from the 
gaseous phase into 3,4-dimethylphenol during enzyme-mediated metab­
olism. An absolute requirement for NADPH in microsomal drug oxidation 
was also demonstrated by several authors including Giliette et al. (1957).
The presence of a pigment in the microsomal fraction, to which 
carbon monoxide readily binds, was discovered independently by Klingenberg 
(1958) and Garfinkel (1958). The pigment was subsequently characterized 
as a haem-containing protein of the b-type which, in the reduced state, 
binds carbon monoxide to give a complex with an absorption maximum in the 
Soret region at 450 nm (Omura and Sato, 1962; 1964a; b). These authors 
termed this pigment "cytochrome P-450" after the absorption maximum of 
the carbon monoxide complex. The cytochrome P-450-dependent micro­
somal enzymes have been termed mixed function oxidases (Mason, 1957), but 
Hayaishi (1962) suggested the term monooxygenases since the action of the 
enzyme is to insert a single oxygen atom into the substrate molecule.
The involvement of cytochrome P-450 in the metabolism of foreign 
compounds was generally accepted by the early 1960’s but its involvement in 
the metabolism of endogenous compounds was established by Estabrook et 
al. (1963). These authors demonstrated that light of 450 nm wavelength 
was optimal for the reversal of the carbon monoxide-inhibition of steroid 
C-21 hydroxylation. The versatility of the monooxygenases is now widely 
accepted since they catalyze many diverse reactions including aliphatic, 
aromatic and N-hydroxylation, N-,S- and O- dealkylation, dehalogenation, 
and desulphuration of a variety of substrates including steriods, fatty acids, 
drugs, insecticides and carcinogens.
1.1.2. Occurrence
Cytochrome P-450 occurs widely throughout nature and has been 
found in many diverse organisms including mammals, birds, fish, amphibians, 
insects, yeasts, bacteria and plants. In mammals cytochrome P-450 has 
been found distributed throughout the tissues including liver, kidney, heart, 
lung, testis, skin, brain, pituitary, pancreas, adrenal gland, intestinal 
mucosa, spleen, aorta wall, lymphocytes, platelets and in both the placenta 
and ovarian corpus luteum. In most tissues the cytochrome P-450 is 
localized in the endoplasmic reticulum but is also found in the mitochondria 
of steroidiogenic tissues such as the adrenal glands (Harding et al., 1964; 
Harding and Nelson, 1966) and copora lutea (Yohro and Horie, 1967). In 
adrenal cortical mitochondria, the cytochrome P-450 is localized in the 
inner membrane (Satre et al., 1969) and is thought to be different from the 
adrenal microsomal cytochrome P-450 (Sweat et al., 1970). The distrib­
ution of cytochrome P-450 has been reviewed by Wickramasinghe (1975).
1.1.3. The nature of the monooxygenase
Thfe hepatic monooxygenase system has been resolved into three 
components (Lu and Coon, 1968) which have been identified as cytochrome 
P-450, NADPH-cytochrome c reductase (NADPH-cytcchrome P-450 reduc­
tase) and phosphatidylcholine (Lu et_al., 1969a; Strobel et al., 1970). When 
reconstituted this monooxygenase catalyzes the biotransformation of fatty 
acids, cholesterol, steriods, drugs and other foreign compounds (Lu and Coon, 
1968; Lu et al., 1969b; 1970; 1972). Although enzyme activity is apparent 
in the presence of cytochrome P-450 and the reductase, all three components 
appear to be necessary for maximal enzyme activity; the phospholipid seems 
to be essential for efficient electron transport although it is not itself an 
electron carrier (Strobel et al., 1970). The NADPH-cytochrome c reductase 
is responsible for the transfer of electrons from NADPH to the cytochrome 
P-450 which is the site of substrate- and oxygen-binding and the component 
which determines the substrate specificity.
Cytochrome P-450 contains an iron-protoporhyrin IX prosthetic 
group and is generally considered to be a b-type cytochrome/ although^since 
it reacts with a substrate and an electron donor and acceptor, it more 
closely resembles catalase and tryptophan 2,3-dioxygenase neither of which 
is considered to be a cytochrome. The characteristic property of 
cytochrome P-450 is the intense absorption maximum at 450 nm observed 
when carbon monoxide (CO) reacts with the reduced haemoprotein. Treat­
ment of the cytochrome with reagents which alter either its lipid environ­
ment (e.g. detergents or lipase) or its protein structure (e.g. proteases) bring 
about a transition to a metabolically inactive form of the cytochrome, 
cytochrome P-420, which has a typical ferrous haemoprotein spectrum with 
a Soret band at 420 nm or complete loss of reduced binding spectrum with 
CO (Omura and Sato, 1964a; Imai and Sato, 1967; Mason et al., 1965). The
protein and lipid environments of the cytochrome are therefore essential for 
the maintenance of the characteristic spectral and metabolic properties.
The active centre of cytochrome P-450 is the iron atom of the 
protohaem IX prosthetic group which has four planar ligand-interactions 
with the basic nitrogen atoms of the tetrapyrrole ring system, and two axial 
ligand-interactions with suitably reactive groups of the protein enviroment. 
Changes in these axial ligand-interactions have been studied using a 
combination of optical spectroscopy and electron spin (paramagnetic) reson­
ance, ES(P)R, which is able to detect unpaired electrons. These investi­
gations have shown cytochrome P-450 to exist in two spin states, low spin 
complexes with 1 unpaired electron and high spin complexes with 5 unpaired 
electrons, (Jefcoate and Gaylor, 1969; Hill et al., 1970) and that normal 
oxidized cytochrome P-450 exists in the low spin state (Tsai et al., 1970). 
The available evidence suggests that the iron atom in cytochrome P-450 
exists in a heterogeneous ligand field (Peisach et al., 1973) and that one of 
the axial ligands is the mercaptide group of a cysteine residue (Hill et al., 
1970; Stern et al., 1973; Peisach et al., 1973; Collman et al., 1975; Tang et 
al., 1976). In a model system Stern and Peisach (1974) demonstrated the 
formation of an absorption maximum at 450 nm following the addition of 
carbon monoxide and concluded that a thiolate anion is required to produce 
this characteristic absorption maximum in cytochrome P-450. The nature 
of the non-mercaptide, 6th ligand, is still undecided but several ligands have 
been proposed including the imidazole nitrogen of a histidine residue 
(Jefcoate and Gaylor, 1969; Tang et al., 1976; Chevion et al., 1977), an 
hydroxyl group (Nebert et al., 1976; Kumaki and Nebert, 1978) and water 
(Peterson and Griffin, 1973; Griffin and Peterson, 1975).
Changes in the spin state of oxidized cytochrome P-450 on the 
addition of substrate have been correlated with changes in the UV/visible
spectral characteristics. In general, the Soret band of high spin haemo- 
proteins is at 390 nm and that of low spin haemoproteins a t 420 nm. The 
addition of a substrate which produces a Type I binding spectrum (increase 
in absorbance at 390 nm and decrease at 420 nm) correlates with the 
conversion of cytochrome P-450 from the low spin to the high spin form 
(Waterman et al., 1973) and this is thought to represent a conformational 
change in the haemoprotein which results in an alteration to the distance 
between the iron and the non-mercaptide ligand (Jefcoate and Gaylor, 1969; 
Hill et al., 1970; Tsai et al., 1970). However, the Type II binding spectrum 
(decrease in absorbance at =400 nm and an increase at -430 nm) is thought 
to result from the formation of a ligand-interaction between the substrate 
and the iron with displacement of the weaker non-mercaptide ligand to 
produce a complex with enhanced low spin character. Displacement of the 
6th ligand is also thought to occur on addition of carbon monoxide to reduce 
cytochrome P-450 with the formation of a carbon monoxide-haem ligand- 
interaction and the resultant low spin complex (Peisach et al., 1973; Chevion 
et al., 1977). Similarly, Peisach et al. (1973) and Peisach and Mannering 
(1975) have attributed the double absorption maxima at 430 nm and 445 nm, 
observed on addition of ethylisocyanide to reduce cytochrome P-450 (Imai 
and Sato, 1966), to the displacement of both axial ligands with the 430 nm 
maximum resulting from displacement of the mercaptide ligand and the 
455 nm maximum from displacement of the non-mercaptide ligand. Dahl 
and Hodgson (1978) suggested that the 430 nm maximum produced by ethyl­
isocyanide is due to displacement of the mercaptide ligand because of a 
combination of a co-ordinate bond to the haem iron and torsional strain in 
the protein resulting from a strong lipophilic interaction of the ethyl group. 
The 455 nm maximum they suggest is a result of a co-ordinate bond but with 
only a weak, non-disruptive lipophilic interaction.
Investigation of the haemoproteins induced by pnenobarbitone and 
3-rnethyichoIanthrene using a combination of EPR and UV/visible spectroscopy 
demonstrated that the phenobarbitone-induced cytochrome P-450 like the 
control cytochrome P-450 appeared to be in the low spin state whilst the 
3-methylcholanthrene-induced cytochrome P-448 appeared to be in the high 
spin state (Peisach et ah , 1973; Estabrook et ah, 1972a). This has been 
attributed by some authors to the presence of 3-methylcholanthrene which 
became bound in vivo and, because of its high lipophiiicity, remained in the 
hydrophobic portion of the haemoprotein during preparation of the micro­
somal fraction since purified cytochrome P-448 tends to lose this high spin 
characteristic during the purification process (Stern et al., 1973).
1.1.4 The spectral interactions of substrates with cytochrome P-450
Addition of various endogenous or foreign compounds to microsomal 
suspensions produces characteristic spectral changes which may be 
measured by difference spectroscopy. Difference spectra are obtained by 
optically substracting the absorbance of the contents of the reference 
cuvette from the absorbance of the contents of the sample cuvette.
Narasimhuiu et al. (1965) first demonstrated a spectral change 
when 17-hydroxyprogesterone bound to adrenal cortex microsomes and 
similar changes were subsequently demonstrated following the addition of 
various compounds to hepatic microsomal suspensions (Imai and Sato, 1966; 
Remmer et al., 1966; Schenkman et al., 1967b). Compounds have been 
classified by the three types of spectral change they produced in microsomal 
suspsensions and the type is defined by the wavelengths of the maxima and 
minima. Type I compounds produce a spectral change with a maximum at 
380-395 nm and a minimum at 415-425 nm; Type II compounds give a 
maximum at 425-435 nm and a minimum at 395-405 nm. The Reverse Type I 
(Type RI) compounds give a maximum at 425-435 nm and a minimum at
380-395 nm, which is essentially a mirror image of a Type I spectrum. The 
similarity in the wavelengths of the Type II and Type RI maxima and minima 
has often led to confusion of the two types of binding and resulted in the 
Type RI erroneously being classified as Type II (Anders, 1971).
Schenkman et al. (1967b) suggested that the added substrate 
interacts with the oxidized form of the cytochrome P-450 to produce the 
observed spectral changes. These authors also suggested that an apparent 
binding affinity could be calculated for a given compound by using a double 
reciprocal plot (Lineweaver and Burk, 1934) of the magnitude of the spectral 
change (ordinate) versus the substance concentration (abscissa). The inter­
cept on the ’X1 axis they termed "Ksfl, the spectral dissociation constant.
The Ks is defined as the concentration of compound which produces 
half of the maximal spectral change and is therefore analogous to the Km 
for enzyme-substrate complexes. By definition, the Kg value is independent 
of the protein concentration of the microsomal suspension, although the 
maximal spectral change ( AA max) is dependent on both the concentrations 
of substrate and cytochrome P-450 (Estabrook et al., 1972b).
The Type I spectral change is produced by a wide variety of 
endogenous and exogenous compounds such as the barbiturates, fatty acids, 
polycyclic hydrocarbons and steroids. The only common factor for all of 
these compounds is their high lipid and low water solubilities. A direct 
correlation between Kg values and lipid solubility has been demonstrated by 
Kitagawa et al. (1972) and Al-Gailany (1975). Schenkman and Sato (1968) 
have suggested that the Type I compounds interact with an hydrophobic 
moiety of the apoprotein and not directly with the haem of the cytochrome 
P-450.
The Type II binding spectra are produced by compounds which are 
nucleophilic in nature, such as primary amines (Schenkman et al., 1967b;
Jefcoate and Gaylor, 1969; Schenkman, 1970). Other compounds which 
also produce Type II spectra are pyridine and imidazole, both contain a 
nitrogen atom with a lone pair of electrons (Temple, 1971). This type of 
spectral change has been shown to be due to ferrihaemochrome formation by 
direct interaction of a basic nitrogenous ligand with the haem of cyto­
chrome P-450. The Type II binding compounds compete with carbon 
monoxide for the reduced cytochrome P-450 (Schenkman et al., 1973) and 
therefore probably compete with oxygen. Very few compounds which 
produce only a Type II spectrum are metabolized by the cytochrome P-450- 
dependent monooxygenase system. One well-known substrate of the 
cytochrome P-450-mediated metabolism is aniline, a Type II compound 
which has also been shown to possess a Type I component (Schenkman, 1970) 
and it is the Type I binding which is presumably related to the metabolism.
The Reverse Type I (Type RI) spectral change has often been 
confused with the Type II interaction (Whysner et al., 1969) but Type RI 
compounds do not displace carbon monoxide from reduced cytochrome P-450 
(Schenkman et al., 1973; Dickins et al., 1975). Schenkman et al. (1972; 
1973) suggested that the Type RI spectral change is due to displacement of 
endogenous Type I substrates from the microsomes but further investi­
gations by Vore et al. (1974) using solvent extracted microsomes and Al- 
Gailany (1975) using fluorescent probes indicated that Type RI compounds 
bind to a specific site and do not produce the spectral change by simple 
displacement of endogenous compounds. Compounds which produce Type RI 
spectral changes are diverse and include phenacetin, acetanilide, short chain 
monohydric alcohols and several allyl-substituted barbiturates. Many of 
these compounds are substrates of the microsomal monooxygenase system.
1.1.5 Mechansim of monooxygenation •
Estabrook et al (1972a) proposed a scheme for the mechanism of 
cytochrome P-450-mediated monooxygenation which is considered to be a 
cyclic reaction (Fig. 1.1).
Initially, a substrate (RH) binds to the apoprotein moiety of the low-
3 +
spin form of the ferric (Fe ) haemoprotein to form a high-spin ferric-
3 +
substrate complex (Fe -RH). This may be observed as a Type I binding
spectrum and an increase in the high-spin EPR signal. The ferric haemo-
protein-substrate complex then undergoes a one electron reduction by
accepting an electron from NADPH via the flavoprotein enzyme NADPH-
2+cytochrome P-450-reductase, which converts the haem iron to the Fe 
2 +
state. This Fe complex reacts with molecular oxygen to produce an
2+
oxygenated-haemoprotein-subststrate ternary complex (02“^e “RH). This
oxycytochrome P-450 complex has a spectral absorption maximum at about 
440 nm (Estabrook et al, 1971; Illing et al, 1974; Werringloer and Estabrook, 
1975; Guengerich et al., 1976).
The oxycytochrome P-450 complex undergoes a further one electron 
reduction and although the origin of the second electron is not known, 
several studies have suggested that this may be mediated via NADH- 
cytochrome b^ reductase and cytochrome b^. This may explain the 
synergistic effect of NADH on microsomal monooxygenation although Lu et 
al. (1974) suggested that this is dependent on both the substrate and the 
cytochrome P-450 species studied. The role of cytochrome b^ has been 
recently reviewed by Schenkman et al. (1976). The ternary complex then 
undergoes an intra-molecular re-arrangement and one atom of oxygen is 
inserted into the substrate together with the elimination of water. Finally, 
the haemprotein-product complex dissociates to give product and free 
enzyme, allowing the cycle to be repeated.
FIGURE 1.1
A generalised scheme for cytochrome P-450-mediated monooxygenation
(from Estabrook et al, 1972)
ROH
Fe3--ROH
Fe3- ■ ■ RH
Fe 3 +
Fe3--R H
( Cyt. P-450 reductase)
Fe
Fe2" - RH 
I
(Cyt. bK?)O Fe2--  RH I
i. 1.6 Multiplicity and induction of cytochrome P-450
An increase in the hepatic monooxygenase activities and cyto­
chrome P-450 content has been demonstrated following in vivo exposure of 
animals to many chemicals including barbiturates, ethanol, polycyclic arom­
atic hydrocarbons, pesticides and steroids (Conney, 1967; Remmer, 1972). 
These compounds have a wide range of chemical structures but the majority 
are lipid soluble and are substrates for cytochrome P-450 mediated metabol­
ism. The compounds which cause this in vivo increase in monooxygenase 
activities have been termed inducers and are broadly classfied into two main 
classes, typified by the barbiturates (e.g. phenobarbitone) or the polycyclic 
aromatic hydrocarbons (e.g. 3-methylcholanthrene). However, there is 
increasing evidence to suggest that other inducing agents may increase the 
levels of different forms of cytochrome P-450.
Evidence for the existence of more than one form of cytochrome 
P-450 was produced by Alvares et al. (1967), who observed differences in the 
A max of the reduced-carbon monoxide absorbance spectrum after pre­
treatment with 3-methylcholanthrene or phenobarbitone. The cytochromes 
induced by phenobarbitone and 3-methylchoianthrene have been termed 
cytochrome P-450 and cytochrome P-448 (also, P^-450 or P-446) respec­
tively since the absorption maxima for the reduced-carbon monoxide spectra 
occur at 450 nm and 448 nm. Further evidence is provided by major 
differences in the catalytic properties of these two induced haemoproteins 
since phenobarbitone increases the metabolism of a wide range of substrates 
but 3-methylcholanthrene is more specific in its action (Conney, 1967). 
Several model substrates of microsomal monooxygenation are metabolized 
to different products by these two cytochromes, with incorporation of the 
oxygen atoms into different positions on the substrate molecule. Substrates 
metabolized in this way include biphenyl (Creaven and Parke, 1966; Burke
and Bridges, 1975), testosterone (Conney et al., 1969; 1973), benzo(a)pyrene 
(Rasmussen and Wang, 1974), n-hexane (Frommer et al, 1974), chlorobenzene 
(Selander et al., 1975) and warfarin (Pohl et al., 1977).
Multiple forms of cytochrome P-450 have been identified as pref­
erentially induced in rat liver microsomes following administration of 
ethanol, phenobarbitone and 3-methylcholanthrene (Comai and Gaylor, 
1973). Three spectrally distinct forms were investigated by using cyanide 
and n-octylamine as ligands. However, Werringloer and Estabrook (1975) 
have found four pools of cytochrome P-450 in control rat liver on the basis 
of their reactivities with carbon monoxide, ethylisocyanide, metyrapone and 
benzphetamine.
The characteristics of purified cytochrome P-450 in reconstituted 
systems, the use of sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis to calculate the molecular weight of the cytochrome P-450 
sub-units after induction and immunological techniques have all recently 
produced further evidence for the multiplicity of the monooxygenase. The 
cytochromes induced by phenobarbitone and 3-methylcholanthrene differ in 
their molecular weight in several species including rat (Alvares and 
Siekevitz, 1973; Welton and Aust, 1974; Ryan et al., 1975), mouse (Haugen 
et al., 1976) and rabbit (Haugen et al., 1975; Haugen and Coon, 1976). The 
calculated molecular weights of the sub-units vary slightly according to the 
conditions used for the gel electrophoresis, but the induced haemoproteins 
are in the 45,000-60,000 molecular weight range and the molecular weight 
of the 3-methylcholanthrene-induced haemoprotein is greater than that 
induced by phenobarbitone. When purified, the induced haemoproteins have 
been shown to have different substrate specificities and they may be used to 
raise antibodies against themselves so that metabolism can be selectively 
inhibited using these immunological techniques. The properties of recon­
stituted mammalian mixed-function oxidases, including multiplicity, have 
been recently reviewed (Lu and West, 1978).
Thomas et al. (1976a) demonstrated that antibodies produced 
against the purified haemoproteins react well v/ith their homologous anti­
gens but cross-react poorly with their heterologous antigens. In further 
studies, at least four immunologically distinct forms were demonstrated in 
purified cytochrome P-450 from phenobarbitone-treated rats and at least 
two distinct forms in purified cytochrome P-448 from 3-methylcholan- 
threne-treated rats (Thomas et al., 1976b). Huang et al. (1976) separated 
and purified four distinct cytochrome P-450 fractions from the liver 
microsomes of phenobarbitone-treated hybrid mice (B6D2F^/3) and these 
differed in their CO-difference spectra, ethylisocyanide difference spectra, 
sub-unit molecular weight and catalytic properties. Although they may 
have identical reduced-carbon monoxide absorption maxima, the cytochrome 
P-450's induced by phenobarbitone and 3-methylcholanthrene in different 
species may have different gel-electrophoretic and immunological propert­
ies. The aryl hydrocarbon hydroxylase activity of cytochrome P-448 
purified from 3-methylcholanthrene-treated rats is up to twenty-fold higher 
than a similar preparation from 3-methylcholanthrene-treated rabbits 
(Kawalek et al., 1975) and the two enzymes are immunologically distinct 
(Thomas et al., 1976a).
It is therefore evident that cytochrome P-450 should no longer be 
considered a single unspecific enzyme, but rather a mixture of several 
distinct enzymes, each with its own substrate specificities which overlap in 
part with the specificities of several other closely related enzymes. These 
enzymes may be preferentially induced by various compounds either individ­
ually or collectively with the resultant change in overall enzyme activities 
and specificities.
The molecular biology of the induction of monooxygenase activity 
has been recently reviewed by Bresnick (1978), but the mechanism(s) of 
induction is not yet fully understood and may be the result of several 
changes in cellular metabolism. Induction by foreign compounds appears to 
be dependent on de novo protein synthesis since the concomitant admini­
stration of several protein synthesis inhibitors prevents the increase in 
monooxygenase activity. Although the inhibitors cycloheximide, actino- 
mvcin D and a-amanitin all differ in their effects on cellular metabolism 
since they inhibit the peptidyl transferase reaction in protein synthesis, 
DNA-dependent RNA synthesis and RNA polymerase II which is responsible 
for formulation of most non-ribosomal RNA, respectively, they all prevent 
induction of monooxygenase activity (von der Decken and Hultin, I960; 
Gelboin and Blackburn, 1963; Conney and Gilman, 1963; Cutroneo and 
Bresnick, 1973; Jacob et al., 1974).
One of the initial effects of an inducer appears to be the de novo 
synthesis of RNA since a-amanitin given up to 8 hr after phenobarbitone 
prevents induction but after this time RNA synthesis is no longer required 
and induction is not prevented (Jacob et al., 1974). This may be due to an 
increase in RNA polymerase activity, chromatin template activity or 
nuclear RNA template activity (Gelboin, 1964; Gelboin and Sokoloff, 1964; 
Bresnick, 1966). It has also been suggested that stabilization and decreased 
degradation of proteins and RNA may contribute to the induction process 
(Shuster and Jick, 1966a; b; Seifert and Vacha, 1970; Louis-Ferdinand and 
Fuller, 1972; Pousada and Lechner, 1972). Although inducers have been 
shown to initiate many changes in cellular metabolism, the primary event 
has yet to be identified. It has been suggested that inducers, like 
hormones, may only exert their biological effects after binding to a receptor 
protein. This may be the mode of action for one of the most potent toxins
and teratogens known, 2,3,7,8-tetrachlorodibenzo-£-dioxin (TCDD), which is 
also a potent inducer of the monooxygenases (Poland and Kende, 1976).
1.1.7 Inhibition of cytochrome-P-450-mediated monooxygenation
Cytochrome P-450-mediated monooxygenation is a complex series 
of reactions, interference with any of these representing possible mechan­
isms of inhibition. The possible sites of inhibition are summarized in Fig.
1.2 (Netter, 1973).
The classical inhibitor of the cytochrome P-450 is carbon monoxide 
(CO) which binds to the reduced haemoprotein in a reversible interaction. 
The ligand interaction of carbon monoxide to the iron of the haem prevents 
the binding of oxygen and thereby inhibits the monooxygenation reaction. 
However, the reduced-CO-haemoprotein complex is photodissociable, with 
the optimal wavelength for the reversal of inhibition being at about 450 nm 
(Diehl et al., 1969; Cooper et al., 1977).
Metyrapone [2-methy-l,2-bis(pyrid-3-yl)propan-l-one] is a potent 
inhibitor of monooxygenation and binds to the oxidized form of cytochrome 
P-450 to give a Type II spectrum, hence the inhibition is probably caused by 
the prevention of oxygen binding. In the reduced state the metyrapone- 
cytochrome P-450-complex exhibits a single absorption maximum at 446 nm 
(Hildebrandt et al., 1969). Inhibition by metyrapone is essentially non­
competitive (Hildebrandt, 1971) but recent evidence suggests a small 
proportion may be oxidatively metabolized by the cytochrome P-450 system 
and may explain the observations of competitive inhibition (Kahl et al., 
1969).
Another widely used inhibitor of monooxygenation is SKF-525A ($- 
diethylaminoethyl-diphenyl-propyl acetate). This compound exhibits a 
Type I binding spectrum and is metabolized by the monooxygenase system 
therefore competing with other cytochrome P-450 substrates for the active
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site. However, the inhibition by SKF-525A is more complex since 
competitive, non-competitive and mixed inhibition kinetics have been 
observed (Anders and Mannering, 1966; Ikeda et al., 1968). Investigation of 
the metabolism of SKF-525A has demonstrated the formation of an absor­
bance peak at 455 nm in vitro and the presence of a similar absorbance peak 
of 452 nm after in vitro administration of the compound (Buening and 
Franklin, 1976). This has been attributed to the formation of an inactive 
complex between reduced cytochrome P-450 and a metabolite or metabolic 
intermediate of SKF-525A and may explain the observed non-competitive 
inhibtion kinetics.
The activity of the monooxygenase is also inhibited by a variety of 
sulphydryl reagents including mersalyl (Franklin and Estabrook, 1971), 
£-chloromercuribenzoate (Orrenius, 1965; Kampffmeyer and Kiese, 1963; 
1964; Illing and Netter, 1975) and N-ethylmaleimide (Kampffmeyer and 
Kiese, 1963; 1964; Illing and Netter, 1975). These compounds probably 
have several sites of action during the reaction cycle of cytochrome P-450- 
dependent monooxygenation. Illing and Netter (1975) have suggested that 
£-chloromercuribenzoate may inhibit NADPH-cytochrome P-450 reductase 
and the formation of the ternary complex although it also converts 
cytochrome P-450 to the inactive cytochrome P-420 and this may be a 
major inhibitory factor (Mason et al., 1965).
The methylenedioxyphenyl compounds are another class of cyto­
chrome P-450 inhibitors which are used commercially as insecticide synerg­
ists. The mode(s) of action of these compounds will be the subject of later 
discussion.
1.2. METHYLENEDIOXYPHENYL (1,3-BENZODIOXOLE) COMPOUNDS
AND THEIR BIOLOGICAL EFFECTS
1.2.1. Occurrence
Methylenedioxyphenyl (MDP) compounds are found widely distrib­
uted throughout nature, frequently occurring in foodstuffs since they 
represent one group of secondary metabolites in plants. The MDP 
compounds are usually present in relatively low concentrations although 
safrole, l-allyl-3,4-methylenedioxybenzene, constitutes about S0-90% of 
sassafras oil derived from the root bark of Sassafras albidium. Several 
MDP compounds including safrole, are components of essential oils such as 
star-anise oil, camphor oil, sesame seed oil, nutmeg, mace, cinnamon leaf 
oil, ginger, black pepper, parsley, mint, parsnip and carrots, (Bejnarowicz 
and Kirch, 1963; Lichtenstein and Casida, 1963; Weil, 1965; Fishbein and 
Falk, 1969; Furia and Bellanca, 1971). MDP compounds have also been 
detected in cigarette smoke (Schmeltz et al., 1966). The structures of 
some naturally occurring MDP compounds are shown in Fig. 1.3. and those 
of some related natural products in Fig. 1.4. In 1942 sesame oil, which 
contains sesamin and sesamolin, was shown to synergize the action of the 
insecticide pyrethrum (Eagleson, 1942). This prompted research into both 
natural and synthetic MDP compounds and led to their widespread use as 
commercial insecticide synergists. Several of the more common synthetic 
MPD compounds, all derivatives of the natural product safrole, are shown in 
Fig. 1.5., the most important of these is piperonyl butoxide.
Since the MDP compounds are so widespread in the environment as 
both natural and synthetic products, there is a large potential for human 
exposure.
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1.2.2 Uses of methylenedioxyphenyl compounds
The major use of safrole, isosafrcle and dihydrosafrole is in the 
manufacture of synthetic MDP compounds which are used to synergize a 
variety of pesticides including the pvrethroids, organophosphates, rotenoids, 
carbamates and chlorinated hydrocarbons.
The presence of MDP compounds and chemically related compounds 
in many of the spices and essential oils (e.g. oils or cloves and anise) has 
resulted in their widespread use as flavouring agents in foods and soft 
drinks. Eugenol, acetyl eugenol, methyl eugenol, anethole, estragole and 
myristicin are all commonly used as flavourings in the USA but the use of 
safrole was banned by the Food and Drug Administration in 1960 following 
evidence that safrole is an hepatocarcinogen when fed to laboratory 
animals. However, safrole still represents a toxic hazard since it is present 
in Sassafras tea, a preparation still available in some parts of the USA.
The spices are not only used as flavouring-agents, but also as folk 
remedies for a wide range of complaints. Nutmeg has been used to treat 
digestive disorders, rheumatism, cholera and boils, it has also been used, 
generally unsuccessfully, as an emmenagogue and abortifactant. Nutmeg 
and mace have also been used in love potions and as aphrodisiacs.
1.2.3 Pharmacological effects of the methylenedioxyphenyl compounds
Several MDP compounds including safrole, isosafrole and myristicin
have a bronchomucotropic action when administered by inhalation (Boyd and 
Sheppard, 1970; 1971).
Oral administration of nutmeg, a common spice from the tree 
Myristica fragrans, produces drowsiness, delerium, stupor and .even death. It 
has often been used to produce effects similar to those of tetrahydro­
cannabinol and lysergic acid diethylamide including prolonged or recurrent 
hallucinations or stupor and distorted perception of sight and sound. The
properties of the spices nutmeg and mace, which are both products of the
same tree, have been widely investigated because of these psychotropic
effects and have been reviewed by Forrest and Heacock (1972). Nutmeg
essential oil contains about 4% myristicin and 0.6% safrole, however the
myristicin fraction is contaminated by about 30% elemicin (l-allyl-3,4,5-
trimethoxybenzene). The myristicin fraction appears to be responsible for
%
the "cerebral stimulation" effects of nutmeg (Truitt et al., 1961) but 
myristicin alone is not totally responsible for these effects v/hich possibly 
involve a joint action or synergism by several MDP compounds as well as 
other, as yet unidentified, non-MDP psychoactive compounds. Shulgin 
(1966) and Weil (1965) have suggested that addition of ammonia to myris­
ticin and elemicin during metabolism, perhaps by hydroxylation of the side 
chain in the 2'-position followed by transamination, would produce known 
amphetamine-type psychomimetic compounds.
The effects of nutmeg vary between species since man seems to be 
more susceptible to the disorientation effects than are many other species. 
In the cat, doses which produce visible behavioural changes appear initially 
to depress the CNS from which the animals recover, only to die two or three 
days later from a hepatic coma (Dale, 1908-9).
Nutmeg and myristicin both show some monoamine oxidase inhibitor 
properties since they potentiate tryptamine induced convulsions, antagonize 
the effects of reserpine and increase brain serotonin. Safrole, however, is 
inactive in the tryptamine potentiation test (Truitt, 1967).
1.2.4 Metabolism of the methylenedioxyphenyl compounds
Metabolism of the MDP compounds involves three principle routes; 
oxidation of the methylene bridge-carbon to yield formate and ultimately 
carbon dioxide (Kamienski and Casida, 1970) and the corresponding catechol; 
extensive modification of the side chain to yield further MDP derivatives;
and finally oxidation of simpler side chains to yield piperonylic acid and its 
derivatives. Clearly, the products of this oxidative metabolism are 
probably metabolized further by different oxidative pathways or conjugated 
to yield numerous derivatives and a complicated metabolite profile which 
has not been comprehensively identified.
Metabolism of piperonyl butoxide has been extensively studied in 
both insects and mammals. Oxidative cleavage of the methylenedioxy
bridge, to yield CC^j is the predominant pathway in rats and mice, with 65%
14 14and 75% respectively of C-radiolabel from a-methylene- C-piperonyl.
14butoxide appearing as CO2  in the first 48 hr after an oral dose with small 
amounts of 6-propylpiperonylic acid and 6-propylpiperonyl glycine appearing 
in the urine (Kamienski and Casida, 1970). Metabolites of piperonyl 
butoxide have been shown to appear rapidly in the bile of the rat and more 
slowly in the urine (Fishbein et al., 1967), a total of 28 different metabolites 
have so far been identified (Fishbein et al., 1969), many of them retaining 
the methylenedioxy group intact, indicating extensive modification of the 
side chain. After the initial rapid elimination of metabolites there is a 
prolonged slower phase with up to 15% of the dose remaining as unmetabol- 
ized material in the fat and lungs 8 hr after an intravenous injection 
(Fishbein and Falk, 1969; Fishbein et al., 1969). In houseflies, metabolism 
of the methylene carbon to CC^ is much slower than in mice (Casida et al., 
1966), but yields a variety of alcohol-, catechol- and carboxylic acid- 
metabolites which are excreted unchanged or as glycosides (Essac and 
Casida, 1969).
The methylene bridge carbon is extensively metabolized to CC> 2  
when safrole, dihydrosafrole and myristicin are administered orally to mice 
with 61%, 64% and 73% respectiviely, appearing as CO2  in the fist 48 hr. 
Piperonylic acid was also identified as one of several urinary metabolites of
safrole and dihydrosafrole (Casida et al, 1966; Kamienski and Casida, 1970). 
Safrole and isosafroie give rise to more biliary metabolites than dihydro­
safrole, in which the side chain is saturated (Fishbein et al., 1967). Oswald 
et al. (1969; 1971) demonstrated ninhydrin-positive N-containing metabo­
lites in the urine of the rat following oral or intraperitoneal administration 
of myristicin, safrole and isosafroie but not dihydrosafrole, which suggests a 
requirement for an allyl or propenyl double bond for formation of these 
metabolites. These metabolites are thought to be condensation products of 
the I’-keto-derivative with dimethylamine, piperidine or pyrrolidine, 
although, the a, 3-unsaturated ketone, l’-keto-safrole, has not been identi­
fied in rat urine after administration of safrole (Borchert et al., 1973; 
Stillwell et al., 1974). Stillwell et al. (1974) investigated the metabolism of 
safrole in both the rat and guinea-pig by gas phase analysis (GC-MS) of the 
neutral (unconjugated) metabolites and the neutral metabolites liberated by 
enzymic hydrolysis of the acid fraction of urine. They concluded that 
safrole is metabolized by:- demethylenation to form a catechol; hydroxy- 
lation to l'-hydroxysafrole (Borchert et al., 1973) and epoxidation to give 
safrole-2', 3'-epoxide which is further metabolized to the corresponding diol 
l,2-methylenedioxy-4-(2,3-dihydroxypropyl)-benezene. The epoxide was 
sufficiently stable that after intraperitoneal administration it could be 
isolated from the urine. They also concluded that since l’-hydroxysafrole 
and l,2-dihydroxy-4allyl-benzene still contain an allylic double bond, they 
could be further metabolized via the epoxides to the corresponding diols, 
which were identified in the urine. In general, the metabolites containing 
available hydroxyl groups, such as the diols or catechols, were excreted 
mostly as the glucuronc acid conjugates with a smaller proportion in the 
free, unconjugated form. The proposed pathways of safrole metabolism are 
shown in Fig. 1.6. Metabolism via an epoxide has also been demonstrated
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for estragole, a similar compound containing an allyiic double bond, with the 
epoxide excreted free in the bile and the corresponding diol [3-(4-methoxy- 
phenyl)-l,2-proprane diol] and its glucuronic acid conjugates in both urine 
and bile (Solheim and Scheline, 1973). The mammalian pharmacokinetics of 
isosafroie are similar to those of piperonyl butoxide since after a single oral 
dose isosafroie is rapidly taken up by body fat and then eliminated during 
the next 72 hr (Hofer, 1976).
Human volunteers, given low doses of safrole orally, were shown to 
produce similar metabolites to other experimental animals, with demethy- 
lenation to give the catechol (l,2-dihydroxy-4-allylbenzene) as the major 
route but no l'-hydroxy safrole was detected in the urine (Benedetti et al., 
1977).
In insects safrole, dihydrosafrole and myristicin are eliminated 
directly by volatilization (Casida et al., 1968) and also by demethylenation, 
although this is less important than in mammals (Casida et al., 1966). In the 
housefly, the major pathway of safrole and isosafroie metabolism is oxidat­
ion to piperonylic acid followed by conjugation with amino acids, while 
dihydrosafrole may be metabolised, in part, to sesamol (Esaacand Casida, 
1968).
Microbial monooxygenase activity has been reported towards safrole 
and dihydrosafrole in several Pseudomonad strains (Harrison and Ribbons, 
1971) and also towards piperonylic acid, which is metabolized by demethy­
lenation (Buswell and Cain, 1973).
In in vitro studies, using rat liver cell cultures, safrole and isosafroie 
are metabolized extensively by demethylenation, hydroxylation and epoxi- 
dation of the side chain to give the epoxide and the corresponding diols 
(Delaforge et al., 1975; Janiaud et al., 1976). In vitro studies using 
microsomal fractions have not been very extensive. Demethylenation of
the methylenedioxy ring has been shown to produce formate from a number 
of the MDP compounds and the corresponding catechol for 6-nitro-3,4- 
methylenedioxybenezene (Kamienski and Casida, 1970). Although several 
other metabolites have been demonstrated, they have not been rigorously 
identified but appear to be similar to those produced in vivo.
1.2.5 Inhibition of monooxygenase activity and insecticide synergism by
methylenedioxyphenyl compounds
The use of MDP compounds as insecticide synergists followed the 
observation that sesame oil (the seed oil of Sesamum indicum) potentiated 
the toxicity of pyrethum in houseflies (Eagleson, 1942). Sesame oil was 
used commercially and the active component was found to be sesamin and 
the more potent sesamolin. Interestingly, sesamin is a natural component 
of pyrethrum extract and therefore co-exists in nature with the insecticidal 
pyrethrins and cinerins (Doskotch and El-Feraly, 1969).
MPD compounds presently used commercially as insecticide syn­
ergists are piperonyl butoxide, sulphoxide, propylisome and tropital, the 
most widely used being piperonyl butoxide. Sesamex is the most active of 
the group but unfortunately decomposes rapidly to yield coloured products in 
the presence of sunlight and moisture and is therefore not used commer­
cially. Although originally used with the pyrethroid insecticides, the MDP 
compounds are used to potentiate the action of a broad spectrum of 
insecticidal compounds including the carbamates, chlorinated hydrocarbons, 
organophosphates and rotenoids. Synergistic-activity shows a rather 
complex relationship with structure since a long polyether- or oxygen- 
containing side chain is required for good pyrethroid synergism but is not 
critical for carbamate synergism which may perhaps reflect metabolism by 
different cytochrome P-450 pools e.g. cytochrome P-450 or cytochrome 
P-448. The simple MDP compounds myristicin, safrole, isosafroie and 
dihydrosafrole are very effective with carbaryl but not with pyrethrum.
The duration of action of most insecticides is dependent upon the 
rate of their inactivation by oxidative metabolism since the parent com­
pound is usually the active compound. Inhibition of oxidative metabolism is 
therefore a method by which the insecticidal action may be potentiated. 
The action of MDP compounds was first demonstrated in insects (Wintering- 
ham et al., 1955; Sunn and Johnson, 1960) and subsequently mice (Robbins 
et al., 1959 Fine and Malloy, 1964). Synergistic inhibition of mixed- 
function oxidase activity will affect not only the rate of metabolism of the 
insecticide but also of endogenous compounds and other xenobiotics, result­
ing in either an enhanced or reduced toxicity depending upon the activation 
or detoxication of the xenobiotic by the mixed-function oxidase system.
MDP compounds inhibit microsomal hydroxylation of naphthalene 
(Philleo et al., 1965), O-demethylation of j>-nitroanisole and N-demethylation 
of N, N-dimethy-£-nitro-phenyl carbamate in houseflies (Hansen and Hodg­
son, 1971). In mice, MDP compounds prolong hexobarbital sleeping time 
and zoxazolamine paralysis time (Fujii et al., 1968; 1970). Piperonyl
butoxide produces a transient stimulation of biphenyl 2-hydroxylase with 
concomitant inhibition of biphenyl 4-hydroxylase in mice both in vivo (Jaffe 
et al., 1969) and in vitro (Epstein et al., 1970). The MDP compounds have 
been shown to alter the enzyme activities for many substrates both in vivo 
and in vitro and these have been reviewed with regard to synergistic action 
(Casida, 1970) and general biological actions (Hodgson and Philpot, 1974; 
Haley, 1978).
Casida et al. (1966) suggested the MDP compounds to be alternate 
substrates for mixed-function oxidation but investigations of the inhibition 
have produced conflicting results with the type of inhibition reported to be 
''competitive", "non-competitive", "partly competitive", "partly progressive" 
and "curvilinear" (Natsatsugawa and Dahm, 1965; Lewis et al, 1967; Anders,
1968a; Hansen and Hodgson, 1971). It was originally suggested that the 
inhibition kinetics in these studies may have been partly due to artifacts 
introduced into the assay system (Hodgson and Philpot, 1974) since many 
studies used nicotinamide or organic solvents in the assay system, both of 
which have been shown to have inhibitory properties in some enzyme assays 
(Schenkman et al, 1967a; Sesame and Gillette, 1970; Anders, 1968b). The 
inhibitory action has since been interpreted as a dual inhibition, initially 
competitive inhibition as the MDP compounds compete with the substrate for 
metabolism and then a transition to non-competitive inhibition due to the 
formation of a very stable MDP metabolite-enzyme complex (Franklin, 
1972; Philpot and Hodgson, 1972a). In this case, competitive, mixed and 
non-competitive inhibition could be observed depending on the assay condi­
tions with the mixed inhibition observed during the transition phase. The
l
results could also depend on the pretreatment of the animals and the species 
since both factors affect the rate of formation of the inhibitory complex 
(Franklin, 1972).
1.2.6 Interactions of the methylenedioxphenyl compounds with cyto­
chrome P-450
The interaction of MDP compounds with the mixed-function oxidase 
was first observed in houseflies (Perry and Bucknor, 1970; Matthews and 
Casida, 1970) and in mice (Matthews et al., 1970) as a decrease in the levels 
of microsomal cytochrome P-450 after in vivo pretreatment with piperonyl 
butoxide. A similar reduction in cytochrome P-450 has been observed in 
vitro after incubation of piperonyl butoxide with mouse hepatic microsomes 
in the presence of NADPH (Philpot and Hodgson, 1971; Franklin, 1971). 
After the formation of a Type I binding spectrum by addition of the MDP 
compound to oxidized microsomes, subsequent incubation with NADPH 
produced a spectrally observable complex which inhibited the binding of
carbon monoxide to the reduced cytochrome and was not readily displaced 
by the carbon monoxide. This explains the apparent loss of cytochrome 
P-450 since the assay of this cytochrome is dependent upon the binding of 
carbon monoxide (CO) to the reduced haemoprotein. The maximum amount 
of CO-binding inhibition found is about 50% which suggests that there are at 
least two pools of cytochrome P-450, only one of which will interact with 
piperonyl butoxide to form the complex (Philpot and Hodgson, 1971).
The inhibitory complex is observed as a cytochrome P-450 differ­
ence spectrum with double Soret peaks at 427 nm and 455 nm in the reduced 
state, i.e. in the presence of NADPH or sodium dithionite, and as a single 
peak at 438 nm in the oxidized state. The two peaks in the reduced 
spectrum are in pH-dependent state (Philpot and Hodgson, 1971) which 
together with the wavelengths of the absorption maxima themselves show a 
similarity to the interactions of ethylisocyanide (EtNC) with cytochrome 
P-450 (Omura and Sato, 1964a). The inhibtion of CO-binding by piperonyl 
butoxide is, however, non-competitive, in contrast to the competitive 
inhibition by ethylisocyanide.
Addition of safrole or piperonyl butoxide to oxidized microsomes 
produces a Type I binding spectrum which is abolished by addition of a 
reducing agent (such as dithionite), an effect expected for this type of 
spectrum (Schenkman et al., 1967). In the presence of NADPH there is a 
time dependent development of the reduced-complex spectrum with peaks 
at 427 nm and 455 nm which may be converted to the oxidized-complex 
spectrum with the single peak at 438 nm, by enzymic oxidation of the excess 
NADPH. An absolute requirement for NADPH has been demonstrated 
(Franklin, 1971; Elcombe, 1976) although Philpot and Hodgson (1971) 
reported that NADH supported partial formation of the reduced-complex 
under aerobic conditions and almost total formation of the complex under
anaerobic conditions, suggesting a possible involvement of cytochrome b^ as 
an electron donor. Investigations of the in-vitro formation of the complex 
by MDP compounds have also demonstrated a requirement for oxygen using 
phenobarbitone-induced rat hepatic microsomes, NADPH and piperonyl 
butoxide (Franklin, 1971) or safrole (Elcombe, 1976). The demonstration of 
a requirement for oxygen and NADPH suggests the involvement of an 
oxidative metabolite or intermediate in the form of the MDP-cytochrome 
P-450 complex.
The formation of this cytochrome P-450 complex in vivo has been 
demonstrated by administration of piperonyl butoxide to mice (Philpot and 
Hodgson, 1971-2) and safrole or isosafroie to rats (Franklin, 1971; Parke and 
Rahman, 1971). The complex is present in the hepatic microsomes for the 
treated animals and may be observed as the oxidized spectrum with a peak 
at 438 nm but may be converted to the double-Soret reduced spectrum by 
the addition of dithionite or NADPH. Philpot and Hodgson (1972b) 
suggested that this complex accounts for the apparent decrease in cyto­
chrome P-450 levels previously observed by other authors (Perrry and 
Bucknor, 1970; Matthews and Casida, 1970; Matthews et al., 1970) since it 
is stable during the preparative procedures and is not displayed by carbon 
monoxide.
Although the complex is stable throughout the preparative proce­
dures and to dialysis for several hours, under certain conditions it is displaced
(Elcombe et al., 1975). Several compounds which bind to oxidized
cytochrome P-450 to produce a Type I spectrum are capable of displacing 
the MDP-metabolite from the cytochrome P-450 resulting in a time 
dependent increase in the magnitude of their own Type I binding spectrum. 
The increase in Type I spectrum was shown to be related to the amount of 
the 455 nm absorbing species in the microsomes and the rate of displace­
ment related to the displacer concentration. Displacement only occurred 
when the complex was present in the oxidized form and subsequent 
measurement of CO-binding showed an increase over that obtained in 
undisplaced microsomes, indicating the release of previously complexed 
haemoprotein. The increase in magnitude of the Type I binding is 
accompanied by the expulsion of isosafrole-related material from the 
microsomes (Elcombe et al., 1976a).
1.2.7 Induction of mixed-function oxidase activity by methylenedioxy­
phenyl compounds
Inhibition of mixed-function oxidase activity has been demonstrated 
in hepatic microsomal preparations from several species following their 
short-term pretreatment with MDP compounds. Inhibition occurs up to 
24 hr but after longer time intervals, induction of the mixed-function 
oxidase activity is observed (Falk and Kotin, 1969; Jaffe et al., 1969; 
Skrinjaric-Spoljar et al., 1971; Wagstaff and Short, 1971; Lake et al., 1973). 
The number of MDP compounds investigated for enzyme inducing properties 
is small (piperonyl butoxide, tropital, safrole and isosafroie) as is the number 
of species used for the investigations (rat, mouse and rabbit), but it appears 
that in all of these species many natural and synthetic MDP compounds have 
an enzyme-inducing effect. The increased enzyme activity is generally 
associated with an increase in cytochrome P-450 levels, but the nature of 
the induced haemoprotein is not yet fully investigated.
The induction of a novel haemoprotein was suggested by Parke and 
Rahman (1971) to explain the presence of a peak at 455 nm in the redox 
difference spectrum .of hepatic microsomes from safrole-treated rats. They 
also reported induction of cytochrome b^ to explain an increase in the 
absorption at 427 nm but, in retrospect, this is clearly the presence of the 
double-Soret redox spectrum of the MDP metabolite-cyctochrome P-450
complex. Lake and Parke (1972) suggested that the presence of the MDP 
metabolite-cytochrome P-450 complex explained, in part, the findings of 
Parke and Rahman (1971) but also considered a new haemoprotein to be 
induced. After 5 days pretreatment with isosafroie, they found an increase 
in the total binding ofi Type I and Type II substrates to the hepatic 
cytochrome P-450, but in contrast to phenobarbitone-induction, which does 
not alter the Kg values for substrate binding (Guarino et al., 1969), they 
found a decrease in the values for Type II binding but no change in the Kg 
Type I binding. Philpot and Hodgson (1971-2) noted biphasic changes in 
several spectral parameters after a single dose of piperonyl butoxide to 
mice. The biphasic effect on the CO-spectrum was an initial lowering to a 
minimum at 2-12 hr due to inhibition by the metabolite cytochrome P-450 
complex, followed by an increase to a maximum at 36-48 hr due to enzyme 
induction. The effect on the CO-spectrum was paralleled by a change in 
Type I and Type II substrate binding and the ethylisocyanide equilibrium 
point as calculated from the pH effect on the 430 nm and 455 nm peaks of 
the ethylisocyanide difference spectrum.
The induced haemoprotein appears to have very different spectral 
and catalytic properties to those normally found in the cytochrome P-450 
peak. The absorption maximum for the reduced CO-spectrum is at 448 nm 
after induction with safrole (Elcombe et al., 1975) which is a characteristic 
of the haemoprotein induced by the carcinogen 3-methylcholanthrene. Lake 
et al. (1973) reported an hepatic and extrahepatic induction pattern, with 
respect to several model substrates, which was similar to that induced by 
3-methylcholanthrene. Similarly, Lotlikar and Wasserman (1972) reported 
that safrole and isosafroie induce 3- and 5-hydroxylation of acetamido- 
fluorene to a greater extent than the N-hydroxylation reaction, once again a 
pattern similar to that induced by 3-methylcholanthrene. However, a
"mixed-induction" has been observed by seme authors for safrole and 
isosafroie since they induce both biphenyl 2- and 4-hydroxylation which are 
considered to be cytochrome P-448- and cytochrome P-450-mediated respec 
tively, and similarly with other enzyme assays (Parke and Rahman, 1970; 
Lake et ah, 1973; Wagstaff and Short, 1971; Vainio and Parkki, 1976). 
Investigation of the isosafrole-induced haemoprotein using SDS-gei electro­
phoresis has also demonstrated that the molecular weight of its subunits is 
intermediate between those of the phenobarbitone- and 3-methylcholan- 
threne-induced haemoproteins (Dickins et al., 1978). The new band is not 
observed following electrophoresis of microsomes in which the MDP met­
abolite-cytochrome P-450 complex has been generated in vitro and presum­
ably requires de novo protein synthesis to produce the new haemoprotein 
which probably also has properties intermediate between those of the 
phenobarbitone- and 3-methylcholanthrene-induced haemoproteins
1.2.8 Toxicity and carcinogenicity of the methylenedioxphenyl compounds
Although the majority of the MDP-compounds have a relatively low 
acute toxicity, safrole and piperonyl butoxide were listed by the Environ­
mental Protection Agency amongst chemicals which they consider may be too 
hazardous to man or environment to allow their continued use.
The acute oral toxicity of the MDP compounds is quite low with 
naturally ocurring compounds being more toxic than the synthetic com­
pounds. The oral LD^q's for several of the MDP compounds are shown in 
Table 1.1. The acute toxicity seems to be related to the length of the side 
chain since piperonyl butoxide, which has a long side chain, is much less 
toxic than other compounds whilst methylenedioxybenezene, which has no 
side chain, is the most toxic. Acute toxicity is manifested by ataxia, hind 
limb paralysis, depression of respiration and then death.
Table 1.1 Acute oral toxicity of several MDP compounds
(taken from *Jenner et al, 1964, 
and fSarles et al, 19493
Compound Species L «D.5Q 
(mg/kg]
95% Confidence Limits 
Cmg/kg3
Dihydrosafrole* Rat 2,260 1840-2780
Mouse 4,300 3420-5420
Isosafroie* Rat 1,340 1140-1590
Mouse 2,470 2010-3040
Safrole Rat 1,950 1760-2160
Mouse 2,350 2010-2750
Methylenedioxy-
benzene*
Rat 580 487-690
Mouse 1 ,2 2 0 976-1520
Piperonyl butoxide t Rat 7500-12,800
The MDP-compounds have many toxic effects through their ability 
to inhibit cytochrome P-450-mediated metabolism, although this may 
decrease the toxicity of a co-administered compound if an oxidative 
metabolite is the toxic agent. For example, piperonyl butoxide increases 
the toxicity of the organophosphates:- parathion and ethylguthion but dec­
reases the toxicity of methylparathion and guthion (Kamienski and Murphy, 
1971). Piperonyl butoxide has been shown to increase the acute toxicity of 
Freons 112 and 113, griseofulvin and benzo(a)pyrene to young mice (Falk and 
Kotin, 1969; Epstein et al., 1967).
The MDP-compounds in sesame oil, namely sesamol, sesamin and 
sesamolin, have been shown to cause contact dermatitis in man (Neering et 
al., 1975). The hypersensitivity developed after repeated use of topical 
pharmaceutical preparations containing sesame oil but the allergic response 
was greatest to sesmolin, which may perhaps photooxidize despite the 
presence of sesamol which has antioxidant properties. These three MDP 
compounds have also been implicated as co-carcinogens following observa­
tions that sesame oil increased the incidence of sarcomas in mice after 
treatment with benzo(a)pyrene (Morton and Mider, 1939). Piperonyl buto­
xide, itself relatively non-toxic, synergized the production of heptomas 
when co-administered with Freons 112 and 113 in infant male mice (Epstein 
et al., 1967b).
In a comparison of the toxicity of several allyl, propenyl and propyl 
compounds in the rat, Taylor et al. (1964) concluded that although several of 
the aromatic compounds produced mild liver lesions, only safrole^ isosafroie 
and dihyrosafrole produced severe liver lesions. Results from this study are 
shown in Table 1.2. Mild liver lesions consisting of slight discolouration, 
mottling and blunting of the lobe edges were seen with a number of 
compounds and these showed no relationship to structure since they included
Table 1 . 2 Liver lesions produced in rats by repeated doses of some 
aromatic allyl, propenyl, propyl and related compounds
Cfrom Taylor et al, 1964]
Compounds 0Dose
(mg/kg)
Macroscopic liver lesions*3 
Average rating
Benzene derivatives
Benzene 1360 0
Allyl benzene 1650 0
Propenylbenzene 1200 1.5
Methoxybenzene derivatives
Anisole... 1230 0
Estragole 605 0.5
Anethole 695 0.5
Dihydroanethole 1470 0.5
Anisaldehyde 500 0.5
Methylenedioxybenzene derivatives
Methylenedioxybenzene 190 0.5
Safrole 650 2.5
Isosafroie 460 2.5
Dihydrosafrole 770 2.5
Piperonal 900 0.5
Hydroxymethoxybenzene derivatives
Eugenol 595 1 . 0
Isoeugenol 520 0
Q
The dose approximately one-third of the LD50 for each compound administered 
daily for four days by stomach intubation. The groups of three male and 
three female rats were Killed on the fifth day, 24 hours after the last 
dose and the livers examined for gross lesions.
k The average of the individual ratings was recorded for each group of six 
animals using the following criteria:
0 , normal
1, slight discolouration (yellowish or greyish),.slight 
mottling, blunt appearance to the edges of the lobes 
without enlargement
2 , moderate yellow discolouration with or without mottling, 
fatty appearance, small white streaks, slight enlargements
3, marked yellow, discolouration with or without mottling, 
fatty appearance, small white streaks, soft mushy texture, 
moderate enlargement
compounds with no 3-carbon side chain (methylenedioxy-benzene), the allyl 
side chain (estragole, eugenol), the propenyl side chain (anethoie), the propyl 
side chain (dihydroanethole) and the aldehyde group (anisaldehyde, piper- 
onai). Moderate liver damage consisting of discolouration, mottiing, 
blunting of the lobe edges, and slight enlargement were seen with propenyl 
benezene. Severe liver lesions were only found with safrole, isosafroie and 
dihydrosafrole which caused discolouration, fatty appearance, loss of text­
ure and enlargement. The authors concluded that although many allyl 
compounds are known to be hepatotoxic (De Matteis, 1973; Levin et al., 
1973) this hepatotoxicity appeared to be independent of the nature of the
3-carbon side chain but that both a 3-carbon side chain and the methylendioxv 
group were necessary for the hepatotoxic actions.
Chronic exposure to the MDP compounds was not widely investi­
gated until the end of the 1950’s when two independent reviews (Jacobs, 
1958; Leidy, 1958) summarized the data from acute and subacute studies 
which consistently indicated liver damage. This prompted investigation of 
chronic exposure which indicated that safrole is a weak heptocarcinogen and 
led to the United States Food and Drug Administration ban in 1960 on its use 
as a food additive. Homburger et al. (1961) found that safrole at the 1% 
level in protein- and riboflavin-deficient diets for 1 year was toxic to CFN 
rats producing weight loss, hepatic adenomas, testicular atrophy and bone 
marrow depletion. In a subsequent study (Homburger et al., 1962), 1% 
safrole in a riboflavin-deficient diet produced similar toxic lesions in both 
male and female rats but the hepatotoxicity was greater in the males than 
the females. Abbott et al. (1961) reported hepatic cellular changes in rats 
compatible with carcinoma, after feeding safrole in the diet for 24 months, 
but did not find any tumours. Long et al. (1961; 1963) reported the
production of benign and malignant tumours in the livers of rat receiving
safrole at a dose level of 500 parts per million and above for up to 22 
months and concluded that safrole is a weak hepatocarcinogen. Chronic 
administration of dihydrosafrole in the diet produced both benign and 
malignant oesophageal tumours in rats (Long and Jenner, 1963; Hagan et 
al., 1965) in addition to hepatotoxicity of a similar type to that observed in 
rats given safrole. Neither safrole nor isosafroie produced oesphageal 
changes as seen with dihydrosafrole but all three compounds produced 
hepatic cell enlargement which was usually focal and resulted in the 
formation of nodules; cystic necrosis, fatty metamorphosis and bile duct 
proliferation. In the case of safrole these changes were severe and resulted 
in tumour formation but with isosafroie and dihydrosafrole these changes 
were slight and although tumours were found, there were not enough to be 
of statistical significance.
Safrole was also found to be carcinogenic 1 year after administrat­
ion of four subcutaneous injections to neonatal Swiss mice (Epstein et al., 
1970). After a total dose of only 6.6 mg of safrole, 58% of male mice had 
hepatomas compared to 0% of female mice and 6% of the male control 
mice. It therefore appears that safrole under the appropriate conditions 
can act as a moderately potent hepatocarcinogen. Pulmonary tumours were 
also observed in these mice although safrole is only an hepatocarcinogen in 
the rat (Homburger et al., 1962; Hagan et al., 1965), however the 
significance of his finding is doubtful since it is thought that many tumours 
in mice may be due to virus activation and result in tumour formation after 
administration of relatively innocuous compounds like phenobarbitone, DDT, 
dieldrin etc. In contrast, safrole did not increase the incidence of 
pulmonary tumours in strain A/He mice, a strain of mouse used for a short­
term carcinogenesis bioassay in which a positive result is represented by an 
increase in the incidence of pulmonary tumours 24 weeks after initiation of
the dosing regimen (Stoner et al., 1973). Safroie was therefore considered 
to be non-carcinogenic by these authors.
1.2.9. Possible mechanism of carcinogenesis by methylenedioxyphenyl com­
pounds
The majority of carcinogens are themselves not reactive enough to 
interact directly with cellular macromoleculas in order to initiate the 
process of tumourigenesis, rather they require metabolic activation to form 
strong electrophiles which are thought to be ultimate carcinogens (Miller 
and Miller, 1969; Miller, 1970). Activation of a carcinogen by the mixed- 
function oxidase may produce a proximate carcinogen which, although more 
electrophilic than the parent compound, requires further metabolic acti­
vation to produce the ulitmate carcinogenic metabolite. Investigation of 
the electrophilic nature of metabolites may therefore produce more insight 
into the mechanism of carcinogensis by a particular compound.
Metabolism of safroie in rats and mice produces l'-hydroxysafrole as 
one of the urinary metabolites (Borchert et al., 1973a;Stillwell et al., 1974) 
which is excreted as the glucuronide.
In an investigation of the acute toxicity of l’-hydroxysafrole in adult 
mice, Wislocki (1974) found that although male mice were able to tolerate a 
dose of 0.35% l ’-hydroxysafrole in the diet for two weeks, all of the female 
mice on the same diet died with extensive liver damage including haemorr­
hage and centrolobular necrosis. However, if the female mice v/ere initially 
fed a diet containing only 0.08% l’hydroxysafrole for 12 days, they were then 
able to tolerate the dose which previously proved hepatotoxic. This 
indicates that enzyme induction may result in a decreased toxicity for this 
proximate carcinogen. This is in agreement with the observation that 
prolonged administration of safroie to rats results in a 50% decrease in the 
excretion of 1’hydroxysafrole after 2 weeks or more (Borchert et al., 1973a).
However, the prolonged co-administration of phenobarbitone and safroie 
results in an increase in the excretion of l'-hydroxysafrole and an increase in 
the incidence of tumours after 22 months compared to the incidence in 
animals adminstered either safroie or phenobarbitone alone (Wislocki, 1974). 
It appears therefore that enzyme induction by phenobarbitone increases the 
rate of formation of the proximate and/or ultimate carcinogenic metab­
olites but induction by safroie or l'-hydroxysafrole may decrease the 
formation of carcinogenic metabolites either by inhibition of the enzymes 
responsible for formation of the ultimate carcinogen or by increasing the 
rate of metabolism by an alternate pathway e.g. demethylenation to form 
the catechol.
Borchert et al. (1973a) synethesized the model ester l’-acetoxy- 
safrole to investigate its properties as an electophilic reactant, since allylic 
and benzylic esters have been strongly implicated as the reactive forms of 
other known carcinogens e.g. the pyrrolizidine alkaloids (Mattocks, 1971; 
Mattocks and White, 1971). The allylic and benezylic ester I'-acetyoxy- 
safroie is an electrophilic reagent and reacts non-enzymically with nucleo­
philes like methionine and guanosine. Administration of the metabolite-1'- 
hydroxysafrole to rats or mice either subcutaneously or in the diet produced 
a much higher incidence of liver tumours than did the parent compound 
safroie and therefore the metabolite may be considered to be a proximate 
carcinogen. However, the synthetic ester l'-acetoxysafrole induced a higher 
incidence of tumours at the site of administration but not in the liver and 
may therefore be considered as a model of the ultimate carcinogen of 
safroie since it is probably so reactive that it never reaches the liver. 
Investigation of safroie, l'-hydroxysafrole and l'-acetoxysafrole in the Ames 
Salmonella/microsome test showed that l'-acetoxysafrole was mutagenic but 
not safroie or l'-hydroxysafrole (McCann et ah , 1975)
Wislocki et al. (1976) investigated the metabolism of l'-hydroxy-
3
safroie in vivo and in vitro. In vivo administration of (2% 3 - H)-l'- 
hydroxysafrole to rats and mice resulted in the formation of hepatic DNA-,
3
ribosomal RNA- and protein-bound H-derivatives. A small amount, 0.1-0.3%
3of the protein-bound H, was identified as 3'-methylmercaptoisosafrole 
a derivative previously found to result from the reaction of methioine with 
l'-acetoxysafrole (Borchert et al., 1973a); and this may possibly indicate the 
formation of an ester of l'-hydroxysafrole in vivo. In vitro metabolism of 
l'-hydroxysafrole by rat and mouse liver microsomal fractions produce its 
2',3'-oxide whilst the corresponding cytosolic fractions contained sulphotrans- 
ferase activity which mediated the formation of the sulphuric acid ester. 
The rate of formation of the ester, in the 3'-phospho-adenosine-5'-phospho- 
sulphate (PAPS)-dependent reaction, was low but it was stongly electrophilic 
since the derivative was trapped by its reactions with RNA. There was no 
evidence for the formation of the phosphoric acid or acetic acid esters and 
therefore the sulphuric acid ester is probably the principal ester formed in 
vivo in addition to the major conjugate which is the glucuronide.
Metabolism of estragole, a flavouring agent related to safroie, has 
been shown to resemble that of safroie (Solheim and Scheline, 1973) and also 
results in the formation of the l'-hydroxy-derivative. Subsequently, 
Drinkwater et al. (1976) demonstrated that l'-hydroxy-estragole induced 
liver tumours in mice to a greater extent than l'-hydroxysafrole. In vitro 
the synthetic ester I'-acetoxyestragole showed electrophilic reactivity 
towards nucleosides since it reacted non-enzymically with guanosine and 
inosine to a similar extent as l'-acetoxy-safrole.
The significance of these findings in relation to human exposure has 
not been fully investigated since dietary levels of safroie and estragole are 
low in comparison to dose levels used in the animal studies. In the chronic
toxicity studies the only animals to develop liver tumours were in the groups 
receiving safroie at 1000 ppm and above in the diet for 2 years (Long et al., 
1963; Haugen et al., 1965) although very slight liver damage was noted at 
1000 ppm. This may indicate that at low levels the metabolism and
excretion of the MDP compounds does not involve the formation of a
carcinogenic metabolite. At higher dose levels the primary metabolic route
may become saturated and result in the formation of an electrophilic
metabolite by a secondary metabolic pathway. Further evidence to support 
this hypothesis was reported by Benedetti et al. (1977) who found no 
evidence of l'-hydroxysafrole in the urine of human volunteers after giving 
very low doses of safroie when compared with the dose levels used in animal 
studies. Another possibility is that at low doses the slow rate of formation 
of the sulphate-conjugate observed by Wislocki et al. (1976) allows this 
reactive metabolite to be eliminated before it exerts any serious biological 
effects. It is also possible that at low dose levels any damage caused by a 
reactive metabolite to nuclear DNA is effectively repaired but at higher 
dose levels the damage exceeds that which can be repaired and hence 
disrupts normal cellular metabolism and leads to necrosis or tumourigenesis.
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2.1 CHEMICALS
Isosafrole and dihydrosafrole were purchased from Merck, G.m.b.H. 
(Darmstadt, West Germany) and safroie was obtained from Hopkin and 
Williams Ltd. (Essex, England). Piperonyl butoxide was kindly donated by 
Mr. G. Pohl (Wellcome Research Laboratories, Berkhamsted, England). All 
other methylenedioxy compounds were supplied by Aldrich Chemical Co.
Ltd. (Middlesex, England).
14[w - C] Isosafrole (5 mCi/mmol) was obtained from the Radio­
chemical Centre (Amersham, Bucks, England). The purity of this radiolabel 
was checked before use by radio-gas chromatography and mass- 
spectrometry; the purity was found to be 99% although gas-liquid chromato­
graphy on 5% OV 17 at 170°C demonstrated the presence of two major 
peaks, these were shown by mass spectrometry to correspond to the cis and 
trans isomers of isosafrole in the ratio of 8% cis : 92% trans.
NADH, glucose-6-phoshate (disodium salt), glucose-6-phosphate 
dehydrogenase, glucose, bovine serum albumin, Tris (Trizma base), 
protease VII (subtilisin) [E.C. 3.4.21.3], hyaluronidase [E.C.3.2.1.35] type II, 
$-glucuronidase, [E.C. 3.2.1.31] type H-l and Coomassie Brilliant Blue G-250 
were obtained from Sigma Chemical Co. Ltd. (Surrey, England). NADPH, 
collagenase [E.C.3.4.24.3] and Combiteck standard proteins were obtained 
from the Boehringer Corporation (Lewes, Sussex, England).
Phenobarbitone (sodium salt) and sodium dodecylsulphate wereobtained 
from B.D.H. Ltd. Ethylmorphine was supplied by May and Baker Ltd. 
(Dagenham, England) and 3-methylcholanthrene by Fluorochem Ltd. 
(Derbyshire, England). Ethoxyresorufin (50 jiM in methanol) and resorufin 
(10 jliM in ethanol) were obtained from Pierce and Warriner (U.K.) Ltd., 
Chester, England. Biphenyl was twice recrystallized from 96% ethanol,
4-hydroxybiphenyl v/as recrystallized from methanol and 2-hydroxybiphenyl
was re-crystallized from light petroleum.
N,N-Dimethylformamide (puriss) and Scintimix SMI scintillant
mixture were obtained from Koch-Light Laboratories (Bucks, England).
Dulbecco's phosphate buffered saline (PBS'A1), Hank's balanced salt
solution, phenol red and trypan blue were obtained from Flow Laboratories
(Irvine, Scotland). Hank's based Eagle's minimal essential medium was
supplied by Media Production, Wellcome Research Laboratories,
(Beckenham, Kent) and foetal calf serum was obtained from Wellcome
Reagents Ltd (Hither Green). Ethylene glycol-bis-(3-amino-ethyl ether)-
NN'-tetra-acetic acid (EGTA) was obtained from Serva (Heidelberg, West
Germany). Gelatine was obtained as Dr. Oetker's gold star sheet gelatine
R(Dr. Oetker, Bielefeld, West Germany) and Ficoll 400 was obtained from 
Pharmacia (Uxbridge, Middlesex, England).
Carbon monoxide, oxygen and carbogen (95% oxygen : 5% carbon 
dioxide) were obtained from British Oxygen Co. Ltd. (Surrey, England).
All other chemicals were purchased from British Drug Houses 
(Poole, Dorset, England) and were of the highest purity commercially 
available.
2.2. ANIMALS
The rats used in this study were male albino s and were obtained 
from two suppliers: COBS (caesarian-derived, barrier-sustained), Wistar
(Canterbury Ash) were obtained from Charies River (Margate, Kent, 
England) and Wistars were also purchased from the Zentralinstitut i\!r 
Versuchstiere (Hannover, West Germany). Animals of 180-220 g body 
weight were used in all experiments unless otherwise specified.
The mice in this study were of two different strains; C57BL/10 
mice were obtained from Bantin and Kingman Ltd. (Hull, England) and 
DBA/2 mice were obtained from OLAC 1976 Ltd. ( Bicester, Oxon., 
England).
All animals were housed in wire bottomed cages over sawdust (dust
free, sterilized) obtained from the Sawdust Marketing Co. (Standon, Herts,
England) and were allowed food, either Heygates 41B rat pellets Bugbrook
RMills (Southampton, England) or Altromin rat pellets (Altromin G.m.b.H., 
Lage, Lippe, West Germany) and water ad libitum. A twelve hour 
light/dark cycle was maintained (0700-1900 hrs. light); animals were all 
dosed and killed at the same time of day (0900-1000 hrs).
2.2.1 Pretreatment of Animals 
Controls
Control animals received isotonic saline (0.9%, w/v) corn oil or 
sunflower oil (2.5 ml vehicle/kg body weight for rats and 10 ml/kg body 
weight of mice) by intraperitoneal (i.p.) injection on each of three conse­
cutive days. Animals were killed 24 h after the final injection.
Phenobarbitone
Phenobarbitone (sodium salt) was dissolved in 0.9% (w/v) saline. For 
induction purposes, rats received 80 mg/kg and mice 100 mg/kg of the drug 
by i.p. injection once daily for three consecutive days. Animals were killed 
24 h after the last injection.
3-Methylcholanthrene
3-Methylcholanthrene was administered as a solution in corn oil or 
sunflower oil. The animals, both rats and mice, received 20 mg/kg i.p. 
administered once daily for three consecutive days and were killed 24 h 
after the final injection.
Pregnenolone-16ct-carbonitrile (PCN)
PCN was administered as a fine suspension in sunflower oil to mice 
at a dose level of 50 mg/kg by i.p. injection. The animals were treated 
once daily for three consecutive days and were killed 24 h after the last 
injection.
MDP compounds
Isosafrole was routinely administered to both rats and mice by i.p. 
injection in sunflower oil at a dose level of 150 mg/kg. The animals were 
treated once daily for three consecutive days and were killed 24 h after the 
last injection. Other MDP compounds were administered by the same route 
and at the same level unless otherwise specified in the text, with the 
exception of piperonyl butoxide which was administered at a dose level of 
500 mg/kg i.p. for three consecutive days.
Phenobarbitone-isosafrole, 3-Methylcholanthrene-isosafrole, water-iso- 
safrole, oil-isosafrole
Animals received either phenobarbitone, 3-methylcholanthrene, 
water or oil once daily for three consecutive days at the dose levels 
described above. On the fourth day all animals received isosafrole 
(150mg/kg i.p.) and were killed 24 h after administration of the isosafrole.
2.3.1. Preparation of microsomes
Rats and mice were killed by cervical dislocation and the liver 
rapidly excised into ice-cold 1.15% (w/v) KC1. (Gall bladders were removed 
from the mouse livers before placing the livers in the ice cold 1.15% KC1.). 
The livers were washed well, to remove adhering haemoglobin, blotted dry 
and then weighed. All subsequent operations were carried out at 0-4 °C. 
The livers were scissor-minced and washed with ice-cold 1.15% (w/v) KC1 
and then homogenized in three volumes 1.15% (w/v) KC1 using a motor
driven Potter-Eivehjem glass-Teflon homogenizer (3 return strokes). The 
liver homogenate was centrifuged in 50 ml polycarbonate Oakridge bottles 
(M.S.E. Ltd.) at 15,000 g (13,500 rev/min) for 20 min using an 8 x 50 ml
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aluminium angle head rotor in a M.S.E. "High Speed 18" refrigerated 
centrifuge. The supernantant was carefully decanted and recentrifuged at 
either 116,000 gav (40,000 rev/min) for 50 min using an 8 x 35 ml aluminium 
angle head rotor or, for smaller volumes, 300,000 gav (65,000 rev/min) for 
20 min in a 10 x 10 ml titanium angle head rotor in an M.S.E. "Superspeed 65" 
refrigerated centrifuge. The supernatant was discarded and the top of the 
crude microsomal pellet rinsed with a small volume of ice-cold 1.15% (w/v) 
KC1. The pellet was resuspended in ice-cold 1.15% (w/v) KC1 using a 
Potter-Eivehjem homogenizer (2 return strokes) and the resultant suspension 
recentrifuged at either 116,000 gav for 50 min or 300,000 gay for 20 min. 
The supernatant was discarded and the washed microsomal pellet was finally 
resuspended in 20 mM Tris-HCl buffer (pH 7.4) containing 250 mM sucrose 
and 5.4 mM EDTA (Netter, 1960) to a concentration equivalent to about 1 g 
of liver per ml (approximately 20 mg microsomal protein per ml). The 
microsomal suspension was stored in 1.5-2.0 ml aliquots in conical poly­
carbonate sample cups (L.I.P. Equipment and Services Ltd.) and stored at 
-20 °C. Microsomes prepared and stored in this way showed no detectable 
loss of cytochrome P-450 or monooxygenase activity relative to freshly 
prepared microsomes, even when stored for up to 2 months.
2.3.2. Preparation of Isolated Rat Hepatocytes 
Solutions
Phosphate Buffered Saline + Glucose (PBSG)
This is a modified Dulbecco's Phosphate Buffered Saline (PBS’A) 
which contains 1 g/litre glucose and is Mg and Ca free.
g/litre H20
NaCl S.00
KC1 0.20
KH2P04 0.20
Na0HPO/f.12H~0 2.892 4 2
Phenol Red 0.01
Glucose 1.00
Hank's balanced salt solution
This is a modified Hank's balanced salt solution and is Mg++ free but 
contains 5 mM CaCl2.
g/litre H20
NaCl 8.00
KC1 0.40
k h 2p o ^ 0.06
Na2HPCy2H20 0.06
NaHC03 0.35
CaCl2 (anhydrous) 0.14
Glucose 1.00
Phenol Red 0.01
Method
The solutions were warmed to 37 °C and gassed with carbogen 
(95% oxygen/5% carbon dioxide). The apparatus was set up so that the 
peristaltic pump could deliver 20-50 ml/min of warm oxygenated, bubble- 
free buffer in either an open or closed (recirculating) system.
After anaesthetising a rat (175-225 g body weight) with ether, the 
abdomen was opened with a mid-line ventral incision and 750-1,000 units of 
Heparin injected into the spleen. Displacement of the intestines to the side 
revealed the vena porta which was cannulated and the cannula held firmly in 
place by two ligatures before severing the vena cava. Immediately, the 
perfusion pump was started and the liver perfused in situ with PBSG at 
30 ml/min. If perfusing correctly the liver immediately turned a light-tan 
colour. The liver was then dissected free of all connective tissue and 
placed on the perfusion dish, taking great care not to rupture the liver 
capsule. Once the liver had been arranged on the perfusion dish in such a 
way that none of the major blood vessels was occluded, the perfusion 
medium was changed to PBSG containing 0.5 mM EGTA and the perfusion 
continued at 30 ml/min until a perfusate volume of 250 ml had been 
collected. After stopping the pump, the system was rapidly changed to a 
closed, recirculating system and the perfusion medium changed to Hank's 
balanced salt solution (50 ml) containing 5 mM CaCl2 and the enzymes 
collagenase (0.0596 w/v) and hyaluronidase (0.10% w/v). Perfusion was then 
continued at 30 ml/min for 20 minutes, during which time the liver 
increased in size, began to exude perfusate from its surface and was very 
soft to the touch. If the perfusion medium turned pale yellow, i.e. acid, 
during the recirculating perfusion, the pH was adjusted by addition of a few 
drops of 4% NaHCO^ solution until the phenol red indicator once more 
turned pink. At the end of the perfusion the liver was transferred to a 
Petri dish containing 10-15 ml of cold PBSG containing 1 mg/ml Bovine 
Serum Albumin (BSA) but no phenol red indicator. After rupturing the liver 
capsule, the hepatocytes were liberated from the connective and vascular 
tissue by gentle stroking of the liver with the rubber bulb of a Pasteur 
pipette until all of the brown hepatocytes had been removed and all that
remained of the liver was a white gelatinous mass of vascular tissue. Any 
hard, i.e. unperfused, lobes of the liver were discarded. The suspension of 
hepatocytes was filtered through a layer of Bolting cloth 125 jjo\ pore size 
(Henry Simon Ltd., Stockport, Cheshire, England) into a beaker, the Petri 
dish and liver residue were washed with a further 10-20 ml PBSG + BSA and 
the washings also filtered and collected. The suspension of hepatocytes was 
centrifuged at 100gav f°r 2 minutes and the supernatant discarded. The 
peilet was resuspended in 10-15 ml PBSG (without phenol red) by gentle 
inversion of the centrifuge tube and recentrifuged at 50 gav for 5 minutes 
and the supernatant discarded. This procedure was repeated several times 
until the supernatant contained very little cell debris and the pellet was 
finally resuspended in Eagle's minimal essential medium (15 mis) and the 
hepatocytes stored on ice until required.
The viability of the cell preparation was estimated by mixing a 
sample of the cells (0.25 ml) with 0.4% (w/v) trypan blue (0.1 ml) and 
counting the percentage of blue-staining i.e. non-viable cells and the total 
number of cells per ml using an improved Neubauer counting chamber and a 
light microscope. The viability index of hepatocytes prepared in this way 
routinely exceeded 90% and some preparations contained hepatocytes of 
98% viability.
2.3.3 Subcellular Fractionation
Hepatocytes prepared by "soft" enzymic digestion of the liver (see 
above) were incubated in vitro with [w -^ C ] isosafrole as described in 
Section 2.8. and were removed from the incubation medium by centri­
fugation (100 g for 5 minutes) and then subjected to the following proce­
dures in order to determine the subcellular distribution of any covalently 
bound radiolabel.
The hepatocytes were suspended in 10 ml of ice-cold 20 mM Tris- 
HC1 buffer (pH 7.4) containing 250 mM sucrose and 5.4 mM EDTA 
(SET buffer) and homogenized using a Potter-Eivehjem Teflon-glass homo­
genizer (ten return strokes). Ail samples were kept at 0-4°C during the 
subsequent procedures. The homogenate was centrifuged at 600 gay 
(2,200 rev/min) for 10 min using an 8 x 50 ml aluminium angle head rotor in 
an M.S.E. "High Speed 18" centrifuge. The crude nuclear pellet so obtained 
was resuspended in SET buffer (5 ml) and recentrifuged at 600 gay for 
10 min. The resultant washed nuclear pellet was resuspended in SET buffer 
(5 ml) and stored in ice. The post-nuclear supernatant was centrifuged at 
5,800 gav (6,500 rev/min) for 10 min and the resultant pellet resuspended in 
SET buffer (5 ml) and recentrifuged at 5,800 for 10 min. The washed 
mitochondrial pellet was resuspended in SET buffer (5 ml) and stored in ice. 
The post-mitochondrial supernatant was centrifuged at 17,000 gav (12,000 
rev/min) for 15 min to obtain the crude lysosomal pellet which was 
resuspended in SET buffer (5 ml) and recentrifuged at 17,000 gay for 15 min. 
The washed lysosomal pellet was resuspended in SET buffer (5 ml) and stored 
in ice. The post-lysosomal supernatant was centrifuged at 116,000 gav 
(40,000 rev/min) for 50 min using an 8 x 35 ml aluminium angle head rotor in 
a M.S.E. ’‘Superspeed 65" centrifuge. The resultant microsomal pellet was 
resuspended in SET buffer (5 ml) and recentrifuged at 300,000 (65,000 
rev/min) for 20 min. The washed microsmal pellet was resuspended in SET 
buffer (5 ml) and stored in ice. The volumes of the final supernatant 
fraction (cytosol) and resuspended pellets were all recorded. The whole of 
this procedure is summarized in Fig. 2.1.
FIGURE 2.1
Flow diagram for a typical subcellular fractionation of liver homogenate
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2.3.4 Protein Assays
Protein was determined by a modified method of Lowry et al (1951), 
using bovine serum albumin as the standard.
Reagents
0.05M NaOH
1% (w/v) CuS0^.5H20
2% (w/v) Sodium potassium tartrate
0.05M NaOH containing 2% (w/v) anhydrous N a^O ^
Folin-Ciocalteau phenol reagent, diluted with water 1:3 (v/v)
Bovine serum albumin in 0.05M NaOH (50, 100, 150, 200, 250 }ig/ml)
Method
Homogenates or microsomal suspensions were diluted to appropriate 
concentrations using 0.05M NaOH. The CuSO^, sodium potassium tartrate  
and Na2CO^ solutions were mixed in the ratio 1:1:100 (by vol) immediately 
prior to use. The mixed solution (5.0 ml) and diluted protein sample (0.5 ml) 
were mixed and allowed to stand for at least 10 minutes at room temper­
ature. Diluted Folin-Ciocalteau phenol reagent (0.5 ml) was added and the 
solutions mixed immediately using a Vortex mixer. After at least 30 min at 
room temperature, the absorbance at 700 nm was recorded using a Pye 
Unicam S.P.500 spectrophotometer. Blanks (0.05M NaOH) and bovine 
serum albumin standards were run in parallel.
2.3.5 Marker Enzyme Assays
Succinate Dehydrogenase (E.C. 1.3.99.1.)
This enzyme was used as a marker for the mitochondrial fraction 
and was determined by a modified method of Pennington (1961) using the 
dye electron acceptor 2-(£-iodophenyl)-3-(£-nitrophenyl)-5-phenyltetra- 
zolium chloride (INT).
Reagents
0.2M sodium phosphate buffer (pH 7,4) containing 1.25 mg/ml INT 
0.3 sodium succinate (pH 7.4)
0.3M sodium malonate (pH 7.4)
96% (V/V) ethanol/ethyl acetate/10% (w/v) trichloracetic acid 
(13:20:2 by vol.)
Method
Phosphate buffer (0.25 ml) containing 1.25 mg/ml INT was added to 
suitably diluted subcellular fractions (0.5 ml). After preincubating the 
tubes for 5 min at 37 °C the reaction was initiated by addition of sodium 
succinate (0.25 ml) and the further 10 min incubation at 37 °C was allowed. 
Tissue blanks were treated similarly but sodium malonate (0.25 ml), an 
inhibitor of succinate dehydrogenase, was substituted for the succinate. The 
reactions were terminated by the addition of the ethanol/ethyl acetate/ 
trichloracetic acid reagent (6 ml) and the solutions were mixed well before 
centrifuging at 2,000 rev/min for 10 min to remove any turbidity. Finally, 
the absorbance of the supernatants at 490 nm was recorded using a Pye 
Unicam S.P.500 spectrophotometer. Actual concentrations of reduced INT 
were calculated using an absorption coefficient of 20 litre.m m ol^cm ”*.
Acid Phosphatase (E.C. 3.1.3.1.)
The distribution of lysosomes was estimated from the activity of the 
acid phosphatase in each fraction. Total acid phosphatase was measured by 
the method of Neil and Horner (1964) using £-nitrophenyl phosphate as the 
substrate.
Reagents
0.01M £-nitrophenyl phosphate 
0.1M NaOH
0.2M Sodium acetate buffer (pH 5.0) containing 0.25% (w/v)
Triton X-100
Method
Suitable dilutions of the subcellular fractions (0.2 mi) were pre­
incubated at 37°C for 5 min with acetate buffer (0.3 ml) containing 0.25% 
(w/v) Triton X-100. The reaction was initiated by addition of the substrate, 
£-nitrophenyl phosphate, (0.5 ml) and the incubation continued for 15 min. 
Suitable substrate blanks were incubated in parallel. The reaction was 
terminated by addition of the NaOH (5.0 ml) and the solutions centrifuged at 
2000 rev/min for 10 min to remove any turbidity. The yellow colour of the 
supernatant was quantified using a Pye Unicam S.P.500 spectrophotometer 
and the amounts of £-nitrophenol produced were calculated using an 
absorption coefficient of 18.5 litre.mmol *.cm~*.
Glucose-6-Phosphatase (E.C. 3.1.3.9.)
This enzyme was used as a marker for the microsomal fraction and 
was assayed by measurement of inorganic phosphorous liberated during the 
hydrolysis of glucose-6-phosphate.
Reagents
0.3M 3,3-dimethylglutarate (pH 6.4) containing 12.5mM EDTA 
0.05M glucose-6-phosphate, disodium salt 
6% (w/v) trichloracetic acid
5% (w/v) perchloric acid, containing 0.6% ammonium molybdate 
0.2% (w/v) ascorbic acid 
Method
Samples of the suitably diluted tissue fractions (0.5 ml) were added 
to 3,3-dimethylglutarate buffer (pH 6.4) containing EDTA (0.4 ml) and 
preincubated at 37 °C for 5 min. The reaction was initiated by the addition 
of glucose-6-phosphate (0.1 ml) and the tubes incubated for a further 20 min
at 37 °C. The reaction was terminated by the addition of trichloracetic 
acid (1.5 ml) and the denatured protein precipitated by centrifugation at 
2000 rev/min for 10 min. Perchloric acid (3.0 ml) containing ammonium 
molybdate was added to the decanted supernatant and mixed well. Ascorbic 
acid (1.0 ml) was added and the tubes allowed to stand at room temperature 
for 30 min before determining the absorbance of the solutions at 720 nm 
using a Pye Unicam S.P.500.
Standards (containing 0.1-1.0 jig atom phosphorus) and blanks were 
run in parallel with the tissue samples.
2.4 SPECTROPHOTOMETRY
All spectral measurements were made using an Aminco DW-2 UV- 
V1S spectrophotometer fitted with a thermostatted cuvette holder and, 
unless otherwise stated, all spectral changes were recorded at 37 °C. 
Measurements were made in either the split beam mode (using two cuvettes, 
' ^ 1  = = sample wave length, = reference wavelength) or the
dual beam mode (using a single cuvette, A^  = A ). The dual beam mode is 
advantageous for kinetic studies since both beams pass through the same 
light path and therefore changes in sample turbidity are automatically 
compensated for during the assay.
2.4.1 Cytochrome P-450 determination
Cytochrome P-450 was measured by the method of Omura and Sato 
(1964a). Microsomes (1 mg protein/ml) were suspended in Tris-HCl buffer 
(pH 7.4) and a sample (5 ml) reduced with sodium dithionite (1-2 mg) and 
divided equally between two cuvettes. A baseline of equal light absorbance 
was recorded between 400 and 500 nm. Carbon monoxide (CO) was bubbled 
through the sample cuvette for 20-30s and the difference spectrum was
recorded. The absorbance change between the absorbance maximum at
about 450 nm was measured relative to that of 490 nm and the cytochrome
P-450 concentration was calculated using an absorption coefficient of
91 litre.mmor^.cm” .^
Accurate determination of the X of the reduced-carbon mon-max
oxide spectrum was carried out using a narrow slit width (1.0 nm), slow scan 
speed (0.1 nm/s) and slow response (2.5s).
2.4.2 Substrate-induced binding spectra
Binding spectra were elicited as described by Schenkman et al 
(1967). Microsomes (5 ml) were diluted to 1 mg protein/ml in 66 mM Tris- 
HC1 buffer (pH 7.4) and divided equally between two cuvettes. The cuvettes 
were placed in the spectrophotometer and a baseline of equal light absor­
bance between 350 and 500 nm was established. Substrate, in jil quantities 
of a solution in buffer or dimethylformamide, was injected into the contents 
of the sample cuvette using a Terumo microlitre syringe (Shandon Southern 
Co. Ltd., Camberley, Surrey, England). An equal volume of solvent was 
added to the contents of the reference cuvette. The contents of both 
cuvettes were mixed well by gentle inversion or by stirring with a plastic 
rod (Sarstedt Ltd., Leicester, England), and the difference spectrum 
between 350 and 500 nm was recorded.
The addition of increasing amounts of substrate to the microsomal 
suspension resulted in corresponding increases in the binding spectrum. 
Measurement of the peak to trough absorbance changes at different 
substrate concentrations permitted the calculation of the spectral binding
constant Kg since the apparent K and apparent A A values can be ^ max
calculated from a double reciprocal plot of substrate concentration versus 
A A peak-trough (Schenkman et al, 1967 .^
2*5 NADPH : Regeneration and Oxidation
A NADPH regenerating system was used in all enzyme assays or 
incubations lasting longer than 2-3 min. This consisted of 4.0 mM glucose-
6-phosphate and 2 units/ml of glucose-6-phosphate dehydrogenase 
(E.C. 1.1.1.49). In the presence of 200-400 p,M NADPH, this system 
maintained a stable reduced cofactor concentration for 30 min or longer.
For certain studies in which NADPH alone rather than a regene­
rating system was used, it was necessary to oxidize the NADPH rapidly and 
efficiently. This was achieved by the addition of 2.5 mM sodium 
a-oxoglutarate, 5.0 mM NH^Cl and 20 units/ml of glutamate dehydrogenase 
(E.C. 1.4.1.2) to the microsomal suspension. This system completely 
oxidized 300 pM NADPH within one minute.
2.6 ASSAYS OF MONOOXYGENASE ACTIVITY IN VITRO
2.6.1 Biphenyl 2- and 4-hydroxylation
Biphenyl is metabolized in vitro to two major products, 2- and 
4-hydroxybiphenyl. These two metabolites can be estimated fluorimetrically 
in the same solution since the fluorescent properties of the 2- and 
4-hydroxybiphenyls are different. The method used was a modification of 
that of Creaven et al (1965).
Reagents
1.0M Biphenyl in dimethylformamide
4M HC1
100 mM NaOH
n-Heptane containing 196 (v/v) 3-methyl-l-butanol 
250 mM Succinic acid
353 jiM 4-Hydroxybiphenyl in 5% (v/v) ethanol
70.5 jliM 2-Hydroxybiphenyl in 5% (v/v) ethanol
66 mM Tris-HCl buffer (pH 7.4)
25 mM NADPH in 66 mM Tris HC1 (pH 7.4)
40 mM Glucose-6-phosphate (disodium salt) containing 20 units/ml 
glucose-6-phosphate dehydrogenase in 66 mM Tris-HCl (pH 7.4)
Methods
Microsomal suspension (1 mg protein/ml), 66 mM Tris-HCl (pH 7.4) 
buffer, glucose-6-phosphate (4.0 mM), glucose-6-phosphate dehydrogenase 
(2 units/ml) and biphenyl (2.0 mM) were placed in 15 ml Sovirel tubes (V.A. 
Howe Ltd., London) on ice. After a preincubation in a shaking water bath 
(120 cycles/min) at 37 °C for 5 min, the reaction was started by the addition 
of NADPH (250 jiM) and the tubes incubated for a further 10 min. 
Metabolism was terminated by plunging the tubes into ice and adding 
4M HC1 (5 ml). The standards, 2-hydroxybiphenyl (14.1 pM), 4-hydroxy­
biphenyl (70.6 i^M) and the substrate, biphenyl (2.0 mM), were added to the 
appropriate standard and blank tubes after termination of the reaction. 
After mixing the contents of the tubes with a Vortex mixer, n-heptane 
containing 1% (v/v) 3-methyl-l-butanol (7.0 ml) was added to each. The 
tubes were capped and extracted using a tumble mixer for 10 min. The 
caps were removed and the tubes centrifuged at 2,000 rev/min for 5 min. 
Portions (2.0 ml) of the upper (n-heptane) layer were pipetted into clean 
10 ml Sovirel tubes and 100 mM NaOH (5.0 ml) was added to all the tubes. The 
tubes were capped and extracted as before. The caps were removed and 
centrifuged at 2,000 rev/min for 10 min. The upper (n-heptane) layer and 
the suspension at the interface were aspirated off using a Pasteur pipette 
attached to a water pump. Aliquots (2.0 ml) of the aqueous layer were 
placed directly in the fluorimeter cuvette, 250 mM succinate (0.5 ml) was 
added and the cuvette contents were mixed well by inversion. The 
fluorescence of the cuvette contents were measured at the wavelengths 
indicated below.
Fluophor Fluorescence Characteristics
excitation emission
4-hydroxybiphenyl 275 nm 338 nm
2-hydroxybiphenyl 295 nm 415 nm
(plus a small contribution from the 4-hydroxybiphenyl)
2.6.2 Ethyimorphine N-demethylation
Ethylmorphine is metabolized in vitro to an N-dealkylated product 
and formaldehyde. The latter product can be reacted with the Nash 
reagent (Nash, 1953) and the intensity of the yellow colour produced may be 
measured spectrophotometrically at 405 nm.
Reagents
2 mM Ethylmorphine in dimethylformamide 
700 mM ZnSO^
320 mM Ba(OH)2 (saturated solution)
2 M Ammonium acetate containing 0.2% (v/v) acetyl acetone
2.3 mM Formaldehyde
66 mM Tris-HCl buffer (pH 7.4)
31.12 mM NADPH in 66 mM Tris-HCl (pH 7.4)
40 mM Glucose-6-phosphate (disodium salt) containing 20 units/ml 
glucose-6-phosphate dehydrogenase in 66 mM Tris-HCl (pH 7.4)
Method
Microsomal suspension (1 mg protein/ml), 66 mM Tris-HCl (pH 7.4), 
glucose-6-phosphate (4.0 mM), glucose-6-phosphate dehydrogenase 
(2 units/ml) and ethylmorphine (2.0 mM) were placed in 10 ml Sovirel tubes 
to give a final incubation voiume of 2.5 mi. The tubes were preincubaied in 
a shaking water bath (120 cycles/min) at 37°C for 5 min. The reaction was 
initiated by addition of NADPH (250 pM) and the incubation continued for 
10 min. Metabolism was terminated by plunging the tubes into ice and
adding ZnSO^ (0.5 ml) and Ba(OH)2 (0.5 ml). After centrifuging the tubes 
at 2,000 rev/min for 10 min, portions (2.0 ml) of the supernatant were 
pipetted into clean tubes. Aliquots (1.0) ml of the freshly prepared mixture 
of acetyl acetone and ammonium acetate were added to each tube and the 
tubes incubated at 37 °C for 30 min. After allowing the tubes to cool to 
room temperature the absorbance of the solutions at 405 nm was deter­
mined. Formaldehyde standards and appropriate blanks were run in parallel.
2.6.3 4-Nitroanisole O-demethylation
Metabolism of 4-nitroanisole by the hepatic microsomal monooxy­
genase results in the formation of the yellow coloured product 4-nitrophenol 
which can be monitored directly in a spectrophotometer cuvette. The 
method used was a modification of that described by Netter and Seidel 
(1964).
Reagents
500 mM 4-Nitroanisole in dimethylformamide 
66 mM Tris-HCl buffer (pH 7.85)
31.12 mM NADPH in 66 mM Tris-HCl (pH 7.85)
Method
The reaction was carried out in the thermostatted cell compartment 
of an Aminco DW-2 dual beam dual wavelength spectrophotometer at 37 °C. 
The instrument was used in the dual wavelength mode with a sample 
wavelength ( A )^ of 420 nm and the reference wavelength (A 2) of 490 nm.
Microsomal suspension (0.5 mg protein/ml in 2.5 ml) was pipetted 
into a cuvette and 4-nitroanisole (200 jiM) added to the microsomes. After 
mixing the cuvette contents they were allowed to equilibrate in the 
spectrophotometer at 37°C for 5 min. After recording a steady baseline, 
the reaction was initiated by the addition of NADPH (250 pM) and the initial
(linear) part of the progress curve was recorded. Values for the amount of 
4-nitrophenoi produced were calculated using an absorption coefficient of
18.5 litre.mmof^.cm”*.
2.6.4 7-Ethoxycoumarin O-deethylation
7-Ethoxycoumarin is metabolized to a single fluorescent product, 
7-hydroxycoumarin (umbelliferone) by the hepatic microsomal monooxy­
genases. The rate of reaction may be measured continuously by recording 
the increase in fluorescence with time. The method used was that of 
Ullrich and Weber (1972).
Reagents
1.0 mM 7-Ethoxycoumarin in 66 mM Tris-HCl (pH 7 A)
1.0 mM 7-Hydroxycoumarin in 66 mM Tris-HCl (pH 7A)
6.2 mM NADPH in 66 mM Tris-HCl (pH 7A)
66 mM Tris-HCl buffer (pH 7A)
Method
Microsomal suspension (1 mg protein/ml in 2.5 mis) was placed in a 
fluorescence cuvette and 7-ethoxycoumarin (100 jiM) added. The contents 
were mixed well by inverting the cuvette several times and were allowed to 
equilibrate at room temperature for 5 min in the cuvette holder of a Hitachi 
Perkin-Elmer MPF-2A spectrophotofluorimeter. NADPH (50 pM) was 
rapidly mixed with contents of the cuvette and the initial increase in 
fluorescence at 450 nm was recorded using an excitation wavelength of 
370 nm. Standards of 7-hydroxycoumarin (0.5 and 1.0 pM) were added to the 
cuvette after the reaction had ceased.
2.6.5 7-Ethoxyresorufin O-deethylation
7-Ethoxyresorufin is metabolized by the hepatic microsomal mono­
oxygenase to a single fluorescent molecule, resorufin. The reaction may be 
monitored directly as a continuous fluorescence assay. The method used 
was a modification of that described by Burke and Mayer (1975).
Reagents
50 pM 7-Ethoxyresorufin in methanol 
10 pM Resorufin in ethanol 
66 mM Tris-HCl buffer (pH 7.4)
31.12 mM NADPH in 66 mM Tris-HCl (pH 6.4)
Method
Microsomal suspension (200 pg protein/ml) was suspended in 66 mM 
Tris-HCl buffer (pH 7.4) to a final volume of 2.5 ml and pipetted into a 
fluorescence cuvette. After the addition of ethoxyresorufin (0.2 pM) the 
cuvette contents were mixed well and allowed to equilibrate at 37 °C in a 
thermostatted cuvette holder. The reaction was initiated by addition of 
NADPH (250 pM) and the time dependent linear increase in fluorescence at 
586 nm was monitored directly using an excitation wavelength of 510 nm. 
Resorufin (0.1 pM) was added at completion of the reaction in order to 
calibrate the measurement.
2.7 SODIUM DODECYL SULPHATE-POLYACRYLAMIDE GEL 
ELECTROPHORESIS
Sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis 
was used as a means of separating microsomal proteins following the 
solubilization of microsomes in buffer containing SDS. The method used 
was that of Laemmli (1970) which utilizes a discontinuous buffer system.
Reagents
Gel stock : 30% (v/v) Acrylamide containing 0.8% (w/v) NN'methyiene bis-
acrylamide (bis)
Buffer 1 : 1.5M Tris-HCl (pH 8.8) containing 0.4% (w/v) SDS
Buffer 2 : 500 mM Tris-HCl (pH 6.8) containing 0.4% (w/v) SDS
Buffer 3 : 25 mM Tris-HCl (pH 8.3) containing 0.1% (w/v) SDS and
192 mM glycine
Buffer 4 62.5 mM Tris-HCl (pH 6.8) containing 2.3% (w/v) SDS, 15%
(v/v) glycerol, 5% (v/v) mercaptoethanol and 0.001% (w/v) 
bromophenol blue
Propan-2-ol/acetic acid/water (25:10:65, by vol) containing 0.05% (w/v) 
Coomassie Blue G-250
Propan-2-ol/acetic acid/water (10:10:80, by vol).
Method
An air-cooled vertical slab gel apparatus was used for these studies 
and electrophoresis was always carried out in a cold-room at 4°C. A glass 
cuvette was used to contain the gel, which had final dimensions of 
120 x 80 mm x 1.5 mm.
The glass cuvette was assembled by clamping perspex spacers 
between the glass plates to form the sides and bottom of the cuvette. The 
gaps between the perspex and glass were sealed by running a warm Agar 
solution (2% w/v) along the edges. The glass cuvette was then clamped in a 
vertical position.
The lower (separating) gel was prepared by mixing Buffer 1 (10 ml), 
gel stock (13.4 ml), water (16.6 ml), ammonium persulphate solution (freshly 
prepared, 10% (w/v), 240 pi) and NjNjNSN’-tetramethyletnylenediamine 
(TEMED, 20pl). The solutions were mixed thoroughly and pipetted into the 
glass cuvette to a height of about 70 mm, using a Pasteur pipette. A layer 
of water (about 5 mm) was carefully introduced above the gel mixture to 
ensure a completely flat interface between the water and the acrylamide 
gel after it had polymerized. When polymerization was complete, the 
water layer was removed and the upper (stacking) gel, consisting of a
mixture of Buffer 2 (2.5 ml), gel stock (1.0 ml), water (6.5 ml), ammonium 
persulphate solution (1096 (w/ y), 60 pi) and TEMED (20 pi) was added to the 
cuvette above the separating gel. A perspex comb was introduced into the 
top of the cuvette to form the sample wells within the stacking gel after 
polymerization had occurred. When the stacking gel had set, the comb was 
carefully removed and a small volume of Buffer 3 introduced into the top of 
the cuvette to ensure separation of the sample wells. The perspex spacer 
was removed from the bottom of the cuvette before clamping the cuvette 
into the electrophoresis apparatus. The upper and lower buffer reservoirs 
were filled to suitable levels with electrode buffer (Buffer 3).
Microsomal suspensions were diluted with sample buffer 
(Buffer 4) to a final concentration of 3 mg microsomal protein/ml. The 
samples were placed in a boiling water bath (2-3 min) prior to application to 
the stacking gel. The amount of microsomal protein typically applied to 
the gel was 15-30 jig. Electrophoresis was carried out using a constant 
current of 20 mA in the stacking gel and this was increased to 40 mA when 
the bromophenol blue tracking dye entered the separating gel. The electro­
phoresis was continued until the tracking dye was within 5 mm of the end of 
the gel.
After the electrophoresis was complete, the cuvette was 
removed from the apparatus and the two halves separated. The stacking 
gel was cut away from the separating gel and the latter immersed overnight 
in a solution which stained for protein (propan-2-ol/acetic acid/water, 
25:10:65, by vol.,. containing 0.05% (w/v) Coomassie Blue G-250). De­
staging of the background gel was achieved by immersion of the gel in a 
mixture of propan-2-ol/acetic acid/water (10:10:80, by vol) for a suitable 
length of time. Gels were stored in 3% (v/v) glycerol at 4°C prior to 
photography.
2.8 PRIMARY HEPATOCYTE CULTURE
2.8.1 Preparation of Culture Flasks
Collagen (acid soluble) was dissolved in water (i mg/ml) and
the solution boiled. When cool, the solution was centrifuged at 2000g for
5 min and the supernatant passed through a 0.22 pm Millipore filter into a
sterile container. Using sterile techniques the collagen solution (0.1 ml per 
225 cm flask) was spread over the culture surface of disposable plastic 
culture flasks (Corning, Stone, Staffs, England) and the capped culture 
vessels incubated at 37°C overnight.
2.8.2 Establishment of Primary Culture
Hepatocytes were isolated under sterile conditions by
collagenase/hyaluronidase (0.0596/0.10% w/v) digestion of EGTA-pretreated
liver slices as described by Fry et al (1976). After washing twice in
phosphate-buffered saline (lacking calcium and magnesium salts) the cells
were resuspended in L-15 medium (Leibovitz, 1963) containing 20% (v/v)
foetal calf serum, 10% tryptose phosphate broth and pencillin (100 units/ml),
counted and diluted to an appropriate cell density.
Portions (2 ml) of the hepatocyte suspension (1 x 10 cells/ml)
were seeded onto the collagen-coated culture surface of disposable piastic
2
culture flasks (25 cm area) and were incubated at 37°C overnight. The 
medium was carefully removed and the culture washed with sterile PBS’A* 
(5 ml) to remove cell debris and unattached cells. The cells were examined by 
light microscopy to confirm that they had attached to the culture surface 
and had become flattened to form a non-confluent monolayer.
The cultures were then incubated with a potential inducer of 
monooxygenase activity in a medium containing fresh L-15 medium, 
tryptose phosphate broth, foetal caif serum and the inducing agent. 
Duplicate cultures were incubated for three days at 37 °C in the complete
L-15 medium containing a range of inducer concentrations (10 p.M - 1 mM), 
without renewal of the culture medium. After incubation with the test 
medium, containing the inducing agent, the culture flasks were shaken 
twice, to remove cell debris, and the medium aspirated off. The cultures 
v/ere washed with PBS'A' (5 ml) before determining the monooxygenase 
activities of the cultured cells.
2.8.3 Estimation of Monooxygenase Activity in Primary Hepatocyte
Cultures
The monooxygenase activity of the cell cultures was 
determined by estimating the rate of metabolism of 7-ethoxycoumarin. 
Ethoxycoumarin is metabolized by the hepatic monooxygenase to 7-hydroxy­
coumarin which is excreted from the cells as the glucuronide or sulphate 
conjugates. The experimental method therefore determines the amount of
7-hydroxycoumarin extracted from the incubation medium following 
hydrolysis of the conjugates using a crude 3-giucuronidase which contains 
some sulphatase activity.
Reagents
140 mM 7-Ethoxycoumarin in dimethylformamide
2.5 mM 7-Hydroxycoumarin in dimethylformamide 
n-Hexane
Diethylether containing 1.5% (v/v) 3-methyl-l-butanol 
200 mM Glycine-NaOH buffer pH 10.4
3-glucuronidase (Type HI, 5 mg/ml) in 200 mM acetate buffer
Method
The cell cultures were washed to remove traces of the 
inducing agent, as previously described, before incubation with L-15 medium 
(4 ml) containing 7-ethoxycoumarin (70 ,uM; 10 j j .1 stock solution/20 ml
medium) at 37°C for 4 hrs. After the incubation the medium was removed 
from the culture flasks and transferred to capped Sovirel tubes. A standard 
of 7-hydroxycoumarin (5 p.M; 10 jul stock solution/5 ml medium) was 
prepared and included with the samples, at which point the samples could be 
stored at -20 °C.
The monolayer cultures were washed with PBS’A’ before 
incubation with crystal violet stain (0.033% (w/v) crystal violet in 100 mM 
citric acid) at 37°C for 1 hr. The cells were then washed off the culture 
surface using a Pasteur pipette and the number of nuclei in the stain were 
counted using an improved Neubauer counting chamber. The number of cells 
in the culture was used to calculate the activity of the monooxygenase.
Suitable volumes of the standard and previously-incubated 
test-medium were diluted with PBS’A' (1:10 v/v) and duplicate samples 
(1 ml) added to crude 3-glucuronidase solution (0.2 ml) before incubation at 
37 °C overnight. The samples were extraced with n-hexane (5 ml) for 5 min 
using a tumble-shaker, the tubes centrifuged at 2,000 rev/min to 
separate the layersA the n-hexane layer discarded. The n-hexane extraction 
was repeated and the organic phase discarded. Similarly, the samples were 
extracted with diethylether containing 1.5% (v/v) 3-methyl-l-butanol (5 ml) 
and samples (1 ml) of the ether-phase back-extracted with glycine-NaOH 
buffer pH 10.4 (5 mis). The extracted ether-phase was discarded and the 
fluorescence of the 7-hydroxycoumarin in the aqueous-phase at 450 nm was 
determined using an excitation wavelength of 370 nm.
The activity of the monooxygenase was calculated by 
comparison of the fluorescence of the samples to that of the standard and to 
the number of cells in the culture.
2*9 COVALENT BINDING STUDIES
/ * 14The apparently irreversible binding (covalent binding) of C-
isosafrole-related material was determined in the subcellular fractions
obtained from isolated hepatocytes incubated in vitro with ^C-isosafrole.
Isolated hepatocytes were obtained from 60-80g male rats by
the method of Fry et al (1976) or from 120-220g male rats by the perfusion
method described in section 2.3.2. The hepatocytes obtained by these
methods were of high viability (>90%), as judged by exclusion of the dye
trypan blue. Hepatocytes obtained by the method of Fry et al (1976) were
suspended in Hank’s based Eagle’s minimal essential medium (approx. 2x10^
14cells/ml) and incubated in 5 ml volumes with 175 jllM C-isosafrole
(0.874 jiCi/ml) for 25 min at 37°C. Hepatocytes obtained by the perfusion
method were suspended in minimal essential medium (approx. 2 x 10
14cells/ml) and incubated in 10 ml volumes with 175 ]iM C-isosafrole
(1.012 pCi/ml) for 30 min at 37°C.
The cells were then sedimented by centrifugation (200gav x
2 min), washed with 1.15% (w/v) KC1 and resedimented. The cell pellet was
homogenized in 20 mM Tris-HCl buffer (pH 7.4) containing 250 mM sucrose
and 5.4 mM EDTA, and the subcellular fractions (nuclear, mitochondrial,
lysosomal, microsomal and cytosol) prepared as described previously.
14The irreversible binding of C-isosafrole-related material to 
these fractions was determined following a sequential extraction with 
aqueous and organic solvents.
2.9.1 Extraction of samples
The various subcellular fractions (5 ml) suspended in 20 mM 
Tris-HCl buffer (pH 7.4) containing 250 mM sucrose and 5.4 mM EDTA were 
pipetted into Sovirel tubes, containing absolute ethanol (10 ml). The
contents of the tubes were mixed and the denatured protein precipitated by 
centrifugation (2,000 rev/min for 10 min). The ethanolic supernatants were 
decanted and saved.
The protein pellets were then extracted sequentially with 5 rnl 
aliquots of the following reagents: 70% (v/v) ethanol, 250 mM Tris-HCl
(pH 7.4) twice, 70% (v/v) ethanol, 96% (v/v) boiling ethanol twice, acetone/ 
chloroform (4:1 v/v) twice and 70% (v/v) ethanol. The extractions were 
carried out using a tumble mixer for 10 min and the protein precipitated by 
centrifugation (2000 rev/min for 10 min) using a bench centrifuge. All 
supernatants were saved and the final protein pellet stored under distilled 
water (4 ml).
2.10 SOLUBILIZATION OF PROTEIN AND SCINTILLATION
COUNTING (DENT AND JOHNSON, 1974)
2.10.1 Preparation of samples
SHT Solubilizer
NaOH 80 g
H20  600 ml
Methanol 300 ml
75% (v/v) Triton X-405 100 ml
tT21 Scintillant
Toluene 1240 ml
Triton X-100 800 ml
Toluene SMI concentrate 360 ml
SMI concentrate consists of a mixture of toluene (2,400 ml) and 
Scintimix SMI (100 g). Scintimix SMI (Koch-Light Ltd., Bucks, England) is 
composed of 91% 2,5-diphenoxazole (PPO) and 9% bis-l,4-di(2-methyl- 
styryDbenzene.
Method
SHT solubilizer (1.0 mi) was added to each of the protein pellets, 
obtained by extraction of the subcellular fractions, and the tubes v/ere 
heated to 60 °C for 2h. Duplicate samples (0.2 mi) of the solubilized 
protein, excess 4.4 M HNO^ (0.1 ml) and water (0.7 ml) were added to the 
scintillation vials followed by addition of the scintillant tT21 (10 ml). The 
vials were mixed thoroughly, using a Vortex mixer,' to obtain an homo­
geneous solution.
Suspensions of the subcellular fractions did not require solubi­
lization, hence, duplicate samples (50 pi) were diluted to 1.0 ml with water 
and added directly to tT21 scintillant (10 mis).
Samples (1 ml) of supernatants from the extraction procedure were 
added directly to tT21 scintillant.
2.10.2 Scintillation Counting
All samples were counted for 4 min with 2% error, using either a
Nuclear Chicago Mk II or an Intertechnique SL40 4K scintillation counter.
Standardization was by an external standard channels ratio method.
Counting efficiencies were calculated by computer; the preexisting quench
14curve being verified for selected samples using C-hexadecane as a 
standard.
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EMENT OF THE ISOSAFROLE METABOLITE-CYTOCHROME P-450
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3.1 INTRODUCTION
Induction of the hepatic microsomal monooxygenase by both natural 
and synthetic MDP-compounds including safrole, isosafrole, piperonyl buto- 
xide and tropital has been widely reported (see Hodgson and Philpot, 1974 
for a review). In particular, isosafrole has been shown to increase both 
hepatic and extrahepatic microsomal cytochrome P-450-mediated activity 
(Parke and Rahman, 1970; Wagstaff and Short, 1971; Lotlikar and 
Wasserman, 1972; Lake et al, 1973; Lake, 1974; Vainio and Parkki, 1976).
The nature of the isosafrole-induced haemoprotein has not been well 
investigated since a proportion of the cytochrome P-450 is present in the 
microsomal preparations as a complex with an isosafrole metabolite. This 
complex is observed spectrally as absorption maxima at 427 nm and 455 nm 
in the reduced minus oxidized difference spectrum (Franklin, 1971, 1972) 
and the cytochrome P-450 compiexed in this way is not metabolically active 
(Dickins, 1978). This isosafrole metabolite - cytochrome P-450 complex 
produced in vivo is relatively stable since it survives the isolation of the 
microsomes, however the addition of certain Type I substrates to the 
oxidized complex results in dissociation of the complex and an apparent 
increase in the cytochrome P-450 content as measured by the magnitude of 
the reduced cytochrome P-450 - carbon monoxide spectrum (Gray and 
Parke, 1973; Elcombe et al, 1976; Dickins, 1978). Dissociation of the 
isosafrole metabolite-cytochrome P-450 complex has been termed "displace­
ment" and this phenomenon, which does not occur under reduced conditions, 
e.g. in the presence of NADPH, is observed as a time dependent intensifi­
cation of the displacer Type I binding spectrum and concomitant decrease in 
the 455 nm absorption maximum of the reduced complex (Elcombe et al, 
1975a). It was therefore possible to arrest the displacement of the complex 
at any time by the addition of NADPH and to simultaneously initiate 
metabolism of the displacing substrate.
The experiments reported in this chapter attempt to investigate 
further the generai pattern of monocxygenase activity induced by isosafrole, 
the nature of the haemoprotein involved in the in vivo isosafrole metabolite 
- cytochrome P-450 complex and to determine whether metabolic compe­
tence changes following displacement of the isosafrole metabolite.
3*2 RESULTS
3.2.1 Comparison of the monooxygenase activities induced by isosafrole 
with those induced by phenobarbitone and 3-methylcholanthrene 
Administration of isosafrole to rats results in a significant induction 
of the hepatic monooxygenase activity. However, a large proportion (40%) 
of the total cytochrome P-450 content of the reduced isosafrole-microsomes 
does not react with carbon monoxide due to the presence of a metabolic 
intermediate complex (Table 3.1). The presence of the complex is 
confirmed by the observation of the characteristic absorption maximum at 
455 nm in the sodium dithionite-reduced minus oxidized difference spectrum 
of isosafrole-induced but not phenobarbitone- or 3-methylcholanthrene- 
induced microsomes. Displacement of this complex results in a decrease in 
the 455 nm absorption maxium, an apparent increase in the cytochrome 
P-450 content and a 0.8 nm - 1.0 nm hypsochromic shift of the reduced carbon 
monoxide absorption maximum.
The metabolic activities of the isosafrole, phenobarbitone- and
3-methylcholanthrene-induced haemoproteins were compared by measuring 
the microsomal ethylmorphine-N-demethylase, biphenyl 2- and 4-hydroxy­
lase and 7-ethoxyresorufin-O-deethylase activities. The results after 
induction of the monooxygenase were compared with those of the micro­
somes from control (saline or sunflower oil treated) animais and are shown 
in Table 3.2. The metabolic activity of the isosafrole-microsomes was
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determined in the presence of the in vivo metabolite complex since the 
substrates were only added to the microsomes after the addition of NADPH. 
Ethylmorphine-N-demethyiase, an enzyme generally associated with cyto­
chrome P-450-mediated monooxygenation was induced by phenobarbitone 
treatment (1 2 0 % increase), slightly induced by isosafrole (46% increase) but 
hardly induced at all by 3-methylcholanthrene (21% increase). Biphenyl
4-hydroxylase, also generally associated with cytochrome P-450-mediated 
monooxygenation, showed a similar pattern of induction with a large 
increase after phenobarbitone treatment (279%), a smaller increase after 
isosafrole treatment (96%) and only a small increase after 3-methylcholan­
threne treatment (34%). Isosafrole therefore induces these cytochrome 
P-450-mediated monooxygenase activities to a lesser extent than phenobarbi­
tone but is better than 3-methylcholanthrene. Biphenyl 2-hydroxylase and 
ethoxyresorufin-O-deethylase are both enzyme activities considered to be 
cytochrome P-448-mediated and both showed large inceases after 3-methyl7  
cholanthrene induction. Biphenyl 2-hydroxylase increased by 1,160% after
3-methylcholanthrene induction and by 442% after isosafrole induction but 
the increase after phenobarbitone induction was quite small (70%). 
Similarly, ethoxyresorufin-O-deethylation showed a marked increase 
(2,650%) after 3-methylcholanthrene induction and a large increase (1,830%) 
after isosafrole induction but only a relatively small increase (2 2 1 %)' after 
phenobarbitone induction. Once again the activities induced by isosafrole 
are between those induced by 3-methylcholanthrene and phenobarbitone but 
this time with respect to cytochrome P-448 induction.
After displacement of the isosafrole complex by incubating the 
microsomes with the substrate before addition of the reduced cofactor, the 
metabolic pattern remained similar to that found before displacement of the 
complex. The activities of biphenyl 2- and 4-hydroxylases and ethoxyreso-
rufin-O-deethylase increased after displacement of the complex but the 
activity of ethyimorphine-N-demethyiase did not. The increases in cyto­
chrome P-448 mediated enzyme activities following displacement were 
similar to the increase in the cytochrome P-450-mediated biphenyl 
4-hydroxylase.
3.2.2. Dissociation of the in vivo isosafrole metabolite - cytochrome P-450 
complex and the concomitant increase in monooxygenase activity 
 ^ The substrates 4-nitroanisole and 7-ethoxycoumarin are both cap­
able of dissociating the cytochrome P-450-metabolic intermediate complex 
when added to oxidized isosafrole-microsomes. However, addition of 
reduced cofactor to a suspension of isosafrole-microsomes containing one of 
these two substrates arrested the displacement process and initiated meta­
bolism of the displacing substrate.
The results of an experiment using 4-nitroanisole as the displacing 
substrate are shown in Fig. 3.1. The isosafrole-microsomes were incubated 
at 37 °C in the presence of 4-nitroanisole for various time periods before the 
addition of NADPH to initiate metabolism. Dissociation of the oxidized 
isosafrole metabolite-cytochrome P-450 complex was measured by the 
decrease in absorption at 438 nm, the wavelength of the absorption 
maximum for the oxidized complex. The results showed that addition of
substrate alone to isosafrole-microsomes resulted in an increasing disso­
ciation of the complex with incubation time (closed circles, Fig. 3.1). 
Addition of reduced cofactor (NADPH) at various times after the addition of 
4-nitroanisole resulted in an increase in the rate of metabolism of the 
4-nitroanisole, the magnitude of which was dependent upon the time of 
preincubation in the presence of substrate alone (open circles, Fig. 3.1). 
The length of time required to produce maximal displacement of the
FIGURE 3.1
Dissociation of the in vivo produced isosafrole metabolite-cytochrome P-450 
complex by 4-nitroanisole and the consequential increase of 4-nitroanisoie-
O-demethylase activity.
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Isosafrole-microsomes (1 mg protein/ml) were suspended in 6 6  mM TrisHCi 
(pH=7.4) and incubated at 37 °C in the presence of 4-nitroanisole (200 yM) 
for various time periods. NADPH (250 yM) was added at various times to 
stop the displacement process and initiate metabolism of the 4-nitroanisole.
q — — Dissociation of the complex as measured by the A A ^g  absor­
bance change.
O O O-demethylation of 4-nitroanisole expressed as % activity at
zero time, i.e. no pre-incubation of the isosafrole-microsomes 
with substrate
4-NA, 4-nitroanisole.
complex was about 30 minutes and resulted in a maximal 2.5 fold increase in 
the activity of 4-nitroanisole-O-demethylase compared with the activity at 
zero time (at which no displacement had occurred).
A similar result was obtained from experiments using 7-ethoxy- 
coumarin as the displacing substrate (Fig. 3.2). As previously demonstrated 
with 4-nitroanisole, displacement of the isosafrole metabolite-cytochrome 
P-450 complex was dependent upon the length of preincubation in the 
presence of 7-ethoxycoumarin alone, and the rate of O-deethylation 
increased in parallel with the displacement process. The length of time to 
produce maximal displacement was about 25 minutes, which is comparable 
with the time taken by 4-nitroanisole. However, the maximal increase in 
7-ethoxycoumarin-O-deethylation was only 35% relative to the activity at 
zero time compared with the 25% observed with 4-nitroanisole.
Incubation of microsomes from control-, phenobarbitone- or
3-methylcholanthrene-treated rats with either substrate for various time 
periods did not show any increase in O-dealkylase activity nor was there any 
time-dependent decrease in the absorbance at 438 nm after addition of the 
substrate.
3.2.3 Time course for the induction of the isosafrole metabolite- 
cytochrome P-450 complex and the concomitant induction and 
activation of biphenyl hydroxylase.
The results presented in Figs. 3.1 and 3.2 have demonstrated that 
the increase in monooxygenase activity after displacement of the isosafrole 
metabolite complex was dependent upon the amount of complex present. 
The time course for the development of the metabolite complex is shown in 
Fig. 3.3. Hepatic microsomes were prepared from rats killed at different 
times after treatment with a single dose of isosafrole (150 mg/kg). The 
presence of an absorbance peak at 455 nm in the sodium dithionite-reduced
FIGURE 3.2
Dissociation of the in vivo produced isosafrole metabolite-cytochrome P-450 
complex by 7-ethoxycoumarin and the consequential increase of 7-ethoxy-
coumarin-O-deethylase activity.
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Conditions as in Fig. 3.1, except that the substrate was 7-ethoxycoumarin 
(200 yM).
▲ A Dissociation of the complex
A---------A O-deethylation of 7-ethoxycoumarin.
The relationship between biphenyl 4-hydroxylase activity, appearance of the 
isosafrole metabolite-cytochrome P-450 complex and dissociation of the 
complex after administration of a single dose of isosafrole to rats.
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A— A Biphenyl 4-hydroxylase activity before dissociation of the complex 
by biphenyl.
0 — 'o Biphenyl 4-hydroxylase activity after dissociation of the complex 
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Displacement was effected by incubation of isosafrole-microsomes (1 mg 
protein/ml) with biphenyl (1 mM) at 37° for 30 minutes.
Results for 4-hydroxylation are expressed as % of values obtained with 
microsomes from control (oil dosed) rats killed at the corresponding time 
points.
minus oxidized difference spectrum was initially observed 8  hrs after 
administration of the isosafrole and this gradually increased with time 
(Fig. 3.3).
The activity of biphenyl 4-hydroxylase was determined at different 
times after the single isosafrole dose. Initially, an inhibition of biphenyl 
4-hydroxylation was seen with the most marked inhibition evident at 4 hrs 
after isosafrole treatm ent. At the same time a transient activation of 
biphenyl 2 -hydroxylase was observed which was maximal at 2  hrs followed 
by a decrease to control activity at 4 hrs. After this time an increase in 
both biphenyl 2- and 4-hydroxylase was observed and an increasingly marked 
induction was evident after 12, 24 and 48 hrs. Since biphenyl is a good 
displacing substrate, the effect of displacement on the activity of biphenyl 
4-hydroxylase was measured in the microsomes (obtained at the various time 
points after dosing with isosafrole) by preincubating them with biphenyl 
alone at 37 °C for 30 minutes prior to initiation of the hydroxylation 
reaction with NADPH. A greater increase in the activity of biphenyl
4-hydroxylase was observed after displacement of the complex from micro­
somes obtained 12 hrs or later after the isosafrole treatm ent. The 
magnitude of the increase in 4-hydroxylation after displacement was always 
dependent upon the original amount of isosafrole P-450 complex present.
The time dependent formation of the isosafrole metabolite-cyto­
chrome P-450 complex and change in biphenyl 4-hydroxylase activity were 
also investigated after administration of two different single doses of 
isosafrole (150 mg/kg and 300 mg/kg). A comparison of the time course for 
the formation of the metabolite complex is shown in Fig. 3.4. With the 
high dose isosafrole (300 mg/kg) a small concentration of in vivo metabolite 
complex was present in the microsomes obtained only 4 hrs after the 
isosafrole treatment. Although the absorbance change A A^^^ ^  not
FIGURE 3.4
Time course for the production of the reduced 455 nm absorbance maximum 
after administration of two different dose levels of isosafrole
^ 4 5 5 -4 9 Q /m g  protein 
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Isosafrole microsomes (1 mg protein/ml) in 6 6  mM Tris-HCL (pH=7.4) from 
rats killed at different times after pretreatment with isosafrole (©— © > 
150 mg/kg; O— O > 300 mg/kg) were divided equally between two cuvettes. 
Sodium dithionite (1-2 mg) was added to the sample cuvette and the 
absorbance change A ^ q  was recorded.
show a significant increase, the presence of the complex was indicated by a 
narrowing of the 427 nm absorbance maximum due to reduced cytochrome b^ 
and the presence of a shoulder at 455 nm in the sodium dithionite reduced 
difference spectrum. Further evidence for the existence of metabolite 
complex at this 4 hr time point was the detection of substrate-elicited 
dissociation, i.e. a time dependent increase in the Type I binding spectrum 
of the displacing substrate and a bathochromic shift of the trough of the 
binding spectrum from 420 nm to 438 nm. Microsomes prepared from 
animals pretreated with phenobarbitone or 3-methylcholanthrene for varying 
time periods produced a broad 425-427 nm absorption maximum due to 
reduced cytochrome b^ but did not display a shoulder at 455 nm in the 
sodium dithionite-reduced difference spectrum. Furthermore, these types 
of microsomes failed to show any time dependent intensification or spectral 
shift of the binding spectrum following addition of a displacing substrate.
Not only did the higher dose level of isosafrole (300 mg/kg) produce 
an in vivo metabolite complex at an earlier time period than the lower dose 
(150 mg/kg), it also increased the amount of isosafrole metabolite-cyto­
chrome P-450 complex present in the microsomes at the later time points. 
The magnitude of the 455 nm peak height at 8  hrs, 12 hrs and 24 hrs was 
65%, 85% and 40% higher, respectively, for animals treated with 300 mg/kg 
isosafrole than for those which were given 150 mg/kg isosafrole (Fig. 3.4).
The time course of biphenyl 4-hydroxylase activity in rat hepatic 
microsomes after a single dose of 300 mg/kg isosafrole showed a similar 
pattern to that observed after administration of 150 mg/kg isosafrole 
(Fig. 3.5). Up to 8  hrs after administration of the isosafrole biphenyl,
4-hydroxylase was inhibited compared with control, but after this time period 
a marked induction was apparent. However, at the higher dose level the 
inhibition of biphenyl 4-hydroxylation was maximal at 2  hrs but the
FIGURE 3.5
Time course of biphenyi 4-hydroxylase activity after administration of two
different dose levels of isosafroie.
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Biphenyl 4-hydroxylase activity was determined (as described in Methods) 
using microsomes from rats killed at different times after pretreatment
with isosafroie (A— A,  150 mg/kg;▲ A , 300mg/kg). Results are
expressed as % of values obtained with microsomes from control (oil dosed) 
rats killed at corresponding time points.
percentage inhibition compared with control was smaller (2 0 % at 2  hrs) than 
that noted for the lower dose level (40%). The subsequent induction of 
activity was greater for the higher dose at 12 hrs (90%) and 24 hrs (220%) 
compared with the corresponding time points for the lower dose (2 0 % and 
95% respectively).
The absence of any MDP metabolite-cytochrome P-450 complex at 
the early time points following a single dose of isosafroie and the lack of 
any displacement in these microsomes was further investigated. Although 
isolation of the microsomes at temperatures as near to 4°C as possible 
should prevent displacement of any metabolite complex present, the micro­
somes were routinely isolated in the "oxidized” state and therefore low 
concentrations of isosafroie present in the microsomal lipid may have 
displaced very small amounts of metabolite complex before they could be 
detected. Microsomes were therefore isolated in the presence of NADH 
to maintain a reduced state throughout the isolation procedures and the 
biphenyl 2- and 4-hydroxylase activities, cytochrome P-450 concentrations 
and redox spectra were determined on the freshly isolated microsomes. The 
results (Table 3.3) show an initial inhibition of biphenyl 4-hydroxylase 
activity followed by an increase relative to control after 8  hrs. An increase 
in biphenyl 4-hydroxylase activity due to displacement was first observed 
after 8-12 hrs. Biphenyl 2-hydroxylase, however, showed an initial increase 
in activity at 2  hrs but this declined before increasing again at 8 - 1 2  hrs. 
Following incubation with substrate an increase in biphenyl 2-hydroxylase 
activity due to displacement was first observed after 1 2  hrs, which also 
corresponds to the time point at which the cytochrome P-450 concentration 
was shown to increase following incubation of the microsomes with a 
displacer. This lack of displacement at the early time points even after 
isolation of the microsomes in the "reduced" state together with the lack of
Table 3.3. Time course for biphenyl 2-and 4-hydroxylase activities of rat hepatic microsomes 
isolated in the presence of NADH following administration of isosafroie
Time after dose
Biphenyl 4-hydroxylase 
(nmoles/min/mg)
Biphenyl 2-hydroxylase 
(nmoles/min/mg)
Cytochrome P-450 Concn. 
(nmoles/mg protein)
Control Isosafroie Control Isosafroie Control Isosafroie
No preincubation 
hr
2 2.25 1.68 0.17 0.41 0.82 0.89
4 2.34 1.73 • 0.16 0.22 0.78 0.80
6 1.32 1.34 0.25 0.37 0.86 0.90
8 1.94 2.04 0.24 0.41 0.84 0.94
12 2.14
i
3.95 ' 0.27 0.78 0.85 0.92
Preincubation
hr
2 1.79 1.56 0.12 0.36 0.78 0.90
4 2.32 1.71 0.14 0.25 0.76 0.81
* 6 1.45 1.39 0.25 0.38 o . e 7 0.92
8 1.91 2.21 0.25 0.46 0.86 0.99
12 2.10 4.56 0.26 0.98 0.85 1.04
Microsomes were prepared in the presence of NADH at various times following administration of 
isosafroie (150 mg/kg) or corn oil. Biphenyl hydroxylase activities were determined before 
and after preincubation with the substrate for 30 mins at 37°C. Cytochrome P-450 concentrations 
were determined before and after incubation of the microsomes with 2-heptyl-benzimidazole (250 yM) 
for 30 minutes at 37°C.
any apparent 455 nm complex before the 8  hr time point in the redox 
difference spectra is in agreement with results previously reported in this 
chapter.
It was also possible that the methodology used in these experiments 
was the reason for the apparent absence of any metabolite-complex in the 
redox spectra at the early time points since it would remain undetected in a 
reduced minus oxidized difference spectrum if it were trapped in the 
reduced state in vivo. This hypothesis was tested by means of "off-balance" 
difference spectra with isosafroie microsomes in the sample cuvette and 
control microsomes of an identical protein concentration in the reference 
cuvette (Fig. 3.6). The results demonstrate that the MDP metabolite- 
cytochrome P-450 complex is not present in the microsomes in either an 
oxidized or reduced state at 2 hrs or 4 hrs, microsomes obtained 24 hrs after 
isosafroie were included as a comparison.
3.2.4 Comparison of the spectral properties and monooxygenase activities 
of rat hepatic microsomes from animals treated with isosafroie, 
phenobarbitone-isosafrole and 3-methylcholanthrene-isosafrole 
before and after dissociation of the MDP-metabolite complex 
Groups of three animals were treated for three days with either 
phenobarbitone, 3-methylcholanthrene or the vehicles saline or corn oil, on 
the fourth day they were all treated with a single dose (150 mg/kg) of 
isosafroie. The animals were killed 24 hrs after treatment with isosafroie 
and hepatic microsomes were prepared. The cytochrome P-450 concent­
ration, Amax of the reduced carbon monoxide spectrum and the magnitude 
of the 427 nm and 455 nm absorption maxima in the sodium dithionite 
reduced difference spectra were all determined before and after displace­
ment of the isosafroie metabolite-cytochrome P-450 complex (Table 3.4).
FIGURE 3.6
"Off-balance" difference spectra of microsomes obtained at different times 
after a single dose of isosafroie compared with control microsomes.
(A )
(B> (K tt A
*10MO
Microsomes prepared at 2 hr, 4 hr and 24 hr after a single dose of isosafroie 
(150 mg/kg, I.P.) were suspended (2 mg/ml) in Tris-HCl buffer (pH 7.4) and 
placed in the sample cuvette. Microsomes prepared from control (sun­
flower oil) dosed rats killed at similar time intervals were suspended in 
buffer, as above, and placed in the reference cuvette. After recording the 
spectrum between 350-500 nm without baseline correction (A), a baseline of 
equal light absorbance was established, sodium dithionite ( 1 - 2  mg) added to
both cuvettes and the spectrum rerecorded: 0 ---------0 , 2  hrs post
dose; , 4 hrs post d o se ;---------- 24 hrs post dose.
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The apparent cytochrome P-450 content of the microsomes prepared 
after induction with the oil-isosafrole, saline-isosafrole and 3-methylcho- 
lanthrene-isosafrole mixed-inducing combinations shewed increases of 27%, 
39% and 14% respectively compared with controls treated with oil, saline or 
3-methylcholanthrene alone (Table 3.1), even before displacement of the 
metabolite complex. In contrast, the phenobarbitone-isosafrole combi­
nation decreased the cytochrome P-450 content by 21% compared with 
induction by phenobarbitone alone, (Table 3.1). Displacement of the 
metabolite complex resulted in increases in the cytochrome P-450 content 
which varied in magnitude between the different inducing combinations. 
Saline-isosafrole and oil-isosafrole microsomes showed increases in the 
cytochrome P-450 content of 22% and 28% respectively after displacement. 
Similarly, phenobarbitone-isosafrole and 3-methylcholanthrene-isosafrole 
microsomes showed increases of 29% and 67% respectively. These figures 
for the percentage increase in cytochrome P-450 content after displacement 
represent the proportion of the total cytochrome P-450 pool which is 
unreactive towards carbon monoxide before dissociation of the complex and 
therefore the proportion of the haemoprotein which is bound in the form of 
the metabolite complex. The phenobarbitone-isosafrole treatment combi­
nation showed a similar proportion of the haemoprotein to be complexed 
with the isosafroie as did the control treatments (saline-isosafrole and oil- 
isosafrole). In contrast, treatment with 3-methylcholanthrene-isosafrole 
showed a twofold increase in the proportion of haemoprotein complexed 
with the isosafroie metabolite compared with control (oil-isosafrole trea t­
ment). After induction with either 3-methylcholanthrene-isosafrole or 
three consecutive doses of isosafroie the proportion of the total cytochrome 
P-450 which is isolated as metabolite complex is the same (40%) (Tables 3.1 
and 3.4). The total inductive effect of the 3-methylcholanthrene-isosafrole
combination on cytochrome P-450 content was more than additive when 
compared with induction by oii-isosafroie and 3-methylchoianthrene alone 
(Table 3.1 and 3.4). In contrast, however, the phenobarbitone-isosafrole 
combination produced a similar induction of cytochrome P-450 content to 
that produced by phenobarbitone alone.
The wavelength maxima of the reduced carbon monoxide spectra 
before displacement were similar to those obtained after administration of 
each inducing agent alone. After administration of phenobarbitone- 
isosafrole and 3-methylcholanthrene-isosafrole the wavelengths of the 
carbon monoxide absorption peaks were at 450.5 nm and 448.5 nm respec­
tively, approximately the wavelengths observed after administration of 
phenobarbitone or 3-methylcholanthrene alone and with the characteristic 
2 nm difference between the maxima of the induced haemoproteins. The 
wavelengths of the reduced carbon monoxide maxima of the microsomes 
from saline-isosafrole and oil-isosafrole treated animals showed a slight 
hypsochromic shift compared with control microsomes (Table 3.1) similar to 
that observed after administration of isosafroie alone. Displacement of the 
isosafroie metabolite-cytochrome P-450 complex resulted in a 0.7-1.0 nm 
hypsochromic shift of the reduced carbon monoxide absorption peak in all of 
the microsomal preparations.
Substrate-elicited dissociation of the isosafroie metabolite-cyto­
chrome P-450 complex was observed in the microsomes from saiine-isosaf- 
role, oil-isosafrole, phenobarbitone-isosafrole and 3-methylcholanthrene 
treated rats as a time dependent increase in the magnitude of the Type I 
binding spectrum produced by 2-heptylbenzimidazole. The largest increase 
in the binding spectrum was observed with 3-methylcholanthrene-isosafrole 
microsomes and since the magnitude of the increase in displacer binding 
spectrum is proportional to the amount of isosafroie metabolite-cytochrome
P-450 complex present in the microsomes, this result correlates with the 
larger proportion of complexed cytochrome in these microsomes.
The sodium dithionite-reduced difference spectra of the microsomes 
from animals treated with the mixed inducers all showed the presence of the 
characteristic absorption maximum at 455 nm, but after incubation of the 
microsomes with the displacer 2-heptylbenzimidazole at 37 °C for 
30 min the 455 nm peaks were no longer present in the reduced spectrum. 
The changes in the absorbance values A anc* A^ 4 5 5 . ^ 9 0  a*ter
displacement of the isosafroie metabolite complex are shown in Table 3.4. 
Displacement of the metabolite complex decreased the AA^^ value by 
varying amounts, the decrease in the 4 9 q value was greatest for the
3-methylcholanthrene-isosafrole microsomes which was about six-fold larger 
than the absorbance change in the control (oil-isosafrole) microsomes. In 
contrast, the decrease in the AA ^ ^ _ ^ g  for the phenobarbitone-isosafrole 
microsomes was less than half that of the saline-isosafrole microsomes.
The activities of 7-ethoxycoumarin-O-deethylase and biphenyl 2- 
and 4-hydroxylase were determined for each of the microsomal preparations 
before and after displacement of the isosafrole-metabolite cytochrome 
P-450 complex (Table 3.5) in an attempt to see whether the haemoprotein 
released from the complex was metabolically more similar to that induced 
by either 3-methylcholanthrene or phenobarbitone alone. Ethoxycoumarin- 
O-deethylation was induced to a similar extent before displacement by both 
3-methylcholanthrene-isosafrole treatment (796) and phenobarbitone-isosaf­
role treatment (6 %) when compared with their respective controls (oil- 
isosafrole and saline-isosafrole). After displacement of the metabolite 
complex the O-deethylase activity for oil-isosafrole and saline-isosafrole 
microsomes increased by 11% and 13% respectively, but the activities for
3-methylchoianthrene-isosafrole and phenobarbitone-isosafrole microsomes 
increased by 104% and 35% respectively.
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Biphenyl 4-hydroxylase activity was similar before displacement for 
the oil-isosafrole, 3-methylchclanthene-isosafrole and saline-isosafrole 
microsomes but was somewhat higher in the phenobarbitone-isosafrole 
microsomes, the activities in 3-methylcholanthrene-isosafrole and pheno­
barbitone-isosafrole microsomes being 11% and 37% of their respective 
controls. After displacement, the 4-hydroxylase activity increased in all of 
the microsomal preparations by 6 - 8 %.
Biphenyl 2-hydroxylase activity was similar before displacement in 
the control (oil-isosafrole and saline-isosafrole) microsomes but 3-methyl- 
cholanthrene-isosafrole and phenobarbitone-isosafrole treatments increased 
the activity by 144% and 54% respectively compared with their relevant 
controls. Displacement of the isosafroie metabolite complex resulted in an 
increase in the 2 -hydroxylase activity of all the microsomal preparations but 
the activity for 3-methylcholanthrene-isosafrole microsomes increased by 
1,423% compared with oil-isosafrole activity in contrast to a much smaller 
increase in activity of 109% for phenobarbitone-isosafrole microsomes 
compared with saline-isosafrole activity. This is similar to the pattern of 
biphenyl 2 -hydroxylase induction which was observed after treatm ent of the 
animals with 3-methylcholanthrene and phenobarbitone alone (Table 3.2).
3.3 DISCUSSION
Although the induction of hepatic drug metabolizing enzymes by 
safrole and isosafroie is well documented, the pattern of induction for the 
cytochrome P-450-mediated reactions following isosafroie treatment has 
not been well investigated. Evidence from the literature suggests that the 
general pattern of metabolism induced by isosafroie is similar to that 
induced by the carcinogen, 3-methylcholanthrene, however isosafroie also 
induces some of the enzyme activities induced by phenobarbitone treatm ent
(Hodgson and Philpot, 1974). In general, however, little consideration has 
been given to the presence of the in vivo produced isosafroie metabolite- 
cytochrome P-450 complex, although certain Type I binding substrates have 
been shown to dissociate the complex with a resultant increase in cyto­
chrome P-450 concentration and substrate binding (Gray and Parke, 1973; 
Elcombe et al, 1975a) and possibly metabolic activity.
Parke and Rahman (1970) reported an increase in microsomal 
cytochrome P-450 content and biphenyl 2- and 4-hydroxylase activities 
following administration of safrole and isosafroie to rats. This they 
attributed to the induction of microsomal haemoprotein since inhibition of 
de novo protein synthesis by actinomycin D prevented these increases. A 
similar increase in biphenyl hydroxylase activity was seen by Lake (1974) 
who compared the induction pattern of isosafroie to that of the classical 
inducers phenobarbitone and 3-methylcholanthrene (Table 3.5). Biphenyl
4-hydroxylase, an enzyme typically induced by phenobarbitone, was induced to 
a similar extent by isosafroie but 3-methylcholanthrene only produced a 
slight increase (Table 3.5). In contrast biphenyl 2-hydroxylase, an enzyme 
typically induced by 3-methylcholanthrene, was also markedly increased by 
isosafroie but to a lesser extent by phenobarbitone-induction (Table 3.5). 
Isosafroie also induced acetanilide- and benzo(a)pyrene hydroxylases, both 
enzymes preferentially induced by 3-methylcholanthrene but only slightly 
increased by phenobarbitone (Table 3.6). Vainio and Parkki (1976) observed 
a marked increase in benzo(a)pyrene hydroxylase activity after induction 
with isosafroie and also a potent induction of 4-nitroanisole O-demethylase 
activity similar to that previously reported by Wagstaff and Short (1971).
The present work has shown a similar pattern of increases in enzyme 
activity following isosafroie induction. Enzyme activities typically induced 
by phenobarbitone, such as ethylmorphine-N-demethylase and biphenyl-4-
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hydroxylase, were both increased by isosafroie treatment to a greater 
extent than 3-methylcholanthrene induction but to a lesser extent than 
phenobarbitone induction (Table 3.2). Biphenyl 2-hydroxyiation and 
7-ethoxyresorufin-O-deethylation were both preferentially induced by 
3-methylcholanthrene and also showed a potent induction by isosafroie.
Displacement of the isosafroie metabolite-cytochrome P-450 
complex present in the isosafrole-microsomes was demonstrated by a 
decrease in the absorbance peak at 455 nm in the redox difference spec­
trum, a slight hypsochromic shift in the  ^max of the reduced-carbon 
monoxide spectrum and an increase in the cytochrome P-450 concentration 
which showed about 40% of the total cytochrome P-450 pool to be com­
plexed with the isosafroie metabolite (Table 3.1). Dissociation of this 
complex released a haemoprotein which was metabolically competent since 
increases were observed in the activity of biphenyl 2- and 4-hydroxylase and 
7-ethoxyresorufin-O-deethylase following preincubation of the isosafroie 
microsomes with the substrate alone (Table 3.2). No increase was observed 
with ethylmorphine-N-demethylase following preincubation with the subs­
trate  since the substrate ethylmorphine does not displace the isosafrole- 
metabolite complex (Elcombe, 1976; Dickins, 1978). The cytochrome 
P-450 species which was released after displacement of the isosafrole- 
metabolite was able to mediate both cytochrome P-450 and cytochrome 
P-448 type metabolism since biphenyl 2- and 4-hydroxylase and 7-ethoxy- 
resorufin-O-deethylase were all increased to a similar extent after displace­
ment. However, the activity of the isosafrole-induced haemoprotein never 
exceeded that of the haemoproteins induced by either phenobarbitone or 
3-methylcholanthrene in the enzyme assays investigated.
The increase in metabolic activity of the isosafroie microsomes 
following dissociation of the in vivo produced isosafroie metabolite-cyto-
chrome P-450 complex by 4-nitroanisole and 7-ethoxycoumarin was shown to 
be proportional to the amount of the complex displaced (Figs. 3.1 and 3 .2 ). 
Following displacement of the complex with 7-ethoxycoumarin the increase 
in metabolic activity was relatively small (3596) compared with the increase 
in cytochrome P-450 content of about 100% (Fig. 3.2) and therefore 
7-ethoxycoumarin does not appear to be metabolized to any great extent by 
the released haemoprotein. In contrast, a 2.5 fold increase in the activity 
of 4-nitroanisole-O-demethylase was observed following complete displace­
ment of the isosafrole-metabolite from the in vivo complex by 4-nitro­
anisole, therefore this substrate appears to be particularly well metabolized 
by the released haemoprotein. Since 4-nitroanisole is a good displacing 
substrate and is a good substrate for the released haemoprotein, this may 
lead to errors in the determination of 4-nitroanisole-O-demethylase activity 
following isosafroie induction. Many in vitro enzyme assays include a 
preincubation of the microsomes with substrate at 37 °C before initiation of 
metabolism with reduced cofactor, however it can be seen from Fig 3.1 that 
a 5 minute preincubation with 4-nitroanisole results in displacement of the 
metabolite complex and a consequent increase in O-demethylase activity of 
1 0 0 % compared with the activity when metabolism was initiated by the 
addition of substrate or when NADPH was added immediately after the 
substrate. Although isosafroie is a potent inducer of 4-nitroanisole-O- 
demethylation, this may not be true for other MDP compounds since 
Wagstaff and Short (1971) have reported that safrole is less effective than 
isosafroie at inducing this activity in the rat.
Biphenyl 4-hydroxylation was also increased following dissociation 
of the isosafrole-metabolite complex with biphenyl (Table 3.2 and Fig. 3.3). 
However, the time course for the induction of biphenyl 4-hydroxylase 
following a single dose of isosafroie initially showed an inhibition which was
maximal at 4 hrs followed by induction (Fig. 3.3). There was little spectral 
evidence for the presence of the cytochrome P-450-metabolite complex 
before the 8  hr time point and a measurable increase in biphenyl-4- 
hydroxylation following preincubation of the microsomes with biphenyl was 
first evident 12 hrs after the isosafroie dose. A similar inhibition of 
biphenyl-4-hydroxylase activity has been reported in mice following admini­
stration of piperonyl butoxide in vivo (Jaffe et al, 1969) or treatm ent of 
mouse hepatic microsomes with piperonyl butoxide in vitro (Epstein et al, 
1970). However, in vivo the mouse hepatic bipheny 1-4-hydroxylase activity 
returned to control levels by 24 hrs but no induction of this enzyme was 
detected (Jaffe et al, 1969). These authors also observed a dose dependent 
activation of biphenyl 2 -hydroxyiase activity concomitant with the inhibi­
tion of biphenyl 4-hydroxylase during the first hour after administration of 
the piperonyl butoxide. This they interpreted as an isozymic transfor­
mation which resulted in the preferential hydroxylation of the substrate in 
the 2-position. My results have also detected a transient dose-dependent 
stimulation of biphenyl 2 -hydroxylase 2  hrs after the administration of 
isosafroie. Although Tong et al (1977) have recently demonstrated the 
formation of fluorescent MDP-metabolites which could interfere with the 
fluorimetric measurement of 2 -hydroxybiphenyl, these probably did not 
interfere in my experiments since a substrate blank was always included for 
each microsomal preparation.
A dose-dependency for the formation of the in vitro metabolite- 
complex, as estimated by the size of the 455 nm absorbance maximum, has 
been demonstrated following administration of 150 mg/kg and 300 mg/kg 
isosafroie to rats (Fig. 3.4). A similar dose-dependency for the formation 
of the in vivo complex has been demonstrated following administration of 
500 mg/kg and 1000 mg/kg piperonyl butoxide to rats (Franklin, 1976a).
Induction of biphenyl 4-hydroxylase was also shown to be dose-dependent 
(Fig. 3.5) although the initial inhibition during the first 8  hrs was decreased 
at the higher dose level (300 mg/kg). The reason, for the decreased 
inhibition is unknown but it is possible that enzyme induction occurs at an 
earlier time following the higher dose of isosafroie.
Administration of a single dose of isosafroie to rats following 
pretreatment with phenobarbitone, 3-methylcholanthrene or the vehicles oil 
and saline resulted in the formation of the in vivo isosafroie metabolite- 
cytochrome P-450 complex. The 3-methylcholanthrene-isosafrole combi­
nation induced cytochrome P-450 to a much greater extent than phenobarbi­
tone-isosafrole, furthermore a larger proportion (40%) of the 3-methyl- 
cholanthrene-isosafrole induced haemoprotein was present in the isosafrole- 
metabolite complex, as seen by the increase in cytochrome P-450 concent­
ration after displacement, compared with the oil-isosafrole (2 2 %), saline- 
isosafrole (18%) and phenobarbitone-isosafrole (2 2 %) induced haemoproteins. 
The presence of a larger absorption peak at 455 nm in the redox difference 
spectrum of 3-methylcholanthrene-isosafrole microsomes, which could be 
displaced by incubation of the microsomes with a displacer, confirmed the 
presence of a larger proportion of isosafroie metabolite-cytochrome P-450 
complex in these microsomes compared v/ith the microsomes from the other 
inducing combinations* Thus a form of cytochrome P-450 which binds the 
isosafroie metabolite in vivo appears to be preferentially induced by 
3-methylcholanthrene-isosafrole treatment, although an increase in the rate 
of metabolism to the complex-forming metabolite may be a contributing 
factor. Recently, Fennell et al (1979) have reported similar results and 
have correlated the in vivo formation of the displaceable isosafrole- 
metabolite complex with the extent of induction of a specific apoprotein by 
comparison of the electrophoretic mobilities of the microsomal proteins
using sodium dodecylsulphate-polyacrylamide gei electrophoresis. These 
authors observed an increase in a band of 53,000 molecular weight following 
administration of isosafroie to rats and this was also the major band induced 
after 3-methylchoianthrene-isosafrole treatment. This band was also 
slightly induced after administration of oil-isosafrole, phenobarbitone-isosa-
i
frole and 3 -methylchoianthrene alone, although the major bands induced by 
phenobarbitone-isosafrole and 3-methylcholanthrene treatments were at 
50,000 and 55,000 molecular weight respectively. The authors concluded 
that the isosafrole-induced band may be the same gene product as the minor 
band induced by 3 -methylcholanthrene.
Comparison of the monooxygenase activities of the microsomes 
from the rats treated with the mixed-inducing combinations before and 
after displacement of the isosafrole-metabolite complex showed the 
released haemoprotein to have high biphenyl 2 -hydroxylase activity and to a 
lesser extent 7-ethoxycoumarin-O-deethylase activity. Biphenyl 2-hydroxy­
lase, an enzyme generally associated with cytochrome P-448 activity, 
showed a dramatic increase in activity following displacement of the 
isosafrole-metabolite complex from the 3-methylcholanthrene-isosafrole 
induced microsomes which was not observed in either phenobarbitone- 
isosafrole or control microsomes (Table 3.5). Ethoxycoumarin-O-deethyl- 
ase, an enzyme generally considered to be both cytochrome P-450 and 
cytochrome P-448 mediated, also showed a considerable increase following 
displacement of the metabolite-complex from 3-methylcholanthrene-isosaf- 
role microsomes and to a lesser extent phenobarbitone-isosafrole micro­
somes. In contrast, biphenyl 4-hydroxylase activity, which is cytochrome 
P-450 mediated, although higher in phenobarbitone-isosafrole microsomes 
showed similar small increases in ail of the microsomes following displace­
ment of the metabolite complex. These results indicate that the haemo-
protein released from the isosafrole-metabolite complex following 
3-methylchoianthrene-isosafroie induction shows enzyme activities which are 
similar to those generally associated with cytochrome P-448 induction. 
These results are therefore in agreement with the hypothesis of Fennell et 
al (1979) that the haemoprotein induced by isosafroie and involved in the in 
vivo isosafrole-metabolite complex may be a gene product usually found to a 
small extent after 3-methylcholanthrene induction.
In summary, isosafroie induces a haemoprotein which exhibits 
enzyme activities distinct from those induced by either phenobarbitone or 
3-methylcholanthrene. In vivo isosafroie metabolite-cytochrome P-450 
complex was not observed until 4-8 hrs after administration of isosafroie. 
The amount of isosafroie metabolite complex in the microsomes and the 
associated monooxygenase activities were shown to increase with time 
following an initial 4 hr lag-phase which is compatible with the hypothesis 
that de novo synthesis of haemoprotein may occur and result in the 
formation of further isosafrole-metabolite complex. The in vivo isosafrole- 
metabolite complex is metabolically inactive but displacement of the 
complex results in an increased metabolic activity which shows some 
similarity to that induced by 3-methylcholanthrene.
There remains, however, one important question which is as yet 
unanswered, why is the isosafrole-metabolite complex not observed at times 
shorter than 4 hrs following isosafroie treatment in vivo when isosafroie 
readily forms the metabolite-complex in vitro? Although isosafroie has 
been shown to form a maximal metabolite-complex spectrum within 
10-15 min in vitro, the complex does not dissociate in the presence of 
compounds known to be active displacers of the in vivo complex (Elcombe, 
1976; Dickins, 1978). In my experiments the metabolite complex which 
was found in vivo was always displaceable even when isolated in low concen­
trations ( 8  hrs) and therefore the haemoprotein which forms the complex in 
vivo is probably the result of de novo protein synthesis. It is possible that 
the metabolite complex was not seen at the early time points for two 
reasons. Firstly, although the in vitro generated 427/455 nm reduced 
complex readily reverts to a 438 nm oxidized complex upon removal of the 
reducing conditions (Elcombe, 1976), the in vivo complex may have been 
trapped in the reduced state. This would not be displaceable since the 
metabolite-complex is only displaceable when in the oxidized state 
(Elcombe, 1976), and would also be undetected as the 427/455 nm complex 
since these characteristic peaks are only observed in a reduced minus 
oxidized difference spectrum. This was investigated by means of an "off- 
balance" spectrum comparing oxidized control-microsomes with the "oxidized" 
isosafrole-microsomes obtained 1  to 2  hrs after administration of isosafroie, 
no characteristic absorbance peak was noted at 455 nm (Fig. 3.6). Secondly, 
since the microsomes are isolated in the oxidized state any isosafroie which 
was present in the microsomal lipid would be able to displace small amounts 
of metabolite complex before the spectral investigations could identify it. 
Although the microsomes are isolated at temperatures as near as possible to 
4°C, a temperature at which displacement should not take place (Dickins, 
1978), this possibility was excluded by addition of NADH to the homo­
genizing medium and again before subsequent centrifugation steps so that a 
reduced state was maintained throughout the preparation of the micro­
somes. No characteristic 455 nm absorption maximum was observed at the 
early time points nor was there any sign of displacement either spectrally or 
as increased metabolic activity following preincubation with substrate 
(Table 3.3).
The formation of the isosafroie metabolite-cytochrome P-450 
complex in vivo and in vitro will be discussed further in later chapters.
CHAPTER 4
INVESTIGATION OF THE NATURE OF THE MICROSOMAL HAEMO- 
PROTEIN INDUCED BY THE METHYLENEDIOXYPHENYL COMPOUNDS
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4.1 INTRODUCTION
It is now generally accepted that the multiple monooxygenase 
activities of liver microsomes are due to several distinct forms of cyto­
chrome P-450. Evidence to support this hypothesis includes studies 
involving the use of sodium dodecyl sulphate (SDS) - polyacrylamide gel 
electrophoresis to separate the various cytochrome P-450 species by nature 
of their differing molecular weights (Alvares and Siekevitz, 1973; Welton 
and Aust, 1974). Studies involving purification of the haemoproteins also 
use SDS-gel electrophoresis to determine the molecular weights of the 
purified cytochrome P-450 species (Haugen and Coon, 1976; Ryan et al, 
1977).
Phenobarbitone and 3-methylcholanthrene are both microsomal 
enzyme inducers which preferentially induce haemoproteins of different 
molecular weights (Welton and Aust, 1974), CO-binding characteristics 
(Sladek and Mannering, 1966; Alvares et al, 1967) and substrate specifi­
cities (Lu et al, 1972). These two inducible haemoproteins have mono­
oxygenase activities which differ in the relative amounts of alternate 
products formed from various model substrates including biphenyl (Creaven 
and Parke, 1966), 2-acetylaminofluorene (Matsushima et al, 1972; 
Thorgeirsson et al, 1973), bromobenzene (Zampaglione et al, 1973), benzo(a)- 
pyrene (Rasmussen and Wang, 1974) and n-hexane (Frommer et al, 1974).
Isosafroie and several other MDP compounds including safrole and 
piperonyl butoxide have been shown to induce hepatic microsomal mono­
oxygenase activities (review: Hodgson and Philpot, 1974). Isosafroie has
(
also been shown to increase extrahepatic microsomal cytochrome P-450- 
mediated activity (Parke and Rahman, 1970; Wagstaff and Short, 1971; 
Lotlikar and Wasserman, 1972; Lake et al, 1973; Lake, 1974; Vainio and 
Parkki, 1976). The nature of the haemoprotein induced by safrole and
isosafroie has not been widely investigated although Elcombe et al (1975) 
demonstrated the Soret absorption maximum of the safroie-induced haemo­
protein to be at 448 nm, similar to that induced by 3-methylcholanthrene 
and other carcinogens. This supported evidence from Lake et al (1973) that 
the metabolic activity of the isosafrole-induced haemoprotein, with respect 
to several model substrates, was more similar to that induced by 
3-methylcholanthrene than phenobarbitone but has some properties in common 
with both. Similarly, Lotlikar and Wasserman (1972) have shown that 
safrole and isosafroie, in common with 3-methylcholanthrene, induce meta­
bolism of 2-acetamidofluorene by the 3- and 5-hydroxylation reactions to a 
greater extent than the N-hydroxylation reaction. This effect is prevented 
if the animals have been previously treated with ethionine to block de novo 
protein synthesis. Recently, isosafroie has been shown to induce a new 
haemoprotein in rat hepatic microsomes which has a molecular weight 
intermediate between that of the 3-methylcholanthrene- and phenobar- 
bitone-induced haemoproteins (Dickins et al, 1978).
The present study investigates further the type of induction by 
isosafroie and piperonyl butoxide and compares it to that of 3-methylcholan- 
threne by utilizing two strains of mouse which differ genetically in their 
response to the enzyme inducing properties of polycyclic aromatic hydro­
carbons such as 3-methylcholanthrene or S-naphthoflavone. The "respon­
siveness" to aromatic hydrocarbon induction refers to the capacity for 
induction of cytochrome P-448 and its associated monooxygenase activities 
in animals treated with polycyclic aromatic hydrocarbons. This genetic 
trait has been shown to segregate as a single autosomal dominant gene 
among certain inbred mouse strains (Nebert et al, 1975) with C57BL/6 mice 
being typically responsive and DBA/2 mice typically non-responsive.
4.2 METHODS
Groups of four responsive (C57BL/10) and non-responsive (DBA/2) 
mice were treated with the enzyme inducers phenobarbitone, piperonyl 
butoxide, isosafroie, pregnenolone-16a-carbonitrile (PCN), 3-methyicholan- 
threne and the vehicles saline and sunflower oil as described in Chapter 2. 
The livers for each treatm ent group were pooled and the hepatic microsomal 
fractions were prepared. The protein concentrations, cytochrome P-450 
concentrations and the activities of biphenyl 2- and 4-hydroxylase, ethyl- 
morphine N-demethylase and ethoxyresorufin O-deethylase were all determ­
ined as previously described (Chapter 2).
The activities of these enzymes were determined before and after a 
preincubation with the substrate, which would allow any MDP metabolite- 
cytochrome P-450 complex to be displaced if it was present in the 
microsomes. Determination of the enzyme activity "before displacement" 
included a 5 minute preincubation in the presence of reduced cofactor 
before initiation of the reaction by addition of the substrate. Determi­
nation of the enzyme activity "after displacement" included a 30 minute 
preincubation in the presence of substrate before initiation of the reaction 
by addition of the reduced cofactor.
Samples of each microsomal preparation were also subjected to 
SDS-polyacrylamide disc gel electrophoresis so that any changes in the 
molecular weight of the apoproteins caused by induction of a new haemo­
protein could be observed by changes in the electrophoretic pattern.
4.3 RESULTS
4.3.1 Comparison of the  spectra l properties of hepatic microsornes from
C57BL/10 and DBA/2 mice following trea tm en t with various
enzyme inducers
The cytochrome P-450 concentrations of the microsornes from C57
and DBA/2 mice (Table 4.1) show increases following treatment of the C57
mice with phenobarbitone, piperonyl butoxide, isosafrole, pregnenolone-16a-
carbonitrile (PCN) and 3-methylcholanthrene and the DBA/2 mice with
phenobarbitone, piperonyl butoxide, isosafrole and PCN but not with
3-methylcholanthrene. It is of interest to note that there is a slight
increase in the cytochrome P-450 concentration if the piperonyl butoxide
and isosafrole microsornes from either C57 or DBA/2 mice are incubated
with 250 pM safrole for 30 minutes at 37 °C before determination of the
reduced-carbon monoxide spectrum. This incubation was similar to the
preincubation used in the enzyme assays and would allow any MDP metabol-
ite-cytochrome P-450 complex to displace prior to determination of the
cytochrome P-450 concentration.
The  ^ of the carbon monoxide spectrum was recorded for each max r
microsomal preparation (Table 4.2) and also for the piperonyl butoxide and
isosafrole-induced microsornes after incubation with safrole as described
above. In the C57 mice there was very little change in the X aftermax
induction with phenobarbitone, piperonyl butoxide, isosafrole or PCN but
there was a characteristic 2 nm hypsochromic shift after induction with
3-methylcholanthrene. In the DBA/2 mice there was no characteristic shift
of the X after induction with 3-methylcholanthrene and very little max J J
change after treatment with the other enzyme inducers. In both strains of 
mouse incubation of the microsornes with safrole to displace any MDP
Table 4.1. Cytochrome P-450 concentrations of hepatic microsomal 
preparations from responsive and non-responsive mice 
after pretreatment with various enzyme inducers.
PRETREATMENT
Concentration of cytochrome P-450 
(n moles/mg microsomal protein]
CL57BL/10 DBA/2
Saline 0.78 ± 0.29 0.84 ± 0.19
Phenobarbitone 1.76 ± 0.29 1.46 ± 0.54
Sunflower Oil 0.64 ± 0.29 0.72 ± 0.24
Piperonyl Butoxide 1.49 ± 0.24 1.00 ± 0.15
Isosafrole 1.18 ± 0.22 1.07 ± 0.27
PCN 1.36 ± 0.37 1.24 ± 0.29
3-Methylcholanthrene 1.54 ± 0.46 0.71 ± 0.08
After Displacement*
Piperonyl Butoxide (1.60, 1.54)+ 1 .13 ± 0.15
Isosafrole (1.34, 1.373+ 1.20 ± 0.18
*Displacement was effected by incubation of the microsomal suspension 
(1 mg protein/ml in Tris-HCl buffer pH=7.43 with safrole (250 yM3 
for 30 minutes at 37°C.
Results represent the mean ± s.d. for three experiments except t 
which are the results of two experiments.
Table 4.2. Wavelength maxima for the carbon monoxide spectra of 
hepatic microsomal preparations from responsive and 
non-responsive mice after pretreatment with various 
enzyme inducers.
PRETREATMENT
^max Carbon Monoxide Spectrum (nm)
C57BL/10 DBA/2
Saline 450.3 450.1
Phenobarbitone 450.2 449.8
Sunflower Oil 450.2 450.3
Piperonyl Butoxide 450.1 450.0
Isosafrole 450.1 449.6
PCN 450.1 449.7
3-Methylcholanthrene 448.3 450.3
After DisDlacement
Piperonyl Butoxide (450.1, 450.03t 450.3
Isosafrole (449.9, 449.8)+ 449.7
*Displacement was effected by incubation of the microsomal suspension 
(1 mg protein/ml in Tris-HCl buffer pH=7.4) with safrole [250 yM) for 
30 minutes at 37°C.
Results represent the mean value for three experiments except t which 
are the results of two experiments.
metabolite-cytochrome P-450 complex present did not alter the ^max 
the reduced-carbon monoxide spectrum.
The spectral investigation of the microsornes from the piperonyl 
butoxide- and isosafrole-induced mice included reduced minus oxidized 
spectra to confirm the presence of the MDP metabolite-cytochrome P-450 
complex observed as an absorption maximum at 455 nm. The isosafrole- 
induced microsornes from both C57 and DBA/2 mice contained a 455 nm 
absorbing species which decreased upon incubation of the microsornes with 
safrole (Figs. 4.1 and 4.2) however, displacement of the complex was not 
complete since a residual amount of 455 nm absorption was apparent after 
30 minutes. After piperonyl butoxide induction a much smaller 455 nm 
absorption was present in both C57 and DBA/2 mice (Figs. 4.3 and 4.4) than 
after isosafrole induction, but after 30 minutes incubation with safrole as a 
displacer the 455 nm absorption was no longer apparent.
The displacement phenomenon was confirmed with the isosafrole- 
induced microsornes from the C57 mice by demonstration of a time- 
dependent intensification of the Type I binding spectrum of safrole 
(Fig. 4.5). The initial Type I binding spectrum gave a peak at 390 nm and a 
trough at 420 nm, however a time-dependent increase in absorption of this 
spectrum was accompanied by a red shift in the wavelength of the trough 
from 420 nm to 438 nm. This is a typical displacement spectrum since the 
shift of the trough to 438 nm is caused by displacement of the oxidized MDP 
metabolite-cytochrome P-450 complex in the sample cuvette, with the 
concomitant appearance of a Type I binding spectrum whereas in the 
reference cuvette the 438 nm peak remains intact. This is visualized as a 
net decrease in absorbance at this wavelength.
FIGURE 4.1
Redox difference spectrum  of hepatic microsornes from isosafro le-treated
C57BL/10 mice before and a fte r  incubation with safrole.
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390 410 430 470 490
Microsornes from isosafrole-treated C57BL/10 mice (0.5 mg/ml) were 
suspended in 66 mM Tris-HCl (pH=7.4) and divided equally: one half was
used to record the reduced minus oxidized spectrum before displacement
(---------); the other half was incubated with the displacer, safrole (250 pM)
for 30 minutes at 37°C before recording the redox spectrum after displace­
ment (----- —).
In both cases the microsomal suspension was divided equally between two 
cuvettes and a baseline of equal light absorbance recorded, after addition of 
sodium dithionite (1-2 mg) to the sample cuvette the reduced 
minus oxidized spectrum was recorded between 350 nm and 500 nm at a scan 
speed of 2 nm/sec.
FIGURE 4,2
Redox difference spectrum  of hepatic microsornes from isosafro le-treated
DBA/2 mice before and a fte r  incubation with safrole.
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390 430410 450 470nm
Microsornes from isosafrole-treated DBA/2 mice (0.5 mg/ml) were 
suspended in 66 mM Tris-HCl (pH=7.4) and divided equally: one half was
used to record the reduced minus oxidized spectrum before displacement
(-------- ); the other half was used to record the redox spectrum after
displacement (---------).
The m easurem ents were carried out as described in the legend to  Fig. 4.1.
FIGURE 4.3
Redox difference spectrum  of hepatic microsornes from piperonyl butoxide-
trea ted  C57BL/10 mice before and a fte r incubation with safrole.
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Microsornes from piperonyl butoxide-treated C57BL/10 mice (0.9 mg/ml) 
were suspended in 66 mM Tris-HCl (pH=7.4) and divided equally: one half 
was used to record the reduced minus oxidized spectrum before diplace­
ment (--------- ); the other half was used to record the redox spectrum after
displacement (-------- ).
The measurements were carried out as described in the legend to Fig. ^.1.
FIGURE 4.4
Redox difference spectrum  of hepatic microsornes from piperonyl butoxide-
trea ted  DBA/2 mice before and a fte r incubation v/ith safrole.
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Microsornes from piperonyl butoxide-treated DBA/2 mice (1.0 mg/ml) were 
suspended in 66 mM Tris-HCl (pH = 7.4) and divided equally: one half was 
used to record the reduced minus oxidized spectrum before displacement
(---------); the other half was used to record the redox spectrum after
displacement (---------).
The m easurem ents were carried out as described in the legend to  Fig. 4.1.
FIGURE 4.5
Displacement of the isosafrole metabolite-cytochrome P-450 complex in 
hepatic microsornes from isosafrole-treated C57BL/10 mice.
i
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Microsornes from isosafrole-treated C57BL/10 mice were suspended in 
66 mM Tris-HCl (pH=7.4) to a protein concentration of 0.7 mg/ml, divided 
equally between two cuvettes and allowed to equilibrate at 37 °C for 
5 minutes. A baseline of equal light absorbance between 350 nm and 500 nm 
was recorded, safrole (250 yM) was added to the sample cuvette and spectra 
were recorded every 2.5 minutes.
4.3.2 Comparison of the monooxygenase activities of hepatic microsornes
from C57BL/10 and DBA/2 mice following treatment with various
enzyme inducers.
The results of the biphenyl 2- and 4-hydroxylase, ethylmorphine 
N-demethylase and 7-ethoxyresorufin O-deethylase assays are summarized in 
Tables 4.3-4.6.
Comparison of the enzyme activities before preincubation with 
substrate confirms the observations from the spectral properties of the 
microsornes that the response to phenobarbitone is similar in both C57 and 
DBA/2 mice but the response to 3-methylcholanthrene is different. In both 
C57 and DBA/2 mice treatm ent with phenobarbitone increased the activity 
of biphenyl 4-hydroxylase and ethylmorphine N-demethylase, reactions 
regarded generally as cytochrome P-450-mediated, but not biphenyl 
2-hydroxylase and 7-ethoxyresorufin O-deethylase commonly thought to be 
cytochrome P-448-mediated. However, following treatment of the mice 
with 3-methylcholanthrene, a strain difference was apparent since in the 
C57 mice there was a significant increase in the activity of biphenyl 
2-hydroxylase and also a large increase in ethoxyresorufin O-deethylase 
activities but in the DBA/2 mice these two enzyme activities remained at 
control levels. Treatment of both strains of mice with PCN resulted in an 
increase in the activity of only one enzyme, ethylmorphine N-demethylase, 
whilst biphenyl 4-hydroxylase showed slight inhibition in both strains of 
mouse and ethoxyresorufin O-deethylase inhibition in C57 mice. The 
induction of ethylmorphine N-demethylase by PCN was not as great as the 
induction of this enzyme by phenobarbitone. Piperonyl butoxide and 
isosafrole appeared to induce enzyme activities in both strains of mouse 
similar to those induced by both phenobarbitone and 3-methylcholanthrene
Table 4.3. Biphenyl 4-hydroxylase activities of hepatic microsomal preparations from C57BL/10 and
DBA/2 mice pfter pretreatment with various enzyme inducers____________________________
C57BL/10 Mouse Microsornes
No.preincubation J hr preincubation
Pretreatment
Specific activity 
(nmoles/min/mgl
% Control
Specific Activity 
(nmoles/min/mg)
% Control
Saline 2.19 ± 0.0S 100 2.92 ± 0.19 100
Phenobarbitone 7.29 ± 0.34f 333 8.04 ± 0.33* 275
Sunflower oil 2.78 ± 0.21 100 - 3^50 ± 0.26 100
Piperonyl Butoxide 5.37 ± 0.13+ , 193 6.18 ± 0.09+ 177
Isosafrole 5.53 ± 0.99 199 6.29 ± 1.03 180
PCN 2.40 ±  0.31 86 ' ' 2.91 ± 0.06 63
3-Methylcholanthrene 3.53 ± 0.50 127 3.71 ± 0.60 105
DBA/2 Mouse Microsornes
Saline 1.60 ± 0.55 100 1.76 ± 0.52 100
Phenobarbitone 5.‘56 ±1.51 348 5.96 ± 1.15 339
Sunflower oil 1.93 ± 0.55 . 100 2.25 ± 0.41 100
Piperonyl Butoxide 2.97 ± 1.74 154 4.70 ± 0.15§ 209
Isosafrole 2.46 ± 0.19 127 3.38 ± 0.57 150
PCN 1.62 ± 0.08 84 1 .'81 ± 0.52 80
3-Methylcholanthrene 1.92 ± 0.24 99 2.47 ± 0.39 110
Sp Act represents mean ± s.d. for rhree experiments 
*p<0.301 +p<0.01 §p<0.02
Table 4.4. Biphenyl 2-hydroxylase activities of hepatic microsomal preparations from C57BL/10 and
DBA/2 mice after pretreatment with various enzyme inducers_____________________________
C57BL/10 Mouse Microsornes
No preincubation j hr preincubation
Pretreatment
Specific activity 
Cnmoles/min/mg]
% Control
Specific activity 
(nmoles/min/mg]
% Control
Saline 0.61 ± 0.14 100 0.88 ± 0.20 100
Phenobarbitone 0.80 ± 0.20 131 1.13 ± 0.40 129
Sunflower oil 0.71 ± 0.09 100 . 0.96 ± 0.14 100
Piperonyl Butoxide 1.09 ± 0.24 155 1.43 ± 0.33 150
Isosafrole 0.72 ± 0.12 102 1.63 ± 0.12 171
PCN 0.67 ± 0.19 94 0.87 ± 0.23 91
3-Methylcholanthrene 1.59 ± 0.191 225 1.56 ± 0.08 163
DBA/2 Mouse Microsornes
Saline 0.32 ± 0.1B 100 0.33 ± 0.22 100
Phenobarbitone 0.47 ± 0.12 146 0.60 ± 0.18 180
Sunflower oil 0.32 ± 0.12 100 0.37 ± 0.12 100
Piperonyl Butoxide 0.82 ± 0.09t 256 0.98 ± 0.16t 269
Isosafrole 0.26 ± 0.03 81 0.78 ± 0.04 212
PCN 0.30 ± 0.11 94 o . 4 6  ± o . i e 126
3-Methylcholanthrene 0.30 ± 0.11 94 0.49 ± 0.31 134
Sp Act represents mean ± s.d. for three experiments
tp<0.01 §p<0.02
Ta
bl
e 
4.
5 
E
t
h
y
l
m
o
r
p
h
i
n
e
 
N
-
d
e
m
e
t
h
y
l
a
s
e
 
ac
ti
vi
ti
es
 
of
 
he
pa
ti
c 
m
i
c
r
o
s
o
m
a
l
 
p
r
e
p
a
r
a
t
i
o
n
s
 
fr
om
 
C5
7B
L/
10
 
a
n
d
 
DB
A/
2 
mi
ce
 
af
te
r 
p
r
e
t
r
e
a
t
m
e
n
t
 
wi
th
 
va
ri
ou
s 
en
zy
me
 
i
n
d
u
c
e
r
s
co
•r)
•P(0ja3
oc
■H
03
P
cl
p
jz
>>-p /-« 
• r t  60
> e
•H \  
-P  C  
O  *H(o £
N  
U  03 
•rH 03 
4 -  rH 
•H O  
O E 
03 C  
CL—'
cn
co•H
-P(0
XI3oc•H
03
P
CL
□Z
•p —•H 60 > E 
•H \  
•P  C  
03 -H
to E
N
O  03 
•H 03 4- rl 
■H O  o E
03 Cawcn
-p
c
03£
•p(0
03P
■P
03P
a.
o  in o
o  o  C3T- «3- r-
O03
O
+1
S3
+!
CM
co co in co
in co in co
03Co 03TJ P
■H JZX ■P03 o cc H -p too ■H 3 rH•p O CO o
■H CD szXI P r—t i—1 oP 03 > □ rHto 3 c P >03 X3 O o 4- JCC O pH p to -P■H c 4- 03 03 03
rH 03 C CL O Z zto xz 3 ■H ID u 1cn CL cn CL M CL CO
o TH o CO T~ CO 03C3 CO o CM rx T™ Or- in r- ’3" CM to r-
4-in O rv. in co03 co in <3 rx in
r~ rs. a CM t” o
+1 +l +1 +i +1 +1 +l
rv. rs. in a CM CO COCO 03 in o CO CM co
CM sf CO in 03 T- COr- T- r~
C3 a CM a CO ino sr o CM CM CO COCO CO CO V
+- icnto in o CO CMCO CO to o co CO T—
v- CO V CO CM CM r~
+1 +1 +1 +1 +1 +1 +1
rv rv O C3 in rv COto CM CM in CM CO CO
CM in CO CO o o «3"t- r-
CDc
03 03T3 P•H x:
X •p
03 o cc rH -p to□ •H 3 rH■p O m O•H CD JZ
X3 P rH rH aP 03 > □ pH
10 3 C P >
03 XI O o 4-c o *H p to +3•H c 4- CD cn 03
rH 03 C CL o z zto JZ 3 •H cn u 1
COcn CL cn 0 . M CL
cn-p
c
03E•HPCDCLX
03
03CDP
JZ■P
Po4-
.
■a CM• o
03 •
o
+1 VCLC ta itoCD
E
01
p
c
3tn
3p
CL3 oP •o
-P V
U CL
< ■P
acn
Table 4.6. 7-Ethyoxyr*esorufin O-deethylase activities of hepatic microsomal preparations from C57BL/1C
and DBA/2 mice after pretreatment with various enzyme inducers____________________ _
C57BL/10 Mouse Microsornes
No preincubation s hr preincubation
Pretreatment
Specific activity 
Cnmoles/min/mg) • % Control
Specific activity 
Cnmoles/min/mg)
% Control
Saline 9.88 ± 4.22 100 7.16 ± 2.47 100
Phenobarbitone 14.38 ± 1.39 146 8.27 ± 1.84 116
Sunflower oil 10.05 ± 2.64 100 . 6.81 ± 1.74 100
Piperonyl Butoxide 29.95 ± 6.23 - 298 22.58 ± 5.86 332
Isosafrole 23.59 ± 7.53 235 26.17 ± 6.10 384
. PCN 6.68 ± 0.70 66 4.74 ± 1.08 70
3-Methylcholanthrene 147.38 ± 123.84 1466 134.81 ± 57.89 1980
DBA/2 Mouse Microsornes
Saline 2.92 ± 2.00 100 2.11 ± 1.26 100
Phenobarbitone 9.75 ± 3.97 334 5.77 ± 1.82 273
Sunflower oil 3.63 ± 1.52 100 2.88 ± 1.07 100
Piperonyl Butoxide 14.15 ± 1.92+ 390 8.85 ± 0.90+ 307
Isosafrole 6.01 ± 1.20 166 .8.51 ± 0.97§ 295
PCN . 3.61 ± 1.05 99 2.26 ± 0.61 76
3-Methylcholanthrene 3.32 ± 1.15 91 2.34 ± 1.07 81
Sp Act represents mean ± s.d. for three experiments 
tp<0.01 §p<0.02
but to a lesser extent than either of these two classical inducers. Piperonyl 
butoxide induced the cytochrome P-450-mediated enzyme activities bi­
phenyl 4-hydroxylase and ethylmorphine N-demethylase to 193% and 341% 
of control respectively in the C57 mice and to 154% and 422% of control 
respectively in the DBA/2 mice. Isosafrole induced these enzyme activities 
to a similar extent, increasing biphenyl 4-hydroxylase and ethylmorphine 
N-demethylase to 199% and 356% of control respectively in the C57 mice and 
to 127% and 320% of control respectively in the DBA/2 mice. Although the 
MDP compounds appear to be better inducers of ethylmorphine N-demethy­
lase than biphenyl 4-hydroxylase, if the induction by isosafrole and piperonyl 
butoxide is compared with that of phenobarbitone it can be seen that the 
MDP compounds induce both of these enzymes by about 60% compared with 
phenobarbitone-induced activity in the C57 mice. In the case of the DBA/2 
mice the proportions are approximately 40% and 60% of the phenobarbitone- 
induced activity for biphenyl 4-hydroxylase and ethylmorphine N-demethy- 
lase respectively. Induction by the MDP compounds increased ethyl­
morphine N-demethylase activity to the same extent as PCN-induction 
which induced only this one enzyme activity. Piperonyl butoxide induction 
also increased the cytochrome P-448 mediated enzyme activities, biphenyl 
2-hydroxylase and ethoxyresorufin O-deethylase in both the C57 and the 
DBA/2 mice but isosafrole induced only ethoxyresorufin O-deethylase in 
both C57 and DBA/2 mice whilst biphenyl 2-hydroxylase activities remained 
at about control levels in both strains.
Comparison of the enzyme activities, after including a preincu­
bation with substrates to displace any MDP metabolite-cytochrome P-450 
complex which may have been present, showed a similar pattern to those obtained 
without the preincubation, with one notable exception, those after isosafrole 
treatm ent. The cytochrome P-450-mediated enzyme activities, biphenyl
4-hydroxylase and ethylmorphine N-demethylase showed very littie 
change in either strain compared to the activities, before the preincubation 
except for biphenyl 4-hydroxylase activities in the isosafrole- and piperonyl 
butoxide-induced DBA/2 mice where slight increases in activity were 
observed. Marked differences in enzyme activities after preincubation with 
substrate were, however, noted for the cytochrome P-448-mediated biphenyl
2-hydroxylase and ethoxyresorufin O-deethylase. In the C57 mice biphenyl
2-hydroxylase showed very little change after preincubation except after 
isosafrole-induction which gave a 70% increase in activity. No change was 
observed in the piperonyl butoxide-induced activity following preincubation. 
In the DBA/2 mice a similar marked increase of 130% following preincu­
bation was observed in the isosafrole-induced biphenyl 2-hydroxylase 
activity with no change in the piperonyl butoxide-induced activity. Ethoxy­
resorufin O-deethylase activities in the C57 mice showed marked increases 
with both isosafrole-and 3-methylcholanthrene-induction giving a 149% and 
514% of control increase, respectively, over the activities before preincu­
bation. A much smaller increase was seen with piperonyl butoxide (34% of 
control) whilst phenobarbitone-induction produced a slight decrease in 
activity. In the DBA/2 mice, once again an incease in activity was observed 
after isosafrole induction with an increase of 129% of control after 
preincubation compared with the ethoxyresorufin O-deethylase activity 
before the preincubation, all other types of induction showed decreases 
after the preincubation.
In summary, it appears that induction by isosafrole and piperonyl 
butoxide increases enzyme activities normally associated with both cyto­
chromes P-450 and P-448 in both strains of mouse whilst 3-methylcholan­
threne failed to induce the cytochrome P-448-mediated enzyme activities in 
the non-responsive DBA/2 mice. After isosafrole-induction and, to a lesser
extent, piperonyl butoxide-induction a portion of the hepatic monooxygenase 
remains inactive until preincubation with a suitable substrate. The 
haemoprotein which is released appears to be "cytochrome P-448-like" in 
the enzyme activities which it mediates.
4.3.3 Comparison of the induction profile of microsomal haemoproteins in
C57BL/1Q and DBA/2 mice using sodium dodecyl sulphate polyacryl­
amide gel electrophoresis
Samples of the hepatic microsomal suspensions from the C57 and 
DBA/2 mice induced with phenobarbitone, piperonyl butoxide, isosafrole, 
pregnenolone-16 a-carbonitrile, 3-methylcholanthrene and the vehicles sun­
flower oil and saline were solubilized and subjected to SDS-polyacrylamide 
gel electrophoresis. A number of standard molecular weight proteins were 
run in parallel to facilitate calculations of the molecular weights of the 
haemoprotein bands by comparison of their mobilities with a standard curve 
(Fig. 4.6). After staining the gel for protein with Coomassie blue, two faint 
and six distinct bands in the 43,000-60,000 mol. wt. region were observed in 
the control (sunflower oil or saline) microsornes from both C57 and DBA/2 
mice (Fig. 4.7). These bands have been numbered 1-8 on the basis of 
increasing molecular weight and are also shown as a diagrammatic represen­
tation of the 43,000-60,000 mol. wt. region of the gel (Fig. 4.8).
In the control microsornes from both C57 and DBA/2 mice there are 
several distinct bands in the 43,000-60,000 mol. wt. region : band 1 (43,000-
44,000 mol. v/t.) is either one intense or two prominent bands; this is 
followed by the faint bands, band 2 (46,000 mol. wt.) and band 3 (48,000 mol. 
wt.); the remaining bands, band 4 (49,000 mol. wt.), band 5 (52,000 mol. wt.), 
band 6 (54,000 mol. wt.), band 7 (55,000 mol. wt.) and band 8 (60,000 mol. 
wt.) were all prominent and of equal intensity.
FIGURE 4.6
SDS-polyacrylamide gel electrophoresis of standard molecular
weight proteins.
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Standard molecular weight proteins were dissolved in 62.5 mM Tris-HCl 
(pH=6.8) containing 2.3% (w/v) SDS, 15% (v/v) glycerol, 5% (v/v) mercapto- 
ethanol and 0.001% (w/v) bromophenol blue. 2 yg of each protein was 
applied to the gel in parallel with the solublized microsomal samples. The 
standard proteins used were cytochrome c (mol. wt. = 12,500) chymotrypsin- 
ogen A (mol. wt. = 25,000) aldolase (mol. wt. = 39,500), hen egg albumin 
(mol. wt. = 45,000) catalase (mol. wt. = 60,000) and bovine serum albumin 
(mol. wt. = 69,000).
The molecular weight of the microsomal proteins was calculated by 
comparing their mobilities with those of the standard mol, wt. proteins from 
the above graph of log mol. wt. versus mobility.
FIGURE 4.7
SDS-polyacrylamide disc, gel electrophoresis of hepatic microsornes from 
C57BL/10 and DBA/2 mice treated with various enzyme inducers.
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Microsornes from mice pretreated with various inducing agents were solubi­
lized and subjected to gel electrophoresis as described in Methods. After 
electrophoresis, the gel was stained for protein with Coomassie blue G-250. 
Samples of the microsomal proteins (15 yg) were applied in the following 
wells: C57. mice pretreated with phenobarbitone 2; saline 3; oil 4;
3-methylcholanthrene 5; isosafrole 6; piperonyl butoxide 7; PCN 8: DBA/2
mice pretreated with phenobarbitone 10; saline 11; oil 12; 3-methylcholan­
threne 13; isosafrole 14; piperonyl butoxide 15; PCN 16 and a mixture of 
the molecular weight standards wells 1,9,17 and 18
FIGURE 4.8
A diagram m atic representation of the 43,000-60,000 molecular weight
region of the  SDS-polyacrylamide electrophoretogram  of hepatic m icro-
somes from C57BL/10 and DBA/2 mice tre a ted  with various enzyme
inducers.
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In both C57 and DBA/2 mice bands 1-3 were all of decreased 
intensity compared with control in the microsornes from all of the animals 
pretreated with the enzyme inducers. Phenobarbitone induced bands 4, 5 
and 6 in both strains of mouse, band 4 (49,000 mol. wt.) and band 6 (54,000 
mol. wt.) were the most markedly induced. PCN induced band 6 (54,000 
mol. wt.) in both strains of mouse. 3-Methylcholanthrene induced bands 6 
and 7 (54,000 and 55,000 mol. wt. respectively) in the C57 mice but did not 
increase the staining intensity of any band in the DBA/2 mice. Isosafrole 
markedly increased the intensity of band 6 (54,000 mol. wt.) and bands 4 
(49,000 mol. wt.) and 5 (52,000 mol. wt.) were also slightly induced in both 
strains of mouse. Isosafrole alone among the enzyme inducers studied 
induced a protein band of low molecular weight in both strains of mouse 
(Fig. 4.7) which ran outside the accurate range of the protein standards and 
therefore the molecular weight could not be calculated with confidence. 
Finally, piperonyl butoxide induced protein bands 4 and 6 (49,000 and 54,000 
mol. wt. respectively) but unlike isosafrole did not increase the staining 
intensity of band 5.
In summary, the electrophoretic pattern of microsomal proteins 
induced in C57 and DBA/2 mice by phenobarbitone, PCN, isosafrole and 
piperonyl butoxide were comparable, with 3-methylcholanthrene failing to 
induce any protein bands in the DBA/2 mice. Isosafrole and piperonyl 
butoxide induced protein bands which were of similar molecular weight to 
proteins induced by both phenobarbitone and 3-methylcholanthrene.
4.4 DISCUSSION
Safrole and isosafrole are known inducers of hepatic and extra- 
hepatic enzymes including UDP-glucuronyl transferase (Parke and Rahman, 
1970; Lucier et al, 1971; Vainio and Parkki, 1976), epoxide hydratase
(Vainio and Parkki, 1976) and several monooxygenase dependent activities 
such as biphenyl 2- and 4-hydroxylase, arylhydrocarbon hydroxylase, aceta- 
nilide hydroxylase, 7-ethoxycoumarin O-deethylase and 4 nitroanisole 
O-demethylase (Parke and Rahman, 1970; Lake et al, 1973; Wagstaff and 
Short, 1971; Vainio and Parkki, 1976; and Chapter 3). Increases in hepatic 
monooxygenase activities and the level of haemoprotein after admini­
stration of safrole or isosafrole to rats were completely inhibited by protein 
synthesis inhibitors such as actinomycin D (Parke and Rahman, 1970). The 
increases in enzyme activity were therefore attributed to enzyme synthesis 
de novo. Parke and Rahman (1971) further suggested that induction by 
safrole and isosafrole resulted in the synthesis of a new haemoprotein. 
However, their conclusions were erroneously based on the observation of an 
absorption maximum at 455 nm in the redox difference spectrum which was 
subsequently demonstrated to be due to the presence of a MDP metabolite- 
cytochrome P-450 complex (Franklin, 1971) which could be formed rapidly in 
vitro.
Recently, Dickins et al (197S) used SDS-polyacrylamide gel electro­
phoresis to demonstrate that isosafrole specifically induced a haemoprotein 
in rats which had an apoprotein of 54,000 molecular weight. This was 
distinct from phenobarbitone- or 3-methylcholanthrene-induced haemo- 
proteins which had apoproteins of 50,000 and 58,000 molecular weight 
respectively. 3-Methylcholanthrene also slightly induced an apoprotein of
54,000 mol. wt.
The catalytic activity of the isosafrole-induced haemoprotein has 
not been thoroughly investigated because of difficulty in assessing the true 
activity due to binding of an isosafrole metabolite to the induced cyto­
chrome P-450. However, the evidence reported in the literature indicates 
that the isosafrole-induced haemoprotein generally exhibits increases in the
enzyme activities which are normally associated with 3-methylcholan- 
threne-induction although certain phenobarbitone-inducible enzymes are 
also increased by isosafrole (Hodgson and Philpot, 1974). In an attempt to 
investigate further the similarity of induction by isosafrole and 3-methyl­
cholanthrene, I have utilized two strains of mouse which are known to differ 
genetically in their response to induction by polycyclic aromatic hydro­
carbons.
In mice the genetic trait of "aromatic hydrocarbon responsiveness" 
refers to the capacity for induction of cytochrome P-448 and the associated 
monooxygenase activities by various polycyclic aromatic hydrocarbons. 
Nebert et al (1975) reviewed the responsiveness of more than 30 inbred 
mouse strains and concluded that about two thirds, including the C57 BL/6, 
were "responsive" and one third, including the DBA/2 were "non-responsive". 
This responsiveness is inherited almost exclusively as an autosomal dominant 
trait and is expressed more or less dominantly in hepatic and probably extra- 
hepatic tissues by the inducibility of the enzyme arylhydrocarbon hydroxy­
lase (Nebert et al, 1975). The mice are therefore considered to differ 
genetically at the Ah locus and the consequences of this difference have 
been reviewed by Thorgiersson and Nebert (1977). They concluded that the 
Ah allele is associated with the induction of cytochrome P-448, about eleven 
monooxygenase activities, including aryl hydrocarbon hydroxylase, and also 
UDP-glucuronyl transferase.
The Ah allele is also associated with electrophoretic differences in 
microsornes since the administration of 3-naphthoflavone (regarded as very 
similar in its properties to 3-methylcholanthrene) results in the induction of 
a single band of 55,000 molecular weight in genetically "responsive" mice 
but not in "non-responsive" mice (Haugen et al, 1976)* Increases in this 
single electrophoretic band have since been resolved into
increases in two distinct bands having a difference of less than 1000 in 
molecular weight (Boobis et al, 1977). Haugen et al (1976) also demon­
strated that increases in the formation of cytochromes P-448 and P-450 
following administration of 3-naphthoflavone and phenobarbitone respec­
tively are essentially due to an increased rate of de novo protein synthesis 
rather than a decreased rate of degradation or a conversion of pre-existing 
polypeptides.
Haugen et al (1976) investigated the electrophoretic pattern and 
various monooxygenase activities of microsornes from responsive (C57 
BL/6N) and non-responsive (DBA/2N) mice following treatment with several 
enzyme inducers. . They concluded that the pattern of induction was similar 
in both strains of mouse except for the response to 3-naphthoflavone : 
phenobarbitone increased proteins of 51,000 mol. wt. and to a lesser extent
49,000 and 55,000 mol. wt; PCN increased a protein of 54,000 mol. wt;
3-naphthoflavone increased a protein of 55,000 mol. wt. in the responsive mice 
but had no effect on the non-responsive mice.
A similar electrophoretic pattern is seen in the present work. 
Although the C57BL/6 mouse strain was not available, a pilot-study showed 
the C57BL/10 strain to be similarly "responsive" to the induction of 
cytochrome P-448 and associated monooxygenase activities by the poly­
cyclic aromatic hydrocarbon, 3-methylcholanthrene, and therefore this 
strain was used for comparison with the non-responsive DBA/2 mouse. A 
similar response to the inducers phenobarbitone, PCN, piperonyl butoxide 
and isosafrole was seen in both strains of mouse but only the responsive 
mouse showed induction by 3-methylcholanthrene. Phenobarbitone induced 
two major bands of 49,000 and 54,000 mol. wt. and slightly induced one 
further band of 52,000 mol. wt; 3-methylcholanthrene induced two bands, 
one of 54,000 mol. wt. and to a lesser extent one of 55,000 mol. wt; PCN
induced one band at 54,000 mol. wt; piperonyl butoxide induced two bands 
of 54,000 mol. wt. and 49,000 mol. wt; and finally isosafole induced two 
major bands of 54,000 mol. wt. and 49,000 mol. wt. and one minor band of
52,000 mol. wt. In general, the electrophoretic pattern induced by the 
MDP compounds resembled that induced by phenobarbitone more closely 
than that induced by 3-methylcholanthrene since the band of 54,000 mol. wt. 
was increased by all of the inducing agents studied and the band of 49,000 
mol. wt. by phenobarbitone and the MDP compounds.
The absence of an induced band in the DBA/2 mice following
treatment with 3-methylcholanthrene but the presence of an induced band in
\.
the C57 mice was supported by the data from the determination of the 
w'avelength maxima of the reduced-carbon monoxide spectra (Table 4.2) and 
cytochrome P-450 concentrations (Table 4.1). These showed that admini­
stration of 3-methylcholanthrene to the responsive C57 mice resulted in an 
increase in the cytochrome P-450 concentration and a 2 nm blue shift in the 
reduced-carbon monoxide absorption maximum which confirmed the induct­
ion of cytochrome P-448. However, 3-methylcholanthrene treatm ent of the 
non-responsive DBA/2 mice failed to increase the cytochrome P-450 
concentration or cause a spectral shift of the reduced-carbon monoxide 
absorption maximum. Enzyme induction by phenobarbitone, PCN, 
isosafrole and piperonyl butoxide was confirmed by increases in cytochrome 
P-450 concentrations in both responsive and non-responsive mice (Table 4.1) 
but none of these inducing agents caused a shift in wavelength of the 
reduced-carbon monoxide absorption maximum. In neither responsive nor 
non-responsive mice did isosafrole induce a cytochrome with an absorption 
maximum at 448 nm (Elcombe et al, 1975) or 449 nm (Chapter 3) as 
previously reported in the rat.
In contrast to the evidence provided by the SDS-polyacrylamide gel 
electrophoresis and reduced-carbon monoxide spectra that induction by the 
MDP compounds is 'similar to phenobarbitone-induction, data from the 
monooxygenase activities suggest that there may still be similarities 
between the haemoproteins induced by 3-methylchoianthrene and the MDP 
compounds. The MDP compounds induced cytochrome P-450- and cyto­
chrome P-448-dependent enzyme activities in both responsive and non- 
responsive mice, however the full activities of the induced haemoproteins 
were often not realised until the microsomes had been preincubated with the 
substrate. This indicates the presence of a MDP metabolite-cytochrome 
P-450 complex which can be displaced to reveal metabolically competent 
enzyme similar to that previously described in rats (Chapter 3). The 
presence of this displaceable complex was confirmed by the presence of an 
absorption maximum at 455 nm in the redox difference spectra of isosa- 
frole- and piperonyl butoxide-induced microsomes from both responsive and 
non-responsive mice (Figs. 4.1-4.5) and a slight increase in the cytochrome 
P-450 concentrations after incubation of the microsomes with a displacing 
substrate (Table 4.1). Although the amount of metabolite-cytochrome 
P-450 complex is lower in the piperonyl butoxide-induced microsomes than in 
the isosafrole induced microsomes, the degree of induction by these two 
MDP compounds is comparable if the enzyme activities are compared after 
displacement of the metabolite complex. This may be due to displacement 
of the piperonyl butoxide metabolite during microsome isolation, or reflect 
a decreased stability of the MDP metaboiite-cytochrome P-450 complex in 
the case of piperonyl butoxide due to possible steric effects of this larger 
molecule in the active site of the enzyme.
The monooxygenase activities were measured before and after dis­
placement of the MDP metabolite-cytochrome P-450 complex by using the
test substrate as the displacer and preincubating the microsomes with the 
substrate before determining the enzyme activity. However, of the four 
enzyme activities measured, the substrate ethylmorphine does not displace 
the metabolite complex (Elcombe, 1976; Dickins, 1978) and ethoxyresorufin 
is a poor displacer (Dickins et al, 1979) and therefore little change in the 
activities of the isosafrole- and piperonyl butoxide-induced microsomes was 
expected following the preincubation with these substrates. In general, 
preincubation of the microsomes with substrate for 30 minutes resulted in 
an increased specific enzyme activity compared to that observed without 
the preincubation. However, the specific activity of ethoxyresorufin 
O-deethylase decreased after the 30 minute preincubation which could be due 
to decomposition of the substrate resulting in a decreased substrate 
concentration or substrate induced lipid perodixation of the microsomes 
resulting in a partially inactive monoxygenase system.
Phenobarbitone-induction increased the activities of biphenyl
4-hydroxylase and ethylmorphine N-demethylase in both strains of mice but 
had little effect on biphenyl 2-hydroxylase or ethoxyresorufin O-deethylase. 
PCN induced only ethylmorphine N-demethylase in both strains. 3-Methyl- 
cholanthrene induced biphenyl 2-hydroxylase activity and ethoxyresorufin 
O-deethylase activity in the responsive mice but failed to induce these two 
enzymes in the non-responsive mice, further confirmation of the genetic 
difference in response to this inducer. Piperonyl butoxide increased the 
activities of all four enzymes studied, in both strains of mouse but showed 
little increase in activity following preincubation with the substrates. In 
contrast, isosafrole-induction increased the activities of biphenyl 4-hydroxy­
lase and ethylmorphine N-demethyiase in both strains of mouse and neither 
of these enzyme activities increased following "displacement". However, 
biphenyl 2-hydroxylase showed no increase prior to displacement in either
strain of mouse but increased after displacement. Ethoxyresorufin 
O-deethylase was induced by isosafrole in both strains and increased still 
further following displacement. Although the MDP compounds induced 
cytochromes with enzyme properties similar to P-448 and P-450 in both 
genetically responsive and non-responsive mice, the enzyme activities which 
increased upon displacement of the MDP-metabolite complex appear to be 
more similar to those which are cytochrome P-448 mediated.
The pattern of increases observed in- enzyme activities, following 
treatment of the mice with the inducing agents, showed no apparent 
similarity to the pattern of induced protein bands observed when the 
microsomes were subject to SDS-polyacrylamide gel electrophoresis. 
Although all of the inducing agents increased the staining intensity of a 
protein of 54,000 mol. wt. in both C57 and DBA/2 mice, none of the enzyme 
activities studied was increased by all of the inducers. SDS-polyacrylamide 
gel electrophoresis is therefore of limited use in establishing the type of 
enzyme induction since proteins of similar molecular weight but different 
substrate specificities will be identified as a single band but it may be useful 
in conjunction with other separation techniques such as isoelectric 
focussing, which separate proteins by properties other than molecular 
weight.
In summary, it appears that treatment of responsive C57BL/10 
mice and non-responsive DBA/2 mice with isosafrole and piperonyl butoxide 
results in the formation of a MDP metabolite-cytochrome P-450 complex 
which can be displaced to reveal metabolically competent enzyme. The 
monooxygenase activities of the induced haemoproteins resemble those of 
both phenobarbitone and 3-methylchoianthrene induction but in both strains 
of mouse the haemoprotein released from the metabolite complex exhibits 
predominantly cytochrome P-448-like enzyme activities. The polycyclic
aromatic hydrocarbon, 3-methylcholanthrene, induced cytochrome P-448 
and its associated monooxygenase activities in The C57 mice but not in the 
DBA/2 mice. Polyacrylamide gel electrophoresis was of limited use in 
determining the nature of induction the MDP compounds since the electro­
phoretic pattern showed similarities to those of both phenobarbitone- and 
3-methylcholanthrene-induced haemoproteins. The fact that the electro­
phoretic pattern resembled that of phenobarbitone-induction whilst the 
metabolic profile showed more similarity to that of 3-methylcholanthrene- 
induction indicates that although the apoproteins of the induced haemo­
proteins may have identical molecular weights, this is totally unrelated to 
substrate specificities.
Overall, the results presented in this chapter indicate that since 
isosafrole induces a cytochrome in the non-responsive DBA/2 mice which 
exhibits characteristics of the cytochrome induced by polycyclic aromatic 
hydrocarbons, then either the mechanism of induction is totally different or 
the cytochrome induced by isosafrole is different from that induced by 
3-methylcholanthrene. Poland et al (1976) postulated that the lack of 
responsiveness in the DBA/2 strain is due to a mutation which results in the 
production of a receptor protein which has a diminished affinity for the 
inducing agent. It is possible that enzyme induction by isosafrole is 
mediated by a different receptor protein, indeed the receptor could be a 
particular species of cytochrome P-450. If the metabolite complex formed 
by MDP compounds with cytochrome P-450 resulted in the destruction or 
temporary inactivation of a specific portion of the cytochrome P-450 pool, 
then either the build up of endogenous substrates within the cell or the 
breakdown products of the cytochrome might act as the initiator of de novo 
enzyme synthesis.
CHAPTER 5
ISOLATED RAT HEPATOCYTES AND THEIR USE IN THE INVESTIGATION
OF SUBSTRATE-CYTOCHROME P-450 INTERACTIONS
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5.1 INTRODUCTION
Our knowledge of the metabolism of drugs, carcinogens, steroids and 
many other xenobiotics or endogenous compounds has progressed far in the 
last ten or twenty years. The majority of the in vitro studies have utilized 
isolated hepatic subcellular fractions or purified enzymes, in particular, the 
heterogeneous mixture of membrane fragments generally called the micro­
somal fraction. Although in vitro studies using hepatic microsomal 
fractions have contributed much towards our understanding of drug metabo­
lism and toxicity, the very fact of their isolation from the intact cell 
presents great difficulty in the comparison with the in vivo situation. 
However, the use of isolated hepatocytes has recently presented an altern­
ative in vitro system which still retains many of the properties of the intact 
tissue with regard to permeability barriers to bdth substrates and metabo­
lites, physiological levels of necessary cofactors, possible competition from 
endogenous compounds and active detoxication pathways. The isolated 
hepatocyte system is therefore a valuable experimental model in which to 
study the metabolic oxygenation and conjugation of drugs.
Isolated hepatocytes have been used to study the oxygenative meta­
bolism of several substrates including benzo(a)pyrene (Vadi et al, 1975), 
biphenyl (Wiebkin et al, 1976), ethoxyresorufin (Burke and Orrenius, 1978), 
ethylmorphine (Erickson and Holtzman, 1976), naphthalene (Bock et al, 
1976), ethoxycoumarin (Fry et al, 1978) and £-nitroanisole (Moldeus et al, 
1976). Conjugation reactions in isolated hepatocytes have also been studied 
with several substrates including 2- and 4-hydroxybiphenyl (Wiebkin et al, 
1976), 1-naphthol (Bock et al, 1976), £-nitrophenol (Moldeus et al, 1976), 
benzoic acid (Shirkey et al, 1979) and resorufin (Burke and Orrenius, 1978). 
Although the majority of the investigations in hepatocytes have been
metabolic studies, spectral studies may also be informative as to possible 
permeability barriers and interactions with cytochrome P-450 within the 
cell. Spectral studies on isolated hepatocytes are more difficult than 
similar studies on hepatic microsomes since the hepatocytes settle out of 
the medium quite rapidly. However, successful spectral studies have been 
reported in a medium containing 2% (w/v) bovine serum albumin and have 
shown that cytochrome P-450 can be measured in isolated hepatocytes 
(Moldeus et al, 1973) and that addition of suitable drugs to the medium 
produces a Type I spectral change characteristic of the binding of substrate 
to cytochrome P-450 (Moldeus et al, 1973; 1974; von Bahr et al, 1974).
The use of a medium containing 2% bovine serum albumin to suspend 
the hepatocytes may, however, produce inaccurate results since albumin is 
an effective binding protein for many substrates (Bridges and Wilson, 1976) 
and has been shown to alter the amount of resorufin formed from ethoxy­
resorufin in hepatocytes (Burke and Orrenius, 1978). Albumin has also been 
shown to produce a Type RI binding spectrum when added to microsomes 
(Powis et al, 1977).
The results reported in this chapter describe a medium which 
suspends hepatocytes for sufficient time to carry out spectral studies, 
without the addition of any bovine serum albumin. Further, they attem pt 
to demonstrate Type I, Type II and Type RI substrate binding spectra in 
hepatocytes following the addition of compounds known to produce these 
spectral changes in microsomal suspensions. The spectral changes produced 
by addition of methylenedioxyphenyl compounds to isolated hepatocytes are 
also described.
5.2 RESULTS
(R)5.2.1 Investigation of Glycerol, Ficoll 400 and Gelatine as possible
suspension media to facilitate spectral investigations in isolated 
hepatocytes.
Isolated hepatocytes suspended in Dulbecco's Phosphate Buffered
Saline ’A1 (PBS'A1) were initially used in an attempt to obtain substrate
induced-cytochrome P-450 binding spectra, but even the use of the 
(R)Aminco "quick-mixing cuvette" did not permit a baseline of equal light 
absorbance to be recorded before the cells settled out of the buffer. 
Clearly, a suspension medium suitable for recording spectra in whole cells 
must contain a substance which is not only capable of increasing the 
viscosity of the buffer sufficiently to suspend the cells for a suitable length 
of time, but is also non-toxic to the viable hepatocytes and must be of low 
light absorbing properties in the region of 350-500 nm. The three 
substances investigated as possible suspension media were glycerol, gelatine 
and Ficoll 400, a high molecular weight polysaccharide used in the sepa­
ration of whole cells by density gradient centrifugation (Drochmans et al, 
1975). The gelatine used in these studies was of high quality, contained 
only sulphur dioxide as a preservative at a level of five parts per million or 
less and gave "glass-clear" gels. In a pilot study, isolated hepatocytes 
(approximately 2 x 10^ cells/ml) were suspended in various concentrations of 
glycerol, Ficoll 400 and gelatine and for each medium a range of concen­
trations which suspended the cells for 3 minutes or longer was selected for 
toxicity testing. The ranges chosen were 10-25% (v/v) glycerol, 5-20% 
(w/v) Ficoll 400 and 1.0-2.5% (w/v) gelatine, all in PBS'A1 containing lg/litre 
glucose since these concentrations suspended the cells for long enough to 
record spectral changes within the cells.
The toxicity of these suspension media was compared by estimation 
of the cell viability using exclusion of the dye trypan blue as the index of
viability. Hepatocytes (approx. 2 x 10^ cells/ml) were incubated in the 
various suspension media at 37 °C without shaking, at intervals of five 
minutes the cells were gently resuspended using a vortex-mixer and samples 
were added to trypan blue (0.1% w/v) and kept on ice until estimation of the 
viability index using an improved Neubauer counting chamber. The results 
are shown in Figs. 5.1-5.3. Examination of the cells by light microscopy 
before incubation with these suspension media showed them to be of a 
smooth rounded appearance but during the incubations with glycerol and 
Ficoll 400 the cell membranes rapidly became irregular in shape, often with 
"ballooning'’ of the membrane although many of these cells still excluded 
trypan blue. This effect on the cell membrane was not observed with 
gelatine since the cells still retained their rounded appearance after 
30 minutes incubation. High concentrations of Ficoll 400 and glycerol were 
required to suspend the cells effectively in the medium compared with the 
low concentration of gelatine and these may have damaged the cell 
membranes. The osmotic pressures of these supension media were not 
measured but this effect on the cells would be expected if the osmotic 
.pressure of the medium was less than isotonic.
Incubation of hepatocytes with glycerol (Fig 5.1) did not appear to 
have any effect on the viability index for the first five minutes but after a 
longer incubation the viability index showed a decline proportional to the 
glycerol concentration. A similar concentration dependent decline in the 
viability of the hepatocytes was observed with Ficoll 400 (Fig. 5.2) although 
the decrease in viability of the cells was more pronounced. In contrast, the 
cells incubated with gelatine (Fig. 5.3) appeared to have a higher viability 
after 30 minutes at 37°C than did the control cells incubated in buffer alone 
and this "protective-effect" was proportional to the concentration of 
gelatine.
FIGURE 5.1
E ffect of various concentrations of glycerol on the viability of
isolated hepatocytes when incubated a t 37 °C
90-i
80-
70-
•  Control
♦ 10 V. (v/v)
60-
015*/. (v/v) 
a 20 V. (v/v)
a 25 V. (v/v)
50-
10 20 3025
Time {min)
\
Isolated hepatocytes (approx. 2 x 10^ cells/ml) were incubated at 37 °C in 
phosphate buffered saline containing lg/litre glucose and various concen­
trations of glycerol. At regular intervals the cells were resuspended and 
the viability of a sample was determined by trypan blue exclusion.
The values plotted are the mean of four determ inations.
FIGURE 5.2
E ffect of various concentrations of Ficoll 400 on the viability
of isolated hepatocytes when incubated a t 37 °C.
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Isolated hepatocytes (approx. 2 x 106 cells/ml) were incubated at 37 °C in 
phosphate buffered saline containing 1 g/litre glucose and various concen­
trations of Ficoll 400. At regular intervals the cells were resuspended and 
the viability of a sample was determined by trypan blue exclusion.
The values plotted are  the mean of four determ inations.
FIGURE 5.3
E ffect of various concentrations of gelatine on the viability of
isolated hepatocytes when incubated a t 37 °C
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Isolated hepatocytes (approx. 2 x 10^ cells/ml) were incubated at 37 °C in 
phosphate buffered saline containing 1 g/litre glucose and various concent­
rations of gelatine. At regular intervals the cells were resuspended and the 
viability of a sample was determined by trypan blue exclusion.
The values plotted are the mean of four determ inations.
A suspension medium containing 2.5% (w/v) gelatine was chosen as 
standard for use in the following experiments since some of the spectra 
were required at 37 °C. However, at room temperature this concentration 
of gelatine forms a gel and therefore the concentration of gelatine may be 
decreased if spectra are to be recorded at ambient temperature.
5.2.2 Observation of transient spectral changes in isolated hepatocytes
Isolated hepatocytes (approx. 2 x 10^ cells/ml) were suspended in 
PBS’A’ containing 1 g/litre glucose and 2.5% (w/v) gelatine. After dividing 
the suspension between two cuvettes a baseline of equal light absorbance 
was recorded before addition of hexobarbital (100 jiM) to the sample 
cuvette. Initially a Type I binding spectrum was recorded but this changed 
with time to show transient troughs at 437 nm and 446 nm (Fig. 5.4a). It 
was subsequently found that these transient changes could also be observed 
in the absence of a Type I substrate if the spectrum between 350-500 nm 
was scanned several minutes after recording the baseline (Fig. 5.4b). These 
transient spectral changes were therefore thought to be due to fluctuations 
in the oxidation/reduction states of the mitochondrial cytochromes since in 
the reduced state cytochrome aa^ exhibits on absorption maximum at 
446 nm. Indeed, measurement of the endogenous rate of respiration using a 
Clark-type oxygen electrode showed that the hepatocytes rapidly consumed 
the available oxygen and that within 4 minutes the conditions in the spectro­
photometer cuvette became anaerobic (Fig. 5.5). Since the mitochondrial 
terminal oxidase is relatively sensitive to cyanide but cytochrome P-450 is 
relatively insensitive, cyanide (200 pM) was added to each cuvette so that 
the mitochondrial cytochromes could reach a steady reduced state whilst 
the suspension medium remained aerobic. The effect of the addition of 
cyanide on the respiration rate of the hepatocytes is shown in Fig. 5.5. 
Although the addition of cyanide to the hepatocytes did not totally inhibit
FIGURE 5.4
Observation of transient spectral changes in a suspension of 
_________________isolated hepatocytes_________________
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Isolated hepatocytes (approx 2 x 10^) were suspended in a medium of
phosphate buffered saline containing 2.5% (w/v) gelatine and lg/litre 
glucose. After dividing the suspension of hepatocytes between two 
cuvettes a baseline of equal light absorbance was recorded.
(a) Hexobarbital (100 jiM) was added to the sample cuvette and the 
spectrum recorded. The spectrum was re-recorded after 2.5 minutes 
(O— O —O), 3.0 minutes (©— ®—©) and 3.5 minutes (-------------- )
(b) In the absence of substrate the spectrum was re-recorded after 4.0
minutes (O—O—O), 4.5 minutes (®—@— ©) and 5.0 minutes 
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FIGURE 5.5
The effect of cyanide on the oxygen consumption of isolated 
________  hepatocytes
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Isolated hepatocytes (1.7 x 10^ cells/ml) were added to an aerated 
suspension medium of 2.5% (w/v) gelatine in phosphate buffered saline 
containing lg/litre glucose and incubated at 37°C in the cuvette of a Clark- 
type oxygen electrode. After recording the aerobic state (A) and the rate 
of oxygen consumption of the hepatocytes, two additions of potassium 
cyanide (100 pM) were made and the rate of oxygen consumption recorded 
after each addition and continued until a steady anaerobic state (B) was 
reached.
the oxygen consumption, presumably due to oxygen consumption during 
cytochrome P-450-dependent monooxygenation, the time available before 
the suspension medium became anaerobic increased to about 20 minutes. 
Addition of cyanide to the hepatocyte suspension facilitated the recording 
of a steady baseline and subsequent investigations of substrate-induced 
spectral changes. The concentration of cyanide used in the spectral 
investigations decreased the cell viabilities by only 5-8% during incubation 
at 37 °C for 10 minutes.
5.2.3 Investigation of substrate-induced spectral changes in isolated
hepatocytes
The addition of several substrates including hexobarbital, naphtha­
lene and biphenyl to a suspension of isolated hepatocytes resulted in the 
appearance of typical Type I binding spectra with peaks at 390 nm and 
troughs at 420 nm. The appearance of these Type I binding spectra was 
rapid, with the maximum binding spectrum developing within a few seconds 
even in the presence of cyanide (Fig. 5.6). The magnitude of these binding 
spectra was concentration dependent (Fig. 5.7) and the spectra were stable 
enough to permit the determination of Kg values from the double reciprocal 
plots with a good fit of the experimental points to a straight line (Fig. 5.8). 
The Ks values obtained for hexobarbital and naphthalene were close to the 
values obtained in microsomes, however, the Kg for biphenyl was lower than 
expected (Table 5.1).
The effects of cyanide on the substrate-induced Type I binding 
spectra in microsomes were examined with regard to the spectral para­
meters K and V . Cyanide (200 uM) was added to the microsomal s max
suspensions before the stepwise addition of substrate and the subsequent 
concentration dependent increases in the magnitude of the Type I binding 
spectrum were recorded. Analysis of the data using a double reciprocal
FIGURE 5.6
Appearance of the type I binding spectrum 
with time
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Isolated hepatocytes (approx. 2 x 10^ cells/ml) were suspended in phosphate 
buffered saline containing 2.5% (w/v) gelatine and 1 g/litre glucose and 
placed in a "quick mixing cuvette" in the sample compartment of an Amino 
DW2‘ spectrophotometer operating in the dual wavelength mode 
( Ai = 390 nm A2 = 420 nm). After recording a steady state, biphenyl 
(250 j i M ) was rapidly mixed with the cuvette contents and the resultant 
absorbance change recorded, (a). The procedure was repeated in the 
presence of 200 j i M KCN, (b).
FIGURE 5.7
Effect of concentration on the Type I binding spectrum of 
naphthalene in isolated hepatocytes
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430390 410 450 470370
Isolated hepatocytes (approx. 2 x 10^ cells/ml) were suspended in phosphate 
buffered saline containing 2.5% (w/v) gelatine, lg/litre glucose and 200 p.M 
KCN. After recording a baseline of equal light absorbance jil quantities of 
a 250 mM solution of naphthalene in dimethylformamide were added and the 
spectrum between 350-500 nm recorded after each addition. The final 
concentrations of substrate were 50-500 jj.M.
FIGURE 5.8
Ks plots of naphthalene and m etyrapone in isolated ra t hepatocytes
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Isolated hepatocytes (approx 2 x 10^ ceils/ml) were suspended in phosphate 
buffered saline containing, 2.5% (w/v) gelatine, lg/litre glucose and 200 jiM 
KCN. After recording a baseline of equal light absorbance the substrates 
naphthalene or metyrapone, as 250 jiM solutions in dimethylformamide were 
added in jil quantities and the spectrum between 350-500 nm recorded after 
each addition. The final concentrations of substrate were 50-500 jliM .
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plot showed that this concentration of cyanide did not alter the value of Kg
but decreased the V • (Table 5.1).max
The addition of metyrapone and pyridine to a suspension of isolated 
hepatocytes resulted in the appearance of concentration dependent Type II 
binding spectra with peaks at 425-430 nm and troughs at 390-400 nm 
(Fig. 5.9). The experimental data also produced a good fit to a straight line 
when plotted as the double reciprocal of concentration versus magnitude of 
the spectral change (Fig. 5.8).
The substrate-induced Type I and Type II binding spectra observed in 
hepatocytes correlate well with those found in microsomes, however, a 
difference in response to compounds such as diazepam, acetanilide and 
imidazole was apparent in hepatocytes. These compounds produced Type RI 
binding spectra when added to microsomes, even in the presence of cyanide, 
but in hepatocytes they result in Type I binding spectra (Fig. 5.10). The 
reason for this difference is not clear but it is discussed later.
5.2.4 Investigation of the spectral interactions of methylenedioxyphenyl
compounds with cytochrome P-450 in isolated hepatocytes
Initially, upon addition of isosafrole to a suspension of hepatocytes a 
Type I binding spectrum was observed, however this rapidly gave way to a 
spectrum with absorption maxima at 427 nm and 460 nm which developed 
with time (Fig. 5.11). Although the major peak at 427 nm developed rapidly 
with time, the spectrum soon stabilized which may indicate either a static 
state, in which the isosafrole had been metabolized to an intermediate 
similar to that observed in microsomes, or a dynamic state, in which the 
spectrum represented the maximum amount of isosafrole metabolite 
complex present at any one time.
Evidence to support the hypothesis that the isosafrole had been 
metabolized was provided by the reduced-carbon monoxide spectra. After
FIGURE 5.9
Effect of concentration on the Type II binding spectrum of 
metyrapone in isolated hepatocytes
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Isolated hepatocytes (approx. 2 x 10** cells/ml) were suspended in phosphate 
buffered saline containing 2.5% (w/v) gelatine, lg/litre glucose and 200 pM 
KCN. After recording a baseline of equal light absorbance the substrate 
metyrapone (250 mM in dimethylformamide) was added in pi quantities and 
the spectrum between 350-500 nm was recorded after each addition. The 
final concentrations of substrate, were 50-500 pM
FIGURE 5.10
Effect of concentration on the binding spectrum of diazepam 
in isolated hepatocytes
0 0 1  A
450 470430390 410370
The conditions were as described in Fig. 5.7 except that the substrate was 
diazepam. Final substrate concentrations were 50-500 pM
FIGURE 5.11
Spectral changes observed in isolated hepatocytes following 
addition of isosafrole
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Isolated hepatocytes (approx. 2 x 10^ cells/ml) were suspended in the 
medium described in Fig. 5.7. After recording the baseline, isosafrole
(200 p,M) was added to the sample cuvette and the spectrum between 350- 
500 nm recorded at 30 sec, 2 min, 3 min, 4 min and 10 min.
formation of the peak at 427 nm, the cytochrome P-450 concentration was
determined by reducing both sample and reference cuvettes with sodium
dithionite and then bubbling carbon monoxide through the sample cuvette.
After recording the spectrum carbon monoxide was bubbled through the
reference cuvette and the spectrum re-recorded (Fig. 5.12). The results
showed a decreased cytochrome P-450 concentration in cells incubated with
isosafrole compared with the cells which were not incubated with this
substrate. After bubbling carbon monoxide through both sample and
reference cuvettes the spectrum showed a trough at 452 nm, the wavelength
for the A of the reduced-carbon monoxide spectrum, which indicates amax
decreased cytochrome P-450 concentration in the hepatocytes incubated 
with isosafrole. These spectra in isolated hepatocytes therefore compare 
well with the results obtained in microsomes since the formation of the 
isosafrole metabolite-cytochrome P-450 complex results in a decreased 
cytochrome P-450 content of the microsomes.
Isosafrole was not the only MDP compound to produce absorption 
maxima at 427 nm and 460 nm following incubations with isolated hepa­
tocytes, similar spectra were also obtained with safrole, dihydrosafrole and, 
to a small extent, methylenedioxybenzene (Fig. 5.13). However, the rate of 
formation and final magnitude of the absorption maxima were different for 
each compound.
There remained unanswered one major question regarding the 
stability of the 427/460 nm absorption maxima, if the metabolite complex is 
formed in vitro in hepatocytes why is the reduced spectrum seen rather than 
the 438 nm peak of the oxidized complex?
To investigate further the spectral characteristics of the metabolite 
complex in hepatocytes, "off-balance" spectra were recorded comparing 
hepatocytes from control rats with hepatocytes from isosafrole-induced 
rats.
FIGURE 5.12
Reduced-carbon monoxide spectra  in isolated
hepatocytes before and a fte r incubation with isosafrole
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Isolated hepatocytes (approx 2 x 10 cells/ml) were suspended in phosphate 
buffered saline containing 2.5% (w/v) gelatine 1 g/litre glucose and 200 pM 
KCN and divided equally between two cuvettes. After obtaining a baseline 
of equal light intensity, sodium dithionite (1-2 mg) was added to both 
cuvettes, the sample cuvette bubbled with carbon monoxide (CO) for 30 sec.
and the spectrum between 410-490 nm recorded (©------- ©). A similar
suspension of hepatocytes was incubated with isosafrole (250 jiM) at 37 °C 
for 15 min before recording the reduced-CO spectrum as described above
(0 --------0), the spectrum obtained after subsequent bubbling of the
reference cuvette with CO is also shown ( ------- ).
FIGURE 5.13
Spectral changes observed in isolated hepatocytes 
following addition of safrole, dihydrosafrole and 
methylenedioxybenzene
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Isolated hepatocytes (approx. 2 x 10^ cells/ml) were suspended in phosphate 
buffered saline containing 2.5% (w/v) gelatine, 1 g/litre glucose and 200 pM 
KCN and divided equally between two cuvettes. After recording a baseline 
of equal light absorbance, 200 pM substrate (either safrole (A), dihydro­
safrole (B) or methylenedioxybenzene (C)) was added to the sample cuvette 
and the spectrum between 350-500 nm recorded at 30 sec, 2 min, 3 min, 
4 min and 10 min.
After suspending the hepatocytes to approximately 2 x 1 0 ^  ceils/mi, control 
hepatocytes were placed in the reference cuvette and isosafrole-induced 
hepatocytes in the sample cuvette and the spectrum between 350-500 nm 
was recorded without any baseline correction (Fig. 5.14). The spectrum 
showed the presence of pronounced absorption maxima at 427 nm and 
455 nm in the isosafrole-induced hepatocytes without the addition of any 
chemical reducing agent. The reduced state of the isosafrole metabolite- 
cytochrome P-450 complex did not change even after bubbling the cuvettes 
with oxygen for several minutes. In an attempt to force the hepatocytes 
into an oxidized state cumene hydroperoxide was added to both cuvettes and 
the spectrum re-recorded (Fig. 5.15). Initially the metabolite complex was 
forced into the oxidized state since a single absorption maximum at 438 nm 
was apparent. However the conditions within the cells rapidly returned to 
the reduced state within 5 minutes since the metabolite complex was 
apparent as the 427 nm and 455 nm absorption maxima. It therefore appears 
that the isosafrole metabolite-cytochrome P-450 complex in hepatocytes is 
"fixed" in the reduced state whether formed in vivo or in vitro.
5.2.5 Effects of isosafrole on the monooxygenase activity of hepatocytes
in primary culture
The observation of 427/460 nm absorption maxima in hepatocyte 
suspensions following addition of isosafrole suggests that a reactive meta­
bolite of isosafrole may have been formed in these cells during the short 
incubation. Since it is possible that the formation of the isosafrole 
metabolite-cytochrome P-450 complex or some other reactive metabolite is 
the primary event in the induction of the monooxygenase in vivo, primary 
hepatocyte cultures were investigated as a possible experimental model for 
the induction of monooxygenase activity in vitro by isosafrole.
FIGURE 5.14
"Off-balance" spectrum of control hepatocytes 
versus isosafrole-induced hepatocytes
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Isolated hepatocytes (approx. 2 x 10 cells/ml) were suspended in phosphate 
buffered saline containing 2.5% (w/v) gelatine and 1 g/litre glucose. After 
dividing the suspension equally between two cuvettes, a baseline of equal 
light absorbance between 350-500 nm was recorded, without external 
baseline corrections. Isolated hepatocytes from an isosafrole-induced rat 
(approx. 2 x 10^ cells/ml) were then placed in the sample cuvette and the 
spectrum between 350-500 nm recorded.
FIGURE 5.15
Spectral changes observed following the addition of cumene 
hydroperoxide to the hepatocytes in an noff-balance" 
spectrum of control versus isosafrole induced hepatocytes
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Hepatocytes isolated from control and isosafrole pretreated rats were 
suspended (approx. 2  x 1 0 ^ cells/ml) in phosphate buffered saline containing 
2.5% (w/v) gelatine and 1 g/litre glucose, the isosafrole-induced hepatocytes 
being placed in the sample cuvette and control hepatocytes in the reference 
cuvette. Cumene hydroperoxide (250 pM) was added to each cuvette, the 
contents rapidly mixed and the spectrum between 350-500 nm recorded at 
30 second intervals, without baseline corrections.
Primary hepatocyte cultures were prepared as described in Methods 
and these were incubated in a medium containing various concentrations of 
isosafrole without further additions of isosafrole. After three days the 
isosafrole-containing medium was removed and, after washing the cultures 
to remove traces of isosafrole, the monooxygenase activity of the cells was 
estimated by incubating them with an ethoxycoumarin-containing medium 
and measuring the product fluorimetrically as described in Methods. The 
results shown in Table 5.2 suggest that isosafrole may cause a slight 
induction of monooxygenase activity when added to the cultures at a 
concentration of 10 jllM  but the increase is small. Concentrations above 
50 fiM appear to inhibit ethoxycoumarin O-deethylase to a small extent but 
there is no indication of a large increase in activity compatible with the
concept of induction. It was also noticeable that the number of cells
estimated in each culture flask decreased with increasing isosafrole concen­
tration, presumably due to a toxic effect of isosafrole on the cells.
5.3 DISCUSSION
Isolated hepatocytes are frequently used in metabolic studies but 
very few reports of their use in spectral studies have been published. 
Moldeus et al (1973) reported a series of experiments on the binding of 
substrates to cytochrome P-450 in hepatocytes but their investigations were 
limited to the binding of Type I compounds and determination of the
cytochrome P-450 content of the cells. These authors suggested that the
major fraction of the cytochrome P-450 in the isolated liver cell is present 
in the oxidized non-substrate bound state since the uptake of drugs into the 
cell was rapid and resulted in the formation of Type I binding spectra. The 
measurement of the spectral binding constant (Kg) was not reported, 
probably because the suspension medium contained 2 % (w/v) bovine serum
Table 5.2 The effect of isosafrole as an inducer of
ethoxycoumarin Q-deethylase activity in 
primary hepatocyte cultures
Concn. of Isosafrole 
. in culture Medium 
CyM)
7-hydroxycoumarin 
formed 
n moles/4 hr/106 cells
% Control
0 3.75 100%
10 4.72 126%
50 3.67 98%
100 3.08 82%
250 3.23 86%
500 3.11 83%
1000 3.17 85%
Primary hepatocyte cultures were incubated with various concen­
trations of isosafrole for three days before estimation of the 
ethoxycoumarin O-deethylase activity
The cultures were incubated for 4 nrs at 37°C with medium containing 
7-ethoxycoumarin and the product 7-hydroxycoumarin estimated as 
described in Methods
albumin which would have resulted in an unknown free substrate concen­
tration being available to the hepatocytes since albumin readily binds 
lipophilic compounds.
The results reported in this study have shown that a 2.5% (w/v) 
solution of gelatine is a suitable medium for the investigations of substrate- 
induced binding spectra. The protective effect on the hepatocytes observed 
with gelatine and the decreased "bubbling’' of the cell membranes may be 
due to a physically supportive effect of the suspension medium on the cell 
membranes. Having found a suitable suspension medium, the addition of 
hexobarbitai to the isolated hepatocytes was observed to result in a Type I 
binding spectrum, however certain transient spectral changes were observed 
soon after recording the binding spectrum (Fig. 5.4a). These transient 
changes, observed as troughs at 437 nm and 446 nm which appeared and 
disappeared alternately are similar to those observed as peaks by Moldeus et 
al (1973). These authors observed the rapid appearance of peaks a t 437 nm 
and 446 nm followed by the total disappearance of the Type I binding 
spectrum and suggested that the peak at 437 nm might be due to an 
oxygenated form of cytochrome P-450, similar to that suggested to be 
present in microsomes during steady state monooxygenation of drugs 
(Estabrook et al, 1971). However, I have observed these transient spectral 
changes in isolated hepatocytes immediately after recording a baseline, in 
the absence of substrate (Fig. 5.4b) and therefore it is unlikely that the 
437 nm absorbance change was due to the oxygenated form of cytochrome 
P-450.
It is possible to explain the transient spectral changes if the 
cytochrome content of the cell is considered as a whole, especially the 
mitochondrial cytochromes which do not interfere with the spectra in 
microsomes. Since the mitochrondrial terminal oxidase is the site of
greatest oxygen consumption within the cell, it is possible that the 
oxidation/reduction states of the cytochromes in the electron transport 
chain would fluctuate as the oxygen content of the medium decreased and 
result in transient spectral changes. These changes would be observed as 
either peaks or troughs depending on which cuvette was the first to 
approach an anaerobic state. Support for the hypothesis of the involvement 
of the mitochrondrial cytochromes is obtained from the fact that reduced 
cytochrome aa^ has an absorption maximum at 446 nm and that Moldeus et 
al (1973) observed the total disappearance of the Type I binding spectrum 
following the transient-changes. Although these authors considered the 
suspension medium to be aerobic, if the cells had gone totally anaerobic the 
intracellular redox state and presumably also the cytochrome P-450 would 
be forced into the reduced state resulting in the abolition of any Type I 
binding spectrum, since this is only present when the cytochrome P-450 is in 
the oxidized state. Measurement of the oxygen consumption of isolated 
hepatocytes showed that, at the ceil density used for spectrophotometry, 
the suspension medium could become anaerobic within 4 minutes after the 
addition of the cells (Fig. 5.5) but that the addition of 200 \xM KCN resulted 
in the inhibition of the mitochondrial terminal oxidase and increased the 
length of time that the medium could remain aerobic to about 2 0  minutes. 
Subsequent spectral studies incorporating cyanide into the suspension media 
did not show these transient spectral changes and the binding spectra 
observed were stable thereby indicating that the hypothesis of mitochondrial 
involvement in the transient spectral changes may be correct.
In agreement with Moldeus et al (1973) I found that the uptake of 
substrate was rapid, taking no more than a few seconds for full development 
of the Type I binding spectra (Fig. 5.6). The uptake of substrate into the 
cell is probably the result of passive diffusion since the addition of cyanide
did not markedly slow the rate of appearance of the spectrum. The rapid 
appearance of the Type I binding spectrum implies that a considerable 
portion of the cytochrome P-450 is in the oxidized non-substrate bound state 
and is therefore immediately available to bind the substrate. The magnitude 
of the Type I binding spectra was shown to be concentation dependentK
(Fig. 5.7), although it must be remembered that the spectra observed in
/
hepatocytes are probably the result of a dynamic equilibrium; since the 
cytochrome P-450 is probably actively metabolizing the substrate so that 
the binding spectrum represents the proportion of cytochrome P-450 which 
is in the oxidised substrate-bound form at any one instant. The values of Kg 
obtained from the binding spectra of hexobarbital, naphthalene and biphenyl 
were all of the same order of magnitude and were similar to the values 
obtained in microsomes (Table 5.1).
The addition of metyrapone to isolated hepatocytes resulted in the 
appearance of a Type II binding spectrum (Fig. 5.9) which was also 
concentration dependent and could be used to calculate a Kg value. 
Addition of diazepam, imidazole or phenacetin to a suspension of isolated 
hepatocytes failed to show a Type RI binding spectrum as observed in 
microsomes at similar concentrations, instead they produced Type I binding 
spectra (Fig. 5.10). The reason for this difference between microsomes and 
isolated hepatocytes could be the presence of an endogenous substrate in the 
hepatocytes which is bound to the "Type Rl-site" on the cytochrome P-450 
and therefore compels the exogenous substrate to bind to the "Type I-site". 
Another possible reason for the difference could be that the substrates 
studied were not available to the cells in the expected concentrations 
because of low solubility in the aqueous system, which was not a problem 
with Type I-binding substrates. The concentration of substrate within the 
cell may therefore have been lower than the calculated value resulting in a
Type I binding spectrum whereas at higher concentrations a Type RI binding 
spectrum would have been apparent. A change of binding spectrum with 
concentration has been previously observed in hepatic microsomes with 
some of the 2-n-alkylbenzimidazoles (Dickins, 1978) which bind to give 
Type I spectra when added in low concentrations but this changes to Type RI 
with increasing substrate concentration.
The spectra obtained after addition of isosafrole to a suspension of 
isolated hepatocytes suggest that the- isosafrole metabolite-cytochrome 
P-450 complex may be formed since absorption maxima at 427 nm and 460 nm 
were apparent (Fig. 5.11).
The maximum extent of fomation of this spectrum is small but it 
may represent a dynamic state in which this is the maximum amount of 
complex present at any one time. Evidence to support the hypothesis of 
isosafrole metabolite-cytochrome P-450 comlex formation was obtained 
from the reduced carbon monoxide spectra which showed a 15-20% decrease in 
cytochrome P-450 content in the hepatocytes incubated with isosafrole 
(Fig. 5.12). This may represent the amount of cytochrome P-450 bound to 
the isosafrole metabolite or possibly the amount of cytochrome P-450 
destroyed by the presence of a reactive metabolite. The "off-balance” 
spectrum of isosafrole-induced hepatocytes versus control hepatocytes 
showed the presence of 427 nm and 455 nm absorption maxima (Fig 5.14), 
both in the presence and absence of cyanide, which indicates that for some 
reason the isosafrole metabolite-cytochrome P-450 complex is "fixed" in the 
reduced state. This was also observed when the hepatocytes were 
incubated with isosafrole since the spectrum observed was that of the 
reduced metabolite complex (Fig. 5.11). Since in microsomes the metabo­
lite is only displaced when in the oxidized state, the observation that it is 
"fixed" in the reduced state in hepatocytes implies that it is not in a readily
displaceable form. In an attem pt to see if the oxidised form of the complex 
could exist in hepatocytes, cumene hydroperoxide was added to both 
cuvettes of this "off-balance" spectrum and the subsequent changes 
recorded (Fig 5.15). Initially the metabolite complex was observed as a 
peak at 438 nm indicative of the oxidized complex but this rapidly reverted 
to the reduced spectrum with peaks at 427 nm and 455 nm as the cells 
returned to a steady state. If the metabolite complex is fixed in the 
reduced state in hepatocytes then the physiological significance of the 
displacement phenomenon is not clear.
Addition of isosafrole to the culture medium of primary hepatocyte 
cultures in an attempt to find an in vitro model for the induction by MDP 
compounds failed to induce the monooxygenase activity of the cultures. 
There are however many variable factors involved in the induction of mono­
oxygenase activity in cell culture and further experiments are required 
before any conclusions can be drawn from the results. The complicating 
factors with isosafrole may be the direct toxic effect of isosafrole on the 
cells, the possible binding of isosafrole to the walls of the culture vessel and 
the possible presence of a MDP metabolite-cytochrome P-450 complex 
within the cells in a non-displaceable reduced state which would mask any 
induction that may have occurred. One answer to the latter problem might 
be to "induce" several large culture flasks of hepatocytes and, after 
detaching the cells from the culture surface, these could be subjected to 
spectrophotometric investigation to see if the MDP metabolite complex had 
been formed to any great extent in these cells.
In summary, a solution of 2.5% (w/v) gelatine in PBS"A" containing 
1  g/litre glucose has been found to be a suitable medium for the investigation 
of substrate-cytochrome P-450 binding in isolated hepatocytes. However, 
the addition of 200 pM KCN appears to be necessary for the stability of the
substrate-induced binding spectra. Type I binding spectra appear rapidly 
following the addition of substrates known to bind Type I in hepatic 
microsomes and the uptake of the substrate appears to be by passive 
diffusion. Type II binding spectra were demonstrated and both Type I and 
Type II spectra were concentration dependent and permitted calculation of 
the Kg values which were similar to those obtained with hepatic micro­
somes. The addition of MDP compounds to isolated hepatocytes initially 
resulted in appearance of Type I binding spectra but these rapidly gave way 
to the development of spectra compatible with the hypothesis of the 
formation of an MDP metabolite-cytochrome P-450 complex which was 
"fixed" in the reduced state. Isolation of hepatocytes from an isosafrole- 
induced rat and the subsequent "off-balance" spectra versus hepatocytes 
from a control rat showed the presence of the isosafrole metabolite- 
cytochrome P-450 complex which also appeared to be "fixed" in the reduced 
state even after being generated in vivo.
CHAPTER 6
INVESTIGATION OF SOME SPECTRAL CHARACTERISTICS OF THE 
ISOSAFROLE METABOLITE-CYTOCHROME P-450 COMPLEX
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6.1 INTRODUCTION
The formation of a product complex between a reactive metabolite 
and reduced cytochrome P-450, manifested spectrally as dual absorption 
maxima at about 427 nm and 455 nm, has been demonstrated for the MDP 
compounds during in vitro hepatic microsomal metabolism in the presence of 
NADPH and oxygen (Franklin, 1971; Philpot and Hodgson, 1971a, b; 
Elcombe, 1976). Similar absorption maxima in the range 448-456 nm are 
produced during the in vitro metabolism of several compounds including 
SKF 525A (Schenkman et al, 19721  ^ Buening and Franklin, 1976), carbon 
tetrachloride (Uehleke et al, 1973); amphetamines (Franklin, 1974a, b, c, d),
2-nitroso-l-phenylpropane (Jonsson and Lindeke, 1976), nitrites (Kahl, 
1978), hydrazines (Prough 1978) and other nitrogenous compounds (Franklin, 
1976b).
iE v^ ro generated MDP metabolite-cytochrome P-450 
complexes may be observed as a single absorption maximum at 437-438 nm 
following removal of the reducing conditions (Elcombe et al, 1975b). 
Following reports that organic hydroperoxides (e.g. cumene hydroperoxide) 
could catalyse a number of cytochrome P-450-dependent reactions such as 
4-nitroanisole-demethylation and steroid hydroxylations in the absence of 
NADPH or oxygen, (Rahimtula and O'Brien, 1974a, b; Hrycay et al, 
(1975a, b), Elcombe et al (1975b) demonstrated the formation of a spectrally 
apparent peak at 438 nm when hepatic microsomes, safrole and cumene 
hydroperoxide were incubated together. This 438 nm maximum changed to 
the characteristic dual absorption maxima at 427 nm and 455 nm following 
reduction of the microsomes with sodium dithionite.
The formation of this MDP metabolite-cytochrome P-450 complex 
results in a potent inhibition of monooxygenation (Franklin, 1972) and
consequential synergism of insecticides. Although one of the metabolic 
routes for the MDP compounds is via demethylenation (Casida et al, 1966; 
Kamienski and Casida, 1970), the methylenedioxy group appears to be 
essential for the production of the 427/455 nm absorption maxima since the 
corresponding catechols are incapable of producing such spectra (Elcombe, 
1976). Replacement of the hydrogen atoms of the methylene group by 
oxygen atoms or methyl groups resulted in the abolition of synergistic 
activity whilst replacement by deuterium reduced this activity (Metcalf et 
al, 1966) These findings suggest that the formation of the MDP metabolite- 
cytochrome P-450 complex is due to a ligand interaction between the 
methylene carbon and the haem-iron of the cytochrome P-450 resulting in 
an inhibition of oxygen binding and hence monooxygenase activity.
Several theories have been proposed for the formation of the 
reactive intermediate responsible for the MDP metabolite-cytochrome 
P-450 complexes. Hennessy (1965) proposed that the loss of a hydride ion 
from the methylene bridge could lead to the formation of an electrophilic 
benzodioxolium ion:-
This ion could react with the nucleophilic centre of a protein or with 
the iron atom of the haem of cytochrome P-450 by means of a pi-bonded 
complex.
Hansch (1968), on the basis of a comparison of homolytic, steric and 
hydrophobic constants with structure-synergistic activity relationships, 
suggested that the methylene bridge may undergo homolytic cleavage 
resulting in the loss of a hydrogen atom:-
The free radical generated by this reaction would be capable of 
interacting with the haem iron.
Ullrich and Schnabel (1973a) investigated the oxidative metabolism 
of fluorene and observed that during metabolism absorption maxima at 
374 nm and 446 nm were produced. Further investigations using model 
systems suggested that the 374 nm peak was due to the presence of an anion 
resulting from the abstraction of a proton from the methylene bridge of the 
fluorene molecule. The carbanion produced in this way then reacts with the 
reduced cyctochrome P-450 to produce a cytochrome P-450-fluorenyl 
complex which has an absorption maximum at 446 nm. Ullrich and Schnabel 
(1973b) further suggested that a similar carbanion may be produced from the 
MDP component during oxidative metabolism:-
The carbanion may be the active species which binds to the haem 
iron to produce the MDP metabolite-cytochrome P-450 complex.
More recently, Ullrich et al (1975a) have suggested the formation of 
a carbene at the methylene bridge of the MDP compounds as being the 
active metabolite responsible for the metabolite complex formation:
Ov / H
0 P '0 H
This hypothesis is supported by evidence from studies on the 
formation of metabolite complexes by the halogenated hydrocarbons. 
Various halogenated hydrocarbons produce absorption maxima at 455 nm 
following metabolism in the presence of NADPH (Uehleke et al, 1973). 
However, the halogenated methanes produced metabolic intermediate 
complexes either enzymically in the presence of NADPH or chemically 
under anaerobic, sodium dithionite-reduced conditions (Wolf et al, 1977). 
Metabolism of these compounds resulted in the formation of carbon mono­
xide and Wolf et al (1977) proposed that the active metabolite was a 
carbene, formed by the abstraction of two halogen atoms from the substrate 
molecule. The formation of a carbene was also proposed by Mansuy et al 
(1974) to explain the absorption maximum at 470 nm generated during the 
metabolism of halothane (l,l,l-trifluoro- 2 -chloro-2 -bromoethane) since the 
chemically produced trifluoromethyl carbene species exhibited almost 
identical spectral characteristics to those produced by halothane under 
anaerobic conditions.
The experiments described in this chapter attempt to investigate 
further the formation of the characteristic MDP metabolite-cytochrome 
P-450 spectra and the relationship between the 427 nm and 455 nm absorption 
maxima.
6.2 RESULTS
6.2.1 The effect of displacement of the in vivo isosafrole metabolite- 
-cytochrome P-450 complex on the in vitro formation of the 
metabolite complex in hepatic microsomes from isosafrole-induced 
rats.
Isosafrole-induced microsomes were preincubated at 37 °C for 2 min 
in Tris-HCl buffer (pH 7.4) containing NADPH and a regenerating system, 
divided equally between two cuvettes thermostatted at 37 °C and a baseline 
of equal light absorbance recorded. Subsequent addition of isosafrole (175 jliM )  
to the sample cuvette resulted in the formation with time of dual 
absorption maxima at 427 nm and 455 nm. The final ratio of 1.0 was 
observed when the peak heights (427-490 nm/455-490 nm) were compared. 
The isosafrole-induced microsomes contained in vivo generated metabolite 
complex since addition of NADPH alone to the sample cuvette produced the 
characteristic 427/455 nm peaks but these did not show a time-dependent 
intensification. Addition of the isosafrole substrate to the sample cuvette 
immediately prior to addition of the NADPH to both cuvettes did not alter 
the rate of formation of the 427/455 nm absorption maxima nor did it affect 
the final absorbance values of the two peaks.
The addition of certain Type I binding compounds, including the 
MDP compounds themselves, to isosafrole-induced microsomes in vitro 
results in displacement of the metabolite complex. The use of substrates of 
the hepatic monooxygenase as the displacers permits subsequent metabolism
of these substrates to be measured (Chapter 3). Isosafrole-induced micro­
somes, in the oxidized state, were therefore suspended in Tris-HCi buffer 
(pH 7.4) and preincubated with the isosafrole substrate for 30 minutes at 
37 °C before addition of the NADPH, to permit displacement to occur prior 
to initiation of the metabolism. Displacement of the in vivo isosafrole 
metabolite-cytochrome P-450 complex resulted in increases of 60% and 
166% in the initial rate (AA/min/mg protein) of formation of the 427 nm 
and 455 nm absorption maxima respectively, compared with the rate 
observed previously in the presence of undisplaced metabolite complex. 
The magnitudes of the 427 nm and 455 nm peaks were increased by 570% 
and 420% respectively compared with those produced by undisplaced 
isosafrole-induced microsomes. The 427/455 nm peak ratio increased to 1.4, 
indicating that the dominant species observed after displacement of the 
metabolite complex was the 427 nm maximum.
6.2.2 The effect of pH on the development of the 427 nm and 455 nm 
absorption maxima during oxidative metabolism of isosafrole in 
vitro by hepatic microsomes from phenobarbitone-, 3-methylcholan- 
threne- and isosafrole-induced rats
The effect of pH on the in vitro development of the dual absorption 
maxima characteristic of the isosafrole metabolite-cytochrome P-450 
complex was investigated in hepatic microsomes from phenobarbitone-, 
3-methylcholanthrene- and isosafrole-induced rats. The phenobarbitone- and 
3-methylcholanthrene-induced microsomes were suspended in various 6 6 m M 
Tris-HCl buffers (pH range 6.5-9.0), divided between two spectrophotometer 
cuvettes and incubated for 5 minutes at 37 °C in the presence of NADPH and 
a NADPH-regenerating system. After recording a baseline of equal light 
absorbance the reaction was initiated by addition of isosafrole (250 jiM) and
the developing spectrum recorded every 30 seconds until no further increase 
in the magnitude of the absorption maxima was observed. The effect of pH 
on the spectrum produced in isosafrole-induced microsomes was measured 
before and after displacement of the in vivo generated complex; one 
sample of the isosafrole-induced microsomes was incubated as above, the 
other sample was suspended in the different pH buffer before being 
incubated for 30 minutes at 37°C with isosafrole (250 jiM) and a NADPH- 
regenerating system, in the absence of NADPH, to displace the in vivo 
complex. After recording a baseline the metabolism was initiated by 
addition of NADPH and the developing spectrum recorded every 30 seconds.
Examples of the pH effects on the spectra produced during oxidative 
metabolism of isosafrole in phenobarbitone-, 3-methylcholanthrene- and iso­
safrole-induced (undisplaced and displaced) microsomes are shown in 
Figs. 6 .1-6.4 respectively. The effect of pH on the final magnitudes of the 
427 nm and 455 nm absorption maxima are shown in Figs. 6.5-6.8, plotted as
A A^27_49(/m£ Prote n^ or A ^455-.49(/m£ Prote*n versus pH of the buffer.
It is apparent from the spectra shown in Figs. 6 .1-6.4, that at this 
concentration of isosafrole, the ratio of the 427 nm species to the 455 nm 
species decreases with increasing pH, indicating that low pH favours the 
formation of the 427 nm species and high pH the 455 nm species. In 
phenobarbitone-induced microsomes (Fig. 6.1) th e '427 nm species predomi­
nated when the complex was formed at pH 6.5, a t pH 7.5 the 427/455 nm 
ratio was approximately 1.0 and at pH 8.5 the 455 nm species had become 
dominant. In contrast, in 3-methylcholanthrene-induced microsomes 
(Fig. 6.2) the 455 nm species was dominant at all of the pH values 
investigated and although the 427 nm species was present at pH 6.5, its 
presence decreased with increasing pH since it was only present as a slight 
shoulder at pH 7.5 and totally absent at higher pH. Furthermore, the rate of
FIGURE 6.1
E ffect of pH on the development of the 427 nm and 455 nm
absorption maxima produced during in vitro metabolism of
isosafrole in phenobarbitone-induced ra t hepatic microsomes
Phenobarbitone-induced microsomes (1.0 mg/ml) were suspended in 6 6  mM 
Tris-HCl buffer pH = 6.5, 7.5 or 8.5, divided equally between two cuvettes 
and incubated for 5 minutes at 37 °C in the presence of NADPH and a 
regenerating system. After recording a baseline of equal light absorbance 
isosafrole (250 pM) was added to the sample cuvette and the spectrum 
between 350 and 500 nm recorded at 30 seconds intervals.
FIGURE 6.2
E ffect of pH on the developm ent of the 427 nm and 455 nm
absorption maxima produced during in vitro metabolism of
isosafrole in 3-m ethylcholanthrene-induced ra t hepatic
microsomes
3-Methylcholanthrene induced microsomes (1.0 mg/ml) were suspended in 
6 6  mM Tris HC1 buffer pH = 6.5, 7.5 or 8.5 and incubated as described in the 
legend to Figure 6.1.
FIGURE 6.3
E ffect of pH on the development of the 427 nm and 455 nm
absorption maxima produced during in vitro metabolism of
isosafrole in "undisplaced" isosafrole-induced ra t hepatic
microsomes.
tm pH . 7 5
Isosafrole-induced microsomes (0.9 mg/ml) were suspended in 6 6  mM Tris- 
HC1 buffer pH = 6.5, 7.5 or 8.5 and then incubated as described in the legend 
to Figure 6.1.
FIGURE 6A
E ffect of pH on the development of the W27 nm and 455 nm
absorption maxima produced during in vitro metabolism of
isosafrole in "displaced11 isosafrole-induced ra t hepatic
microsomes.
pH* 7*5
Isosafrole-induced microsomes (0.9 mg/ml) were suspended in 6 6  mM Tris-
HC1 buffer pH = 6.5, 7.5 or 8.5, incubated with isosafrole (250 jiM) a t 37°C 
for 30 minutes and then divided equally between two cuvettes. After 
addition of an NADPH regenerating system, a baseline of equal light 
absorbance was recorded before initiation of the reaction by the addition of 
NADPH. The spectrum between 350-500 nm was recorded at 30 second 
intervals.
formation of the isosafrole-metabolite complex in the 3-methylcholan- 
threne-induced microsomes was much slower at pH 6.5 than at pH 7.5 or 
higher. In "undisplaced” isosafrole microsomes (Fig. 6.3) dual absorption 
maxima were apparent at pH values up to pH 8.0 and only one peak at
455 nm was present at pH 8.5. At the lower pH values the 427 nm species 
was predominant and the second absorption maximum started at 465 nm and 
this underwent a spectral shift to 460 nm at pH 6.5, 458 nm at pH 7.0 and
456 nm at pH 7.5 as the intensity of the absorption maximum increased. 
This spectral shift of the "455 nm" absorption maximum was not observed 
following displacement of the in vivo isosafrole metabolite-cytochrome 
P-450 complex and subsequent in vitro metabolism of isosafrole. In the 
"displaced" isosafrole microsomes (Fig 6.4) the 427 nm species became the 
dominant species over the whole pH range studied although formation of the 
455 nm species increased with increasing pH.
The effect of pH on the formation of the 427 nm and 455 nm species 
is also shown in Figs. 6.5-6.8 which, in addition, demonstrate differences in 
the apparent absorption of the complex when reduced with NADPH or 
sodium dithionite. In phenobarbitone-induced microsomes (Fig. 6.5) the 
optimum pH for the formation of the 455 nm species was pH 8.0 and for the 
427 nm there appeared to be an optimum pH at 7.5 although chemical 
reduction of the microsomes appeared to be necessary for this to become 
apparent. In 3-methyicholanthrene-induced micrbsomes (Fig 6 .6 ) a similar 
pH optimum for the formation of the 455 nm species was observed (pH 8.0-9.5) 
and similarly the optimum for 427 nm species formation was pH 7.0-7.5. 
Once again the chemical reduction of the microsomes with sodium dithionite 
was necessary to reveal the full extent of 427 nm formation. Interpretation 
of the results for isosafrole-induced microsomes is more difficult since 
there is apparently no optimum pH for the formation of either the 427 nm or
FIGURE 6.5
E ffect of pH on the ex ten t of development of
the 427 nm and 455 nm absorption maxima following in vitro
metabolism of isosafrole in phenobarbitone-induced microsomes.
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Phenobarbitone-induced microsomes were suspended in Tris-HCl buffers of 
varying pH and the in vitro metabolism of isosafrole recorded as described 
in the legend to Fig. 6.1. When no further increase in either the 427 nm or 
455 nm absorption maximum was recorded sodium dithionite (1-2 mg) was 
added to both cuvettes and the dithionite-reduced spectrum recorded.
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FIGURE 6.6
Effect of pH on the ex ten t of development of the
427 nm and 455 nm absorption maxima following in vitro
metabolism of isosafrole in 3-methylcholant-hrene-induced microsomes
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The effect of pH on the extent of development of the isosafrole metabolite- 
cytochrome complex in 3-methylcholanthrene induced microsomes
under NADPH- or sodium dithionite-reduced conditions was recorded as 
described in the legend to Fig. 6.5.
♦ — 0 , Ai,27-«0/ms Protein
0 ----------0>,  A it 5 5 . i > 9 0 / mg protein
NADPH-reduced spectrum
EH--SI, A427-490^mg protein - i
| .Sodium dithionite-reduced spectrum 
□  A^55_^9Q/mg protein -J
FIGURE 6.7
.c
*<D
e
CL
cn
E
' o
X
<
<
0
1JC
£
CL
Effect of pH on the ex ten t of developm ent of the
427 nm and 455 nm absorption maxima following in vitro metabolism
of isosafrole in "undisplaced" isosafrole-induced microsomes
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The effect of pH on the extent of development of the isosafrole metabolite 
cytochrome P ^ q complex in "undisplaced" isosafrole-induced microsomes 
under NADPH- or sodium dithionite-reduced conditions was recorded as 
described in the legend to Fig. 6.5.
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FIGURE 6.8
E ffect of pH on the ex ten t of development of the
427 nm and 455 nm absorption maxima following in vitro metabolism
of isosafrole in "displaced" isosafrole-induced microsomes.
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The effect of pH on the extent of development of the isosafrole metabolite- 
cytochrome P ^ q complex in "displaced" isosafrole induced microsomes 
under NADPH- or sodium dithionite-reduced conditions was recorded as 
described in the legend to Figs. 6.4 and 6.5
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o —  <>, Ai#5 5 _((9 0/mg protein3 NADPH-reduced spectrum
H ------ ® ,  AZf27_^ f90/mg protein
□ ------ □ ,  A455_49(/mS Protein 3
Sodium dithionite-reduced spectrum
455 nm species within the range studied. In undisplaced isosafrole- 
microsomes the pH at which the 427/455 nm ratio is 1.0 appears to be 
pH 7.5 in the presence of NADPH but 8.0-8.5 in the presence of sodium 
dithionite. In the displaced isosafrole-microsomes in the presence of 
NADPH the 427/455 nm ratio is always greater than 1.0 however in the 
presence of sodium dithionite the 427/455 nm ratio is 1.0 at pH 8.0. This 
difference between the results obtained in the presence of NADPH and 
those obtained in the presence of sodium dithionite is not due to changes in 
the pH of the buffer, since the concentrations of sodium dithionite used in 
this study were found not to alter the pH of the contents of a spectrophoto­
meter cuvette.
6.2.3 Investigation of the spectral changes produced during in vitro
metabolism of methylendioxynaphthalene in rat hepatic microsomes
The in vitro metabolism of methylenedioxynaphthalene has been 
observed to result in spectra which are atypical of the spectra obtained with 
the methylenedioxyphenyl compounds during in vitro metabolism. The 
addition of methylenedioxynaphthalene to a suspension of oxidized micro­
somes produced a Type I binding spectrum (Fig. 6.9). Subsequent metabo­
lism of the methylenedioxynaphthalene in the presence of NADPH and a 
regenerating system initially produced 427 nm and 455 nm absorption 
maxima typical of the formation of a MDP metabolite-cytochrome P-450 
complex. However, further metabolism resulted in a sudden rapid increase 
in the size of the 455 nm absorption maximum and a spectral shift of the 
peak to 452 nm followed by a slight decrease in the size of the absorption 
peak before reaching a steady state with no further changes (Fig. 6.9).
After observing these rapid spectral changes it was found that 
reduction of both sample and reference cuvettes with sodium dithionite 
resulted in the appearance of a peak at 450 nm which resembled that of the
FIGURE 6.9
Spectral changes observed during metabolism of methylene­
dioxynaphthalene in vitro in phenobabritone-induced rat 
hepatic microsomes. ____________
0-02 A
400 420380 440 460 480
Phenobarbitone-induced rat hepatic microsomes were suspended (2 mg 
protein/ml) in 66 mM Tris-HCl pH 7.4, divided equally between two cuvettes 
and a baseline of equal light absorbance recorded. After addition of 
methylenedioxynaphthalene (200 jliM) the spectrum was recorded
( 6 -------- ©). 7 he spectral changes following addition of NADPH and a
regenerating system to both cuvettes were also recorded between 350-500 nm 
at 1 min intervals. Incubation temperature 37 °C.
reduced-carbon monoxide spectrum. Subsequent bubbling of carbon 
monoxide through the sample cuvette resulted in an increase in the size of 
the 450 nm peak but this did not increase to the size expected from the 
measurement of the reduced-CO spectrum in a sample of the microsomes 
prior to metabolism of the substrate (Table 6.1). Metabolism of methylene­
dioxynaphthalene by phenobarbitone-induced and 3-methylcholanthrene- 
induced microsomes produced similar results to those observed in control 
microsomes except that the decrease in the value for A A ^ q ^g /m g  
protein was only 36% in control microsomes but 62% in both phenobar- 
bitone- and 3-methylcholanthrene-induced microsomes. These results 
suggest that the metabolism of the substrate either produces a metabolic 
intermediate which binds to the cytochrome P-450 to give a single 
absorption maximum at 452 nm and decreases the apparent cytochrome 
P-450 concentration or the metabolic intermediate destroys some of the 
cytochrome P-450.
6.2.4 Investigation of the possible role of cytochrome b^ in the characte­
ristic 427/455 nm dual absorption maxima produced during the 
metabolism of MDP compounds by the hepatic monooxygenase
The amount of MDP metabolite-cytochrome P-450 complex present 
in a microsomal preparation has been routinely estimated by means of a 
reduced minus oxidized difference spectrum, the heights of the 427/455 nm 
absorption maxima used as a measure of the amount of metabolite complex. 
However, this method of estimation must be used with care since the 
cytochrome b^ content of the microsomes is not taken into account and yet 
reduced cytochrome b^ also has an absorption maximum at 427 nm. Indeed, 
estimation of the cytochrome b^ content is complicated by the presence of 
the MDP-metabolite complex and vice versa, therefore it has not yet been 
demonstrated whether the MDP compounds induce the microsomal cyto-
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chrome b^ content as well as the cytochrome P-450 content or whether the 
increased absorption maximum at 427 nm is entirely due to the presence of 
the metabolite complex.
Sato et al (1969) reported the selective solubilisation of cytochrome 
b^ from hepatic microsomes by incubation of the microsomes with 
Nagarase, a protease from Bacillus subtilis whilst the cytochrome P-450 
remained attached to the microsomal particles. The conversion of 
cytochrome P-450 to the inactive cytochrome P-420 was minimised by the 
addition of 25-30% glycerol to the incubation medium (Ichikawa and 
Yamano, 1967).
In the present work a similar system was used to attem pt the 
selective removal of cytochrome b^ from the hepatic microsomes of animals 
pretreated with MDP compounds and which therefore contained in vivo MDP 
metabolite-cytochrome P-450 complex. Safrole-, isosafrole- or dihydro- 
safrole-induced microsomes were suspended (2.5 mg/ml) in 66 mM Tris-HCl 
buffer (pH 7.4) containing 20% (v/v) glycerol and two 25 ml samples placed 
in conical flasks. One sample was stirred with 2 mg Sigma Protease VII 
(subtilisin) for 14 hrs at 4°C under an atmosphere of nitrogen and the other 
control sample was incubated similarly in the absence of the protease. 
After the incubation the samples were centrifuged at 116,000g for 50 min 
and the resultant supernatant decanted and stored on ice. The pellet was 
resuspended in the Tris-HCl/glycerol buffer and recentrifuged as before, the 
resultant supernatant was discarded and the pellet resuspended in Tris- 
HCl/glycerol buffer (10 ml). Samples of the reddish-brown supernatant and 
the pale pink microsomal suspension were investigated spectrophoto- 
metrically and the dithionite-reduced minus oxidized spectra and the 
reduced-CO spectra recorded for each fraction. The results are shown in 
Table 6.2.
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The results show a decrease in the content of the 427 nm absorbance 
and in cytochrome P-450 concentrations after the protease-treatment, even 
when adding the values obtained for the pellet and supernatant. The 
recoveries of the 427 nm absorbing species and cytochrome P-450 are about 
25-35% for the protease-treated microsomes compared with the control 
microsomes, however the recovery of the 455 nm absorbing species was 
95-105%. Although protease-treatment resulted in the appearance of a 
shoulder at 420 nm in the reduced-carbon monoxide spectrum for both pellet 
and supernatant, the enzyme treatment did not generally convert the 
cytochrome P-450 to the denatured cytochrome P-420.
Incubation under similar conditions except for the absence of 
protease did not result in the significant removal of cytochrome P-450, 
427 nm or 455 nm absorbing species from the pellet nor was there a 
significant conversion of cytochrome P-450 to cytochrome P-420. 
Similarly, in the protease-treated microsomes there was little transfer of 
cytochrome P-450 to the supernatant and no transfer of the 455 nm species 
to the supernatant. However, in the safrole-induced microsomes the 
protease treatment removed all of the 427 nm species and in isosafrole- 
induced microsomes only 17% of the recovered 427 nm species remained in 
the pellet but in the dihydrosafrole-induced microsomes 55% of the 
recovered 427 nm species remained in the pellet. In general it appears that 
treatment of safrole- and isosafrole-induced microsomes with protease VII 
removes the 427 nm species from the microsomal pellet leaving the 455 nm 
species in situ.
The absolute spectra of the supernatants obtained after protease- 
treatment of the microsomes were recorded in an attempt to find some 
evidence that the red pigment which was removed from the microsomes by 
this treatment was cytochrome b^. The absolute spectrum of the
supernatant from protease-treated safrole-microsomes, shown in Fig. 6.10, 
demonstrates that the supernatant contains cytochrome since the absorp­
tion maxima at 557 nm, 526 nm and 422 nm in the reduced spectrum 
correspond to the correct wavelengths for the a, 3 and y Soret peaks of 
cytochrome by  Further evidence is obtained from the shape of the a-Soret 
peak since for cytochrome b^ this is an asymmetrical peak at 557 nm with a 
slight shoulder at 560 nm whereas for the other b-type cytochromes with 
protohaem IX prosthetic groups this peak should be symmetrical at 
599-560 nm (Hagihara and Furuya, 1978).
6.3 DISCUSSION
Incubation of several MDP compounds in vitro with NADPH and 
hepatic microsomes results in the formation of absorption maxima at 427 nm 
and 455 nm, which are thought to be the spectral manifestations of 
complex formation between a MDP-metabolite and reduced cytochrome 
P-450 (Franklin, 1971; Hodgson et al, 1973). In the oxidized state, the MDP 
metabolite-cytochrome P-450 complex is reported to be observed as a single 
absorption maximum at 437-438 nm (Philpot and Hodgson, 1971b; Elcombe 
et al, 1975a) or at 442 nm in the case of the MDP-juvenile hormone analogue 
RO-203600 (Mayer and Prough, 1976). In both cases the single oxidized 
peak was readily converted to the characteristic 427 nm and 455 nm 
absorption maxima by reduction with sodium dithionite, indicating that the 
spectra observed represent different redox states of the same complex.
Formation of the 438 nm oxidized spectrum has been demonstrated 
following the addition of the organic hydroperoxide, cumene hydroperoxide 
to a suspension of hepatic microsomes containing various MDP compounds 
(Elcombe et al, 1975b; Dickins, 1978). Subsequent dithionite reduction of 
the microsomal suspensions resulted in the appearance of the 427 nm and
FIGURE 6.10
Absolute spectrum  of the supernatant obtained a fte r
protease VII trea tm en t of safrole-induced microsomes.
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Undiluted supernatant obtained after protease VII treatment of safrole-
induced microsomes was placed in the sample cuvette and 66 mM Tris-HCl 
buffer (pH 7A) containing 20% (v/v) glycerol in the reference cuvette. The
spectrum between 350 and 600 nm was recorded (-------- ), sodium dithionite
(1-2 mg) added to both cuvettes and the spectrum re-recorded (— — ).
455 nm absorption maxima and therefore cumene hydroperoxide probably 
catalyses the formation of a metabolite-complex comparable to that 
produced by NADPH and molecular oxygen but differing in redox state.
The relationship of the 438 nm oxidized peak to the dual 427/455 nm 
reduced peaks is not clear since the 438 nm peak appears not to be 
exclusively related to either the 427 nm or 455 nm peaks. Elcombe (1976) 
demonstrated a linear relationship between the magnitude of the 438 nm 
peak generated in vitro by isosafrole in the presence of cumene hydroper­
oxide and phenobarbitone-induced microsomes and the magnitudes of both 
427 nm and 455 nm peaks produced by subsequent reduction of these 
microsomes. Furthermore, calculation of the affinity constants for the 
formation of the 455 nm and 438 nm complexes with cytochrome P-450 
showed them to be identical (17 jiM). However, Dickins (1978) has 
demonstrated the formation of a 438 nm peak during incubation of methy- 
lenedioxycyclohexane with cumene hydroperoxide and phenobarbitone- 
induced microsomes and yet subsequent reduction of the microsomes 
produces only a single absorption peak at 427 nm thereby indicating a direct 
relationship between the 438 nm oxidized species and the 427 nm reduced 
species.
The relationship of the 427 nm and 455 nm peaks to each other is 
unclear. Dickins (1978) reported that the relative heights of the two 
absorption peaks generated during in vitro metabolism of MDP compounds 
were related to the state of induction of the microsomes since considerably 
more of the 455 nm species was apparent in 3-methylcholanthrene-induced 
microsomes than in phenobarbitone-induced or control microsomes. Similar 
results were obtained during the present studies, comparison of the spectra 
shown in Figs 6.1-6.4 at pH 7.5 demonstrated that in phenobarbitone-induced 
microsomes the 427 nm and 455 nm species were present in approximately
equal amounts but in the 3-methylcholarxthrene-induced microsomes the 
455 nm species was dominant. In isosafrole-induced microsomes the two 
peaks were generated in a ratio of about 1:1, however displacement of the in 
vivo generated complex and subsequent in vitro metabolism resulted in a 
large increase in the rate of formation of the 455 nm species and yet the 
dominant species overall was the 427 nm peak.
The 427 nm and 455 nm species have also been reported to be in a 
pH-dependent equilibrium during their in vitro generation from piperonyl 
butoxide in mouse (Philpot and Hodgson, 1971) and rat (Franklin, 1971) 
hepatic microsomes. These authors reported that generation of the in vitro 
complex at high pH (pH = 7.5-8.0) resulted in the formation of the 455 nm 
species as the dominant species but at lower pH (pH = 6.5) the 427 nm 
species was dominant similar to the pH dependence of the double Soret 
spectra obtained with ethyl isocyanide (Imai and Sato, 1966). Similar 
results have been obtained in this study using isosafrole as the substrate and 
comparing the effect of pH on the formation of the 427/455 nm complex in 
variously induced rat hepatic microsomes. In both phenobarbitone- and 
3-methylcholanthrene-induced microsomes there appeared to be pH optima for 
the 427 nm and 455 nm species at about pH 7.5 and pH 8.0 respectively. In 
the isosafrole-induced microsomes no pH optimum was apparent for the 
formation of the 427 nm or 455 nm species. The spectra recorded for the in 
vitro generation of the isosafrole-metabolite complex in "undisplaced" 
isosafrole-induced microsomes at pH 6.5-7.5 showed a hypsochromic shift of 
the "455 nm" absorption maximum from 465 nm to about 460 nm at pH 6.5 
and a concomitant decrease in the apparent trough at 455 nm. This shift in 
wavelength could be explained by a time-dependent decrease in the absorp­
tion at 455 nm in the reference cuvette, since both sample and reference 
cuvettes contained isosafrole-induced microsomes and NADPH, any in vivo
generated metabolite complex would have been in the reduced state, i.e. 
exhibiting 427 nm and 455 nm absorption peaks although these would, cancel 
each other out in a difference spectrum. It is possible that at the low pH 
values, the NADPH in the reference cuvette caused lipid peroxidation and 
subsequent destruction of a portion of the cytochrome P-450 including the 
metabolite complex and hence a net decrease in the interference at 455 nm. 
Franklin (1971) investigated further the nature of the relationship between 
the 427 nm and 455 nm species by changing the pH of the buffer once the 
complex generation was complete and demonstrated that a decrease in pH 
from 7.4 to 5.9 decreased the absorption a t 455 nm and increased it a t 430 nm, 
however addition of alkali to raise the pH failed to restore the balance 
of the 430/455 nm peaks. Addition of alkali to raise the pH from 7.4 
decreased the 427 nm peak with little or no increase at 455 nm. In this way 
the 427 nm and 455 nm peaks resemble further the interaction of ethyliso- 
cyanide with cytochrome P-450 since the interconversion of 427 nm to 455 nm 
and vice versa is not a simple reversible interconversion from one form 
to the other. Dahl and Hodgson (1978) have attempted to explain the 
interactions of ethylisocyanide with cytochrome P-450 by proposing the 
existence of two 455 nm species and one 430 nm species. One of the 455 nm 
species is suggested to result from a coordinate bond with the haem iron and 
the other from an interaction at the iron atom combined with a weak, non- 
disruptive lipophilic interaction with the protein. The 430 nm species is, 
they suggest, due to a 5 to 6 coordinate species when the axial mercaptide 
ligand to metal bond has been ruptured or lengthened by the trans influence 
of the ethylisocyanide and finally displaced by torsional strain in the protein 
caused by lipophilic interactions of the ethyl group of the ethylisocyanide. 
Displacement of the mercaptide in this way would eliminate the mercaptide 
to porphyrin charge transfer which is thought to be responsible for the
anomalous red shifted Soret bands found when strong £i-acceptor ligands 
combine with cytochrome P-450 (Dahl and Hodgson, 1977; Hanson et al, 
1976). This hypothesis requires the formation of the 455 nrn species before 
the 427 nm which may not be the case with the methylenedioxyphenyl 
compounds since at low safrole concentrations Elcombe (1976) has demon­
strated that only the 427 nm species is formed. The hypothesis also fails to 
explain the 427 nm formation during metabolism of methylenedioxycyclo- 
hexane since there is no evidence at all that even a transient 455 nm species 
is formed (Dickins, 1978). Methylenedioxycyclohexane does presumably 
interact with cytochrome P-450 at the iron atom since it is reported to be 
the best inhibitor of carbon monoxide binding to reduced cytochrome P-450 
of any methylenedioxy compound tested using mouse microsomes (Hodgson 
et al, 1973). However, the presence of a saturated ring system presumably 
means that methylenedioxycyclohexane is not as strong a £i-acceptor as the 
methylenedioxyphenyl compounds which have a planar ring and delocalised 
pi-bonds and therefore this compound should be less efficient at forming the 
427 nm species, if the ethyl isocyanide hypothesis is correct.
Anomalous spectra were observed during the metabolism of 
methylenedioxynaphthalene by hepatic microsomes in the presence of 
NADPH (Fig 6.9). Initially, there was an increase in absorption at 455 nm 
with a slight shoulder at 427 nm but this rapidly changed to an increasing 
absorption peak at 452 nm which decreased slightly in size before 
stabilizing. Subsequent determination of the reduced-carbon monoxide 
spectrum showed a decrease in the apparent cytochrome P-450 concen­
tration. This result is similar to that observed during metabolism of the 
MDP juvenile hormone analogue (E)-4-[(6,7-epoxy-3,7-dimethyl-2-nonenyl)- 
oxyl]-l,2-(methylenedioxy)benzene, (RO-203600) (Mayer and Burke, 1976; 
Mayer and Prough, 1976). Mayer and Burke (1976) considered this to be due
to carbon monoxide produced during haem catabolism as a result of NADPH- 
mediated lipid peroxidation, since the peak shift was only evident under 
anaerobic conditions and subsequent gassing of the cuvette with oxygen 
resulted in a return to the 455 nm form. It is possible that the contents 
inside the cuvette used in my studies did go anaerobic during the meta­
bolism, since naphthalene itself is a very good substrate for monooxy­
genation and results in a rapid stimulation of oxygen consumption when 
added to hepatic microsomes in the presence of NADPH (Wolf et ai, 1975). 
Methylenedioxynaphthalene may also be a good substrate for monooxy­
genation, since although the methylenedioxy group may have altered the 
lipid solubility of the compound, the ring system of the naphthalene moiety 
probably represents a better substrate for the cytochrome P-450 pool than 
the side chains of the methylenedioxyphenyl compounds and hence results in 
a greater cytochrome P-450 dependent oxygen consumption than the MDP 
compounds previously studied. The source of the carbon monoxide which 
bound to the reduced cytochrome P-450 when it reached the anaerobic state 
may have been a methylenedioxy metabolite found during the metabolism of 
the substrate. It is also possible that catabolism of the haem could have 
occurred due to lipid peroxidation or the formation of the metabolite- 
complex which may have had a disruptive influence on the haemoprotein 
structure.
The results obtained from protease-treatment of the MDP-induced 
microsomes are interesting since they may indicate an involvement of 
cytochrome b^ in the formation of the characteristic 427 nm and 455 nm 
absorption maxima of the reduced MDP metabolite complex. Protease- 
treatm ent of the safrole-induced microsomes totally removed all traces of a 
427 nm species from the microsomal pellet leaving behind the 455 nm 
species. The absolute spectrum of the supernatant indicated that cyto­
chrome had been removed by the protease treatment. Very little 
cytochrome P-450 was removed as judged by the lack of a 450 nm peak in 
the reduced-carbon monoxide spectrum and very little of the cytochrome 
P-450 was converted to cytochrome P-420 either in the supernatant or in the 
pellet. However, since the recovery of cytochrome P-450 is only 25-3596, 
quite a large proportion appears to be unreactive to carbon monoxide 
following protease-treatment and, since there is little evidence of a 
conversion to cytochrome P-420, this must be considered to have been 
destroyed during the enzyme digestion. Similarly, the recovery of the 427 nm 
species is also quite small (25-35%) and therefore some of this species 
was presumably destroyed during the digestion. In contrast, the recovery of 
the 455 nm species was 95-105% which implies that this species may be 
buried deep within the microsomal membrane and therefore not available to 
attack from the protease. The implications of this result are very 
interesting since either the 427 nm species formed is a result of the 
interaction of the MDP metabolite with cytochrome b^ or the 427 nm and 
455 nm species are the result of interaction of the MDP-metabolite with 
two different pools of cytochrome P-450. This could be true if the 427 nm 
species was due to an interaction with a cytochrome P-450 located on the 
surface of the microsomal membrane and the 455 nm species was due to an 
interaction with a cytochrome P-450 located within the membrane. This 
hypothesis could explain the observed results since cytochrome P-450 on the 
surface of the membrane would be open to attack by the protease enzyme 
which would result in the destruction or removal of this haemoprotein. The 
low recovery of both cytochrome P-450 and the 427 nm species and the fact 
that only a small amount of cytochrome P-450 was found in the supernatant 
suggests that the protease destroys the cytochrome P-450 with which it 
comes into contact. This conclusion is supported in part by the observation
of a small amount of cytochrome P-420 in both supernatant and pellet, since 
destruction of cytochrome P-450 by protease-treatment probably resuits 
from an initial conversion of the haemoprotein to the inactive cytochrome 
P-420 (Sato et al, 1969). It is possible, however, that the presence of the 
reactive metabolite is a stabilizing influence which protects the cytochrome 
P-450 with which it is complexed, since the cytochrome P-450 complexed 
with the 455 nm species appears to be intact after protease-treatment. It is 
also possible that the supernatant contained a cytochrome P-450 complexed 
with the 427 nm species which remained undetected because the 427 nm 
absorption was masked by that of the cytochrome b^ and since metabolite- 
complexed cytochrome P-450 does not react with carbon monoxide and 
therefore remains undetected in the reduced-CO spectrum. If this is true 
then the protease VII treatment of the microsomes might be a convenient 
method of separating the haemoproteins containing the two spectrally 
observable metabolite species following induction with a MDP compound.
In summary, the results presented in this chapter have demonstrated 
that the in vitro metabolism of isosafrole by rat hepatic microsomes results 
in the formation of 427 nm and 455 nm absorption maxima in a ratio that is 
dependent upon the pH of the buffer in which the incubation was carried 
out. At pH 7.5, phenobarbitone-induced microsomes tend to produce the 
two species in approximately equal quantities and 3-methylcholanthrene- 
induced microsomes tend to produce the 455 nm species to a much greater 
extent than the 427 nm species. In isosafrole-induced microsomes in the 
presence of the in vivo generated complex, the 427 nm and 455 nm species 
are produced in approximately equal quantities but after displacement of 
the isosafrole-metabolite complex the initial rate of production of both 
species is dramatically increased with the 455 nm species more rapidly 
produced than the 427 nm species although the 427 nm species was dominant
when metabolism ceased. Increases in the pH tended to increase the 
production of the 455 nm species and decrease the 427 nm species whilst 
decreases in the pH tended to favour formation of the 427 nm species.
Metabolism of methylenedioxynaphthalene in vitro produced an 
atypical spectrum which may be due to formation of carbon monoxide during 
the incubation and subsequent binding to the cytochrome P-450 when the 
incubation went anaerboic. The carbon monoxide could be derived from 
metabolism of the substrate, since formate is a metabolite of the methylene 
carbon of some MDP compounds (Kamienski and Casida, 1970), or from 
haem catabalism due to lipid peroxidation or binding of the metabolite. 
These atypical spectra have been observed previously by Dickins (1978) 
although infrequently, possibly because metabolism of the other MDP 
compounds at sites other than the methylene carbon is less rapid or 
extensive than the possible ring hydroxylation of methylenedioxynaph­
thalene, thereby giving less chance for the incubation to go anaerobic.
Incubation of safrole-, isosafrole- and dihydrosafrole-induced micro­
somes with Sigma Protease VII resulted in an apparent removal of the 427 nm 
species from the pellet into the supernatant whilst leaving the 455 nm 
species in the pellet. This may indicate that the 427 nm species is due to 
an interaction of the MDP-metabolite with cytochrome b^ or that two pools 
of cytochrome P-450 are involved in the in vivo interaction with MDP 
compounds. One pool of cytochrome P-450 may be attached to the surface 
of the microsomal membrane and be responsible for production of the 427 nm 
species whilst the other is buried deep within the structure of the 
membrane and is responsible for the 455 nm species. This could explain the 
production of only a 427 nm peak during incubation of low concentrations of 
safrole (Elcombe, 1976) since in low concentrations the substrate would only 
come into contact with the surface cytochrome P-450. Similarly, induction
of the hepatic monooxygenase by 3-methylcholanthrene results in the 
induction of cytochrome P-448, which is probably buried within the 
membrane where it would come into contact with the lipid soluble 
compounds and which also produces an increase in the amount of the 455 nm 
species produced during metabolism of isosafrole in vitro and in vivo 
following mixed induction (Chapter 3).
If the hypothesis proposed above is correct, then a structure- 
activity relationship should exist between the polarity of the MDP compound 
and the extent to which it forms a 427 nm absorption maximum during 
metabolism with the more polar compounds tending to form only the 427 nm 
species and the more lipophilic compounds tending to form the 455 nm 
species. The hypothesis could also be tested using purified cytochromes 
P-450, to observe which species were formed by "pure” cytochrome P-450 
compared to "pure" cytochrome P-448. Similarly, the involvement of 
cytochrome b^ could be tested using purified cytochrome b^ and cytochrome 
b^ reductase as the metabolizing system or by selective inhibition of 
cytochrome b^ reductase or NADPH-cytochrome P-450 reductase using 
specific antibodies raised against these components of the monooxygenase 
system.
CHAPTER 7
THE APPARENTLY IRREVERSIBLE BINDING OF ^  C-ISOSAFROLE- 
RELATED MATERIAL TO THE PROTEINS OF ISOLATED RAT HEPATQ- 
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7.1 INTRODUCTION
For many foreign compounds their metabolic activation to reactive
intermediates or products is now generally considered to be the primary
event in what may be a complex series of interactions leading to the
production of hepatotoxic, carcinogenic, mutagenic or teratogenic effects.
The apparently irreversible binding (frequently termed covalent binding) of
these metabolites to hepatic tissue was recognised over 30 years ago by
Miller and Miller (1947) following the dietary administration of the azo dye
butter yellow to rats. In later studies, Hultin demonstrated that
14C-methyl butter yellow was preferentially bound to the hepatic microsomal 
fraction in vivo (Hultin, 1957) and that in the presence of NADPH, aniline 
and 2-aminofluorene became irreversibly bound to the proteins of rat 
hepatic microsomes in vitro (Hultin, 1959).
Although the irreversible binding of foreign compounds to DNA is 
the most likely direct source of carcinogenic, mutagenic or teratogenic 
effects, the hepatotoxic effects of many compounds may be due to the 
binding of reactive metabolites directly to the macromolecules of the 
endoplasmic reticulum. Cytochrome P-450-dependent monooxygenation has 
been shown to be essential for the formation of many reactive metabolites 
and subsequent covalent binding to hepatic tissue (for reviews see Gillette 
et al, 1974; Uehleke, 1974) therefore modification of the activity of the 
cytochrome P-450 system (e.g. by inhibitors and inducers) will change the 
toxic effects observed. The covalent binding of several therapeutic
compounds (e.g. paracetamol, phenacetin and furosemide) to hepatic 
proteins has been demonstrated following administration of overdoses of 
these compounds (Mitchell et al, 1973; Mitchell and Jollow, 1975). These 
authors have also demonstrated the effects of known inducers and inhibitors
of cytochrome P-450-mediated reactions on the hepatotoxicity of such 
compounds.
The methylenedioxyphenyl compounds, safrole and isosafrole, have 
been shown to be hepatotoxic and carcinogenic (Taylor et al, 1964; Hagan et 
al, 1965). Metabolism of these two compound, is cytochrome P-450- 
dependent and results in the production of several different metabolites by 
oxidation of the methylenedioxy ring or the allyl side-chain and/or the 
methylene carbon. Borchert et al (1973a,b) and Wislocki et al (1976) have 
suggested that metabolism of safrole at the 1-position on the side-chain 
may result in the formation of several electrophilic metabolites which are 
probably the proximate and/or ultimate carcinogenic metabolites in the 
mouse. Indeed, Wislocki et al (1977) have demonstrated the binding of some 
of these putative toxic metabolites to mouse hepatic macromolecules, which 
may be responsible for producing the toxic, mutagenic or carcinogenic 
effects. The irreversible binding of isosafrole-related material to hepatic 
macromolecules has been demonstrated in vivo in the rat (Elcombe, 1976; 
Dickins, 1978) and mouse (Dickins, 1978) and in vitro with rat hepatic 
microsomes prepared from normal rats and those pretreated with various 
enzyme inducers (Dickins, 1978). The degree of covalent binding was much 
higher in the in vitro system than in vivo and since this may reflect a 
protective effect of non-microsomal enzymes, it was decided to investigate 
further the covalent binding of isosafrole in vitro in isolated hepatocytes 
and to study the effects of enzyme induction on the degree of covalent 
binding.
7.2 RESULTS
r  14 n7.2.1 Covalent binding of [u - CJ isosafrole-related material in Isolated
rat hepatocytes and the subcellular distribution of the covalently
14bound material following incubation with C-isosafrole in vitro
Hepatocytes were isolated from the livers of 60-80g rats by the 
method of Fry et al (1976) and suspended in Hank’s based Eagle’s minimal 
essential medium containing glutamine but in the absence of foetal calf
serum. The hepatocytes (>90% viability by trypan blue exclusion) v/ere
6 14incubated in 5 ml volumes (approx. 2 x 10 cells per ml) with 175 pMw - C-
isosafrole (0.874 pCi/ml) for 25 minutes at 37°C. The reaction was 
terminated by cooling to 4°C before sedimentation of the cells by centri­
fugation and isolation of the subcellular fractions as described in Methods. 
14The binding of C-isosafrole-related material to the proteins of the cell
14components was considered to be covalent if the C activity was detectable 
in the protein samples after the exhaustive solvent extraction as described 
in Methods (Kappus and Remmer, 1975). This extraction procedure appeared 
to be efficient since negligible quantities of radioactivity were removed by 
the final extractions compared with the amount of radioactivity remaining in 
the pellet; Table 7.1 illustrates a typical extraction procedure. The 
distribution of marker enzymes showed that there was a significant conta­
mination of the nuclear fraction since the activities of glucose-6-phospha- 
tase, succinate dehydrogenase and acid phosphatase were all high in this 
fraction. This was attributed to contamination of the nuclear fraction by
undisrupted cells and cell debris which were observed by light microscopy.
14The subcellular distribution of covalently bound C-isosafrole-related 
material is shown in Table 7.2. Clearly, the isosafrole was metabolized by 
the hepatocytes and resulted in the binding of a reactive metabolite to the 
proteins throughout the cell. There was a fairly even distribution of the
Table 7.1 A typical sequential extraction procedure for a
subcellular fraction from hepatocytes incubated 
14
with oj- C-isosafrole in vitro
Extraction Medium Total nCi radioactivity in 
extraction
Absolute ethanol (10 ml) 230.0
70% (v/v) ethanol (5 ml) 7.9
0.25M Tris-HCl pH 7.4 (5 ml) 6.0
0.25M Tris-HCl pH 7.4 (5 ml) 3.4
70% (v/v) ethanol (5 ml) 0.1
96% (v/v) boiling ethanol (5 ml) 0.1
96% (v/v) boiling ethanol (5 ml) 0.1
Acetone/CHCl^ (4:1) (5 ml) 0.6
Acetone/CHCl^ (4:1) (5 ml) 0.4
70% (v/v) ethanol (5 ml) 0.1
Protein pellet 38.1
The subcellular fraction, before extraction, contained 271 nCi of 
radioactivity of which 86.7% was extracted by this procedure with 
a total recovery of 105.8%. Limit of detection = 0.01 nCi.
14
Table 7.2. Covalent binding of C-isosafrole-related material to
the cellular components of isolated rat hepatocytes 
14
incubated with C-isosafrole in vitro
Fraction % Recovery ^ C * nmol bound per 
mg protein
ng bound per 
mg protein
Nuclear t 111.4 0.194 31.4
Mitochondrial 97.5 0.088 14.2
Lysosomal 108.2 0.129 20.9 '
Microsomal 99.3 0.141 22.9
Cytosol 82.6 0.139 22.5
14 14
* 0 . 140 . _ , , _ E C in extracts + C in protein pellet
* Recovery of C calculated from — ^ — :----------------------- -------- -------
C in original subcellular fraction 
f Observed to be contaminated with undisrupted cells 
Values quoted are for one experiment
x100
covalent binding in the lysosomal, microsomal and cytosolic fractions with a
, 14 rsmaller amount 0 1  C-radio label bound in the mitochondia. The large
amount of covalent binding in the nuclear fraction is probably due, at least
in part, to the presence of undisrupted cells.
147.2.2 Comparison of the covalent binding of C-isosafrole-related
material to the cellular components of hepatocytes isolated from
rats treated with phenobarbitone, 3-methylcholanthrene, isosafrole
1^and sunflower-oil following incubation with C-isosafrole in vitro
Hepatocytes were isolated from 200-225g rats which had been
treated with phenobarbitone, 3-methylcholanthrene, isosafrole o r  , the
vehicle, sunflower oil in vivo as described in Methods. The hepatocytes,
isolated by the perfusion method described in Methods, were all of high
viability (>94%) and were suspended (approx. 2 x 10^ cells/ml) in 10 ml
volumes of Hank’s based Eagle’s minimal essential medium containing
glutamine but no foetal calf serum. The incubation flasks for each
hepatocyte preparation were divided into four groups, diethylmaleate (DEM)
at a concentration of 90 nmoles/10 cells was added to two of the groups
and all four groups were then incubated for 30 minutes at 37 °C. At the end
of this preincubation the viability of the hepatocytes had decreased in both
the untreated and DEM-treated cells by a similar extent (5-10%). The 
14substrate w- C-isosafrole was then added to one untreated group and one
14DEM treated group to give a final concentration of 175 pM C-isosafrole 
(1.012 pCi/ml) and these were incubated under air for 30 minutes at 37°C. 
The two remaining groups, untreated and DEM treated, were bubbled with 
carbon monoxide (CO) for two minutes before addition of the substrate (as 
above) and these were then incubated in a closed atmosphere containing 
carbon monoxide for 30 minutes at 37 °C. At the end of the incubations the
viabilities of the cells had decreased but were all within the range of
70-85%. The cells were sedimented, homogenized and subcellular fractions
prepared as described in Methods. Measurement of the activities of
glucose-6-phosphatase, succinate dehydrogenase and acid phosphatase
showed that the nuclear fraction was contaminated with components of the
other cell fractions but that the mitochondrial, lysosomal, microsomal and
cytosolic fractions were relatively free from contamination. Further
examination of the nuclear fraction by light microscopy showed that the
contamination of this fraction was due to the presence of cell debris and
some undisrupted cells. The extent of covalent binding was measured after
an extraction of the subcellular fractions similar to that shown in Table 7.1.
The results are shown in Tables 7.3-7.6 for control, phenobarbitone-induced,
3-methylcholanthrene-induced and isosafrole-induced hepatocytes, respec-
14tively. Unfortunately, a shortage of the radiolabelled substrate (w - C- 
isosafrole) made it impossible to repeat this study and therefore the results 
presented in Tables 7.3-7.5 are figures obtained from single determinations.
The covalent binding to the subcellular fractions of control (sun­
flower oil-treated) hepatocytes is shown in Table 7.3. The distribution of 
14C-isosafrole-related material throughout the various fractions is similar
in both untreated and diethylmaleate-treated cells but it appears to be
generally decreased in the carbon monoxide-treated cells with perhaps a
14relatively higher proportion of the recovered C appearing in the cytosol.
However, after extraction of the unbound radioactivity from the subcellular
14fractions, comparison of the percentage of C bound in each fraction shows
that incubation of the cells under carbon monoxide decreased the protein 
14binding of the C-radiolabel in every fraction except the mitochondrial 
fraction with the most marked decreases in the microsomal and cytosolic 
fractions.
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14The distribution of the C-radiolabel throughout the cell seems to 
have been constant in isosafrole- and 3-methylcholanthrene-induced hepato­
cytes whether these were treated with carbon monoxide, diethyimaleate or
14the combination of the two. However, the distribution of C among the
cell fractions was similar for untreated or diethylmaleate-treated phenobar-
bitone-induced hepatocytes but was much higher in every fraction in the
cells which were treated with carbon monoxide or carbon monoxide and
14diethyimaleate. Comparison of the percentage of C-radiolabel which
was covalently bound compared to the amount of radioactivity found in each
fraction is probably the best way to quantitate the degree of covalent
binding because although covalent binding expressed as ng or nmoles 
14C-isosafroie-related material bound per mg protein appears to be more
specific, the binding may be concentration dependent and no account is
14taken of the concentration of C-radiolabel isolated in each fraction. The
14results of Tables 7.3-7.6 expressed as the percentage of C found in each 
fraction which appears to be covalently bound are summarised in Table 7.7.
Induction with phenobarbitone results in a large increase in the 
amount of covalent binding in all of the subcellular fractions with increases 
of about 500%, 650%, 400%, 1,500% and 1,600% in the nuclear, mito­
chondrial, lysosomal, microsomal and cytosolic fractions respectively. 
These large increases, notably in the microsomal and cytosolic fractions, 
were prevented by the incubation of the induced hepatocytes under carbon 
monoxide which indicates a requirement for oxidative metabolism to
produce a reactive metabolite, although covalent binding of the 
14C-isosafrole-related material to the various cellular components was still 
higher than in the control hepatocytes. Treatment of the phenobarbitone- 
induced hepatocytes with diethyimaleate slightly decreased the amount of 
covalent binding in all of the ceilular components except the mitochondria
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and diethyimaleate in combination with carbon monoxide decreased the 
covalent binding slightly more than carbon monoxide alone.
Induction with 3-methylcholanthrene increased the covalent binding
14of C-isosafrole-related material to all of the cellular components with
increases of about 200%, 150%, 60%, 200% and 550% respectively in the
nuclear, mitochondrial, iysosomal, microsomal and cytosolic fractions.
These increases in covalent binding were not as large as those previously
found with phenobarbitone-induced hepatocytes but once again there were
large increases in the microsomal and cytosolic fractions but this time the
increase in cytosol binding was much larger that the microsomal binding.
14Once again the covalent binding of the C-isosafrole-related material was 
inhibited by incubation of the hepatocytes under carbon monoxide indicating 
the requirement of cytochrome P-450-mediated metabolism to produce a 
reactive metabolite, although covalent binding in the nuclear, mitochondrial 
and lysosomal fractions was greater than that found in the control hepato­
cytes whilst the binding in the microsomal and cytosolic fractions was 
similar to that found in control hepatocytes. Diethyimaleate treatm ent of 
the 3-methylcholanthrene-induced hepatocytes decreased the amount of 
covalent binding in the nuclear, lysosomal and microsomal fractions but did 
not alter the binding in mitochondria and slightly increased the binding in 
the cytosol. Treatment with diethyimaleate and carbon monoxide produced 
a further slight decrease in covalent binding compared with treatment of the 
cells with carbon monoxide alone.
Isosafrole-induction produced only small increases in the binding of
14C-isosafrole-related material to the cellular components of hepatocytes 
with increases of 40%, 100%, 120%, 230% and 330% in the covalent binding 
to the nuclear, mitochondrial, lysosomal, microsomal and cytosolic fractions 
respectively. The increases were smaller than observed following induction
by phenobarbitone or 3-methylcholanthrene but once again covalent binding
to microsomal and cytosolic fractions was greater than in the other
fractions. Incubation of the hepatocytes under carbon monoxide resulted in
a decreased amount of covalent binding in all of the subcellular fractions
whilst diethyimaleate treatment had little effect with only very slight
14decreases in the binding of C-isosafrole-related material to the lysosomal 
and microsomal fractions. The combined diethyimaleate and carbon mon­
oxide treatment showed little effect on the levels of covalent binding 
compared with carbon monoxide treatm ent alone.
In summary, -^C]-isosafrole was metabolized in isolated hepa­
tocytes in vitro to a reactive species which bound tightly to the proteins of 
the cellular components and was not removed by exhaustive solvent extrac­
tion. This apparently covalent binding required activation of the substrate 
molecule by cytochrome P-450-dependent monooxygenation since inhibition
of the monooxygenase with carbon monoxide reduced the amount of 
14C-isosafrole-related material found in the cellular fractions. Pretreatment of 
the control hepatocytes with diethyimaleate resulted in a slight increase in 
the degree of covalent binding particularly in the microsomal fraction. 
Induction by phenobarbitone resulted in a high proportion of the radio­
activity isolated in the cellular components being covalently bound 
especially in the microsomal fraction and cytosol. Induction by 
3-methylcholanthrene and isosafrole resulted in a higher proportion of the 
radioactivity being covalently bound than in control hepatocytes but much 
less than in phenobarbitone-induced hepatocytes. Once again the micro­
somal and cytosolic fractions contained the highest proportions of covalent 
binding.
7.3 DISCUSSION
Isosafrole has been shown to be hepatotoxic to rats, producing
hepatic ceil enlargement, cystic necrosis, fatty metamorphosis and bile
duct proliferation and to be a weak hepatocarcinogen (Taylor et al, 1964;
Hagan et al, 1965). Administration of -^ C ] isosafrole to rats resulted
14in an apparently irreversible binding of C-isosafrole-related material
to the hepatic cellular components with a high proportion of the "covalently
bound" material located in the microsomal fraction (Elcombe, 1976).
Dickins (1978) demonstrated that the degree of covalent binding to rat
hepatic microsomes and tissues was decreased by inducing the animals
with phenobarbitone or 3-methylcholanthrene prior to administration
14of the isosafrole. However, in vitro incubation of [or- C]-isosafrole
with the microsomal fractions from phenobarbitone-, 3-methylcholanthrene-
and safrole-treated rats in the presence of NADPH resulted in an increased
14amount of covalent binding of C-isosafrole-related material to the 
microsomal protein of the induced microsomes compared with control micro­
somes (Dickins, 1978). These differences in the degree of covalent binding 
were ascribed to the lack of any conjugating system in the in vitro studies 
since in vivo a reactive metabolite might be "inactivated" by the actions 
of the glutathione-S-epoxide transferases, epoxide hydratases, sulphotrans- 
ferases and glucuronyl transferases. A model system in which these 
conjugation pathways were active might represent a useful tool for the
investigation of covalent binding in vitro and therefore the covalent binding 
14of [w- C] isosafrole was studied in isolated hepatocytes.
Comparison of my results obtained in hepatocytes with those
obtained in vivo, Table 7.8 (Elcombe, 1976), shows that the distribution of 
14C-isosafrole-related material throughout the cellular components was 
similar to that found in vivo. The amount of covalently bound material
14
Table 7.8 Covalent binding of C-isosafrole-related material to
rat hepatic cellular components after administration of 
14
C-isosafrole in vivo
CtaKen from Elcombe, 1976)
Fraction
14
% Recovery C* nmol bound per 
mg protein
ng bound per 
mg protein
Nuclear 116.6 0.245 39.7
Flitochondrial 70.2 0.157 25.5
Lysosomal 63.8 0.247 40.0
Microsomal 79.9 0.627 101.6
Cytosol 97.8 0.342 55.3
14 14
n S C in extracts + C in protein pellet
^Recovery calculated from ------------------------- ---------------- x100
C in original subcellular fraction
found in each fraction in vivo expessed as "nmoles bound per mg protein" 
compares well with the values obtained in hepatocytes Table 7.2. The 
nuclear fraction of the isolated hepatocytes is contaminated with undis­
rupted whole cells since the effectiveness of a Potter-homogeniser is 
decreased when the tissue already exists as isolated cells, and this probably 
accounts for the higher amount of covalent binding in this fraction 
compared with the other subcellular fractions. In contrast, the values
14
obtained for the covalent binding of C-isosafrole in vitro to hepatic 
microsomes, Table 7.9 (Dickins, 1978) shows a marked discrepancy since the 
amount of covalent binding was between 10 and 100 times higher than that 
found in vivo (Table 7.8) or in vitro in hepatocytes (Table 7.2). These 
results suggest that isolated hepatocytes are a much closer model system to 
the situation found in vivo since they retain active conjugation pathways 
which may be responsible for the decreased amount of covalent binding 
compared with that found in vitro in hepatic microsomes.
14
In general, incubation of isolated hepatocytes with C-isosafrole 
under an atmosphere of carbon monoxide resulted in a decreased extent of 
covalent binding, indicating the involvement of cytochrome P-450- 
dependent monooxygenation in the formation of the reactive metabolites. 
Although carbon monoxide specifically inhibits the microsomal mono­
oxygenase, it also binds to mitochondrial cytochromes and has been shown to 
alter the pattern of drug metabolism in normal hepatocytes (Poland and 
Kappus, 1971). This is possibly the reason for the lack of a decrease in the 
binding of isosafrole to the mitochondrial proteins when the cells were 
incubated under carbon monoxide. Carbon monoxide may also bind to other 
cellular macromolecules, including those within the mitochondria, resulting 
in an increased or decreased affinity for the reactive metabolite and have a 
change in the degree of covalent binding. However, isosafrole may bind
14
Table 7.9 Covalent binding of C-isosafrole-related material to 
variously induced rat hepatic microsomal suspensions 
in vitro
(taken from Dickins, 1978)
Treatment nmol bound/mg microsomal protein
Gil 10.36
Phenobarbitone 21.37
3-Methylcholanthrene 14.44
Safrole 24.36
14 o
Microsomes were incubated with C-isosafrole (180 yM) at 37 C for
30 minutes in the presence of an NADPH-regenerating system
specifically to the mitochondrial macromolecules since MDP compounds 
added in vitro to mitochondrial preparation result in an uncoupling of 
oxidative phosphorylation although this has not been observed in vivo 
(Nelson e ta l, 1971).
14Comparison of the covalent binding of C-isosafrole-related 
material to the cellular components of hepatocytes isolated from phenobar­
bitone-, 3-methylcholanthrene- and isosafrole-induced rats showed a pattern 
of binding in the microsomal fractions which was similar to the results of
Dickins (1978) in rat hepatic microsomes in vitro (Table 7.9). Incubation of 
14C-isosafrole with variously induced hepatic microsomes resulted in a large 
amount of covalent binding in phenobarbitone-induced microsomes and 
safrole-induced microsomes with the binding to 3-methylcholanthrene- 
induced microsomes being more similar to that obtained in the control 
microsomes. Covalent binding to control hepatocytes (Table 7.3) was 
greater in the cells produced by perfusion of the liver than in the cells 
isolated from liver slices (Table 7.2) but was still very close to the values 
obtained in vivo. The difference is only 3 to 4 fold and is probably due to 
the two different ages of rats used in the study since the rat used to prepare 
hepatocytes by the liver-slice method (Table 7.2) was only 60-80g body 
weight and probably did not have a fully developed monooxvgenase system 
when compared with the 200-240g rats routinely used for preparation of
hepatocytes by a perfusion method. Phenobarbitone-induced hepatocytes
14showed a large increase in the covalent binding of C-isosafroie-related 
material to all of the subcellular fractions especially the microsomal and 
cytosol in fractions. However, as in the microsomes, 3-methylcholan- 
threne-induction increased the covalent binding but to a lesser extent than 
phenobarbitone-induction whilst being greater than the value obtained for 
control hepatocytes. The one big difference between in vitro metabolism
of C-isosafrole in hepatocytes and in hepatic microsomes is the degree of 
covalent binding following induction by the MDP compounds. Safrole- 
induced microsomes showed a similar amount of covalent binding to that 
produced by phenobarbitone-induction, if not a greater amount (Table 7.9), 
however, the hepatocytes induced by isosafrole showed very little increase 
in covalent binding compared to control hepatocytes (Table 7.7).
The observation of only a small increase in covalent binding in 
isosafrole-induced hepatocytes was unexpected since induction of the 
hepatic - monooxygenase by isosafrole results in a large increase in the 
cytochrome P-450 concentration, although up to 40% of the cytochrome 
P-450 is complexed with an isosafrole-metabolite which is displaceable 
by certain Type I binding compounds (Chapter 3). In isosaf role-induced 
hepatocytes the isosafrole metabolite-cytochrome P-450 complex was 
observed as the reduced spectrum (Chapter 5), in contrast to the situation 
in microsomes where the complex is in the oxidized state. It is possible 
that the isosafrole metabolite complex never goes into the oxidized state 
in hepatocytes and would therefore remain undisplaced even by the subst­
rates which displace the metabolite from the oxidized complex in micro­
somes. This hypothesis could explain the observed discrepancy between 
the degree of in vitro covalent binding observed in isosafrole-induced 
hepatocytes and that observed in isosafrole-induced microsomes since 
the presence of a non-displaceable metabolite-cytochrome P-450 complex 
would decrease the amount of active cytochrome P-450 and hence the 
formation of reactive metabolites capable of covalent binding. Not 
only would the rate of metabolism be decreased by the presence of the 
inhibitory complex but possibly also the route of metabolism since in 
isosafrole-induced microsomes, displacement of the metabolite-complex 
results in a change in the ratio of 427/455 nm absorption maxima produced
by in vitro metabolism of isosafrole (Chapter 6) which could indicate 
a change in metabolic product. Once again results obtained in isolated 
hepatocytes indicate that the physiological significance of the displacement 
phenomenon in vivo may not be as great as might be expected from an 
extrapolation of the results obtained in microsomal suspensions.
The effects of enzyme induction on the covalent binding and 
hepatotoxicity of bromobenzene have been investigated by Zampaglione 
et al (1973) and Jollow et al (1974). These authors have demonstrated 
that differences in the covalent binding of bromobenzene following phenobar­
bitone- or 3-methylcholanthrene-induction are due to alteration of the 
primary metabolic route. Induction of the monooxygenase by phenobar­
bitone resulted in an increase in the formation of bromobenzene-3,4- 
epoxide, the chemically reactive metabolite responsible for the hepato­
toxicity, but induction by 3-methylcholanthrene increased the formation 
of bromobenzene-2,3-epoxide an unstable metabolite which decomposed 
to 2-bromophenol. Induction of the hepatic monooxygenase by phenobar­
bitone and 3-methylcholanthrene has already been shown to alter the 
metabolic pathways of isosafrole metabolism with respect to the formation 
of the isosafrole metabolite-cytochrome P-450 (Chapter 3). Administration 
of isosafrole after the prior induction of rats with phenobarbitone or 
3-methylcholanthrene resulted in a much larger proportion of the cyto­
chrome P-450 being reversibly bound to an isosafrole-metabolite following 
3-methylcholanthrene induction. Similarly, formation of the isosafrole 
metabolite-cytochrome P-450 complex in vitro in phenobarbitone induced 
microsomes resulted in the formation of dual absorption maxima at 427 nm 
and 455 nm whilst in 3-methylcholanthrene induced microsomes the 
complex was evident as essentially only a 455 nm maximum (Chapter 6).
Both of these observations could be due to alterations in the primary 
metabolic route of isosafrole by the two classical inducers.
Reactive metabolites formed during cytochrome P-450-dependent 
monooxygenation do not always cause hepatotoxic symptoms since there 
are several other enzymes present in the cell to "deactivate" these metabo­
lites. Epoxidation of a double bond in a substrate molecule often results 
in the formation of a chemically reactive metabolite, however the micro­
somal enzyme epoxide hydratase and soluble enzyme glutathione-S-epoxide 
transferase are present in the cell to "deactivate" the epoxides by hydration 
to the <A«ol or conjugation with glutathione respectively. Indeed, 
depletion of liver glutathione has been correlated with an increase in 
the hepatotoxic effects of several compounds in vivo (Gillette et al, 1974) 
and a ' comparable correlation has also been reported during paracetamol 
metabolism in vitro in isolated hepatocytes (Hbgberg and Kristoferson, 
1977). The cellular glutathione levels may be reduced by diethylmaleate- 
treatm ent since this compound is conjugated with glutathione by the enzyme 
glutathione-S-alkene transferase before excretion from the cell (Chasseaud, 
1974). Diethyimaleate has also been shown to deplete the glutathione 
levels of isolated hepatocytes by about a half within 30 minutes of the 
addition of 90 nmoles per 10^ cells, but within 60 minutes a linear increase
in the glutathione level was observed (Hbgberg and Kristoferson, 1978).
14The effect of diethyimaleate on the covalent binding of C-isosafrole 
to the cellular components of isolated hepatocytes was therefore studied 
in control and induced cells.
Isolated hepatocytes from control, phenobarbitone-induced, 
3-methylcholanthrene-induced and isosafrole-induced rats were treated
with diethyimaleate (90 nmoles/10 cells) for 30 minutes prior to the 
14addition of C-isosafrole and the results compared with those obtained
for untreated cells. In control hepatocytes the diethylmaleate treatment 
increased the amount of covalent binding to the nuclear, lysosomal and 
microsomal fractions with the greatest increase in binding observed in 
the nuclear fraction although this may be due to contamination of the 
fraction with whole cells. The covalent binding in the microsomal fraction 
was increased by about 30% which may reflect a decreased inactivation 
of the reactive metabolite resulting in an increased binding. In phenobar- 
bitone induced hepatocytes the diethylmaleate treatment reduced the 
amount of covalent binding in all of the fractions except the mitochondria 
despite the large amounts of covalent binding observed in all of the fractions. 
Similarly in 3-methylcholanthrene- and isosafrole-induced hepatocytes 
the diethylmaleate treatment decreased the amount of covalent binding 
except in the mitochondrial fractions and the cytosol of the 3-methylcholan- 
threne induced hepatocytes. The latter observation may perhaps indicate 
an increase in the formation of an epoxide in the 3-methylcholanthrene 
induced hepatocytes with a consequent increase in covalent binding to 
the cytosolic proteins in the cells with reduced glutathione contents, 
since glutathione conjugates themselves are water soluble and would 
have been extracted during the solvent extractions.
In general the lack of effect of diethylmaleate treatm ent on 
the covalent binding in the induced hepatocytes indicates that the reactive 
metabolite is probably not the epoxide. This is supported, in part, by 
the observation that safrole epoxide is very stable and can be isolated 
unchanged from the urine of animals dosed with the synthetic compound 
(Stillwell et al, 1974). The formation of reactive metabolites which 
bind to hepatic nucleic acids and proteins has been reported for
safrole (Wislocki et al, 1976; 1977). Metabolism of
safrole has been shown to result in the formation of several metabolites
which may be proximate and/or ultimate carcinogens including safrole- 
2’3'-epoxide and the sulphate ester of l ’-ketosafrole, l ’hydroxysafrole-
2'3’-epoxide and the sulphate ester of l ’-hydroxysafrole all of which are
(
electrophilic and react with guanosine (Wislocki et al, 1976). The metabo­
lite l'-hydroxysafrole has also been shown to be more carcinogenic than 
safrole itself (Borchert, 1973a, b). A similar metabolic route for isosafrole 
could also produce some of these reactive metabolites (Fig. 7.1). Epoxi- 
dation of the double bond would produce the l ’,2'-epoxide which could 
be hydrolysed non-enzymically to the 1’-hydroxy-derivative or to the 
clt ol by epoxide hydratase. Glutathione-S-epoxide transferase could 
form the glutathione conjugate from the epoxide and the UDP-glucuronyl 
transferases and sulphotransferases the respective glucuronide or sulphate 
conjugates of the hydroxy derivatives.
14In summary, the metabolism of C-isosafrole in isolated hepato­
cytes resulted in the formation of a reactive metabolite which bound 
to hepatic cellular proteins in an apparently covalent manner. The amount 
of covalent binding in isolated hepatocytes corresponded well with that 
previously reported in vivo and had a similar subcellular distribution. 
Covalent binding in induced hepatocytes was increased, with the highest 
degree of binding in phenobarbitone-induced hepatocytes and a much 
smaller amount bound in the 3-methylcholanthrene- and isosafrole-induced 
hepatocytes. Incubation of the hepatocytes under carbon monoxide resulted 
in only a small amount of covalent binding indicating that the binding 
measured in these studies was cytochrome P-450 mediated. Preincubation 
of the cells with diethylmaleate to deplete the cellular glutathione levels 
did not cause an increase in covalent binding in the induced hepatocytes 
but caused a small increase in control hepatocytes. This indicates that 
the reactive metabolite responsible for the covalent binding may be the
FIGURE 7.1
Postulated metabolic route for isosafrole
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epoxide or dependent upon the formation of the epoxide in the control 
cells but in induced cells another reactive metabolite may be responsible 
for the covalent binding due to alteration of the primary routes of metabo­
lism.
t
It should be noted however that the binding referred to in this 
chapter is essentially irreversible, unlike the reversible formation of 
the metabolite-cytochrome P-450 complex which is displaceable when 
in the oxidized state. Since metabolism of the methylene carbon is thought 
to be the mechanism of formation of this particular reactive metabolite 
it is probable that the metabolite responsible for the covalent binding 
is due to oxidation of the side chain.
Covalent binding of metabolites to cellular components represents 
a direct method by which hepatotoxic or carcinogenic effects can be 
mediated, however Wislocki et al (1977) have reported marked discrepancies 
between the degree of covalent binding and the number of tumours which 
develop. Similarly, in the experiments reported in this chapter, there 
is a high degree of covalent binding but. the significance of these findings 
must be interpreted with care since isosafrole is only a weak hepatocar- 
cinogen but comparable in hepatotoxicity to safrole. The covalent binding 
measured in these experiments represents the total binding to macromole­
cules and gives no indication of the extent of binding to the essential 
macromolecules such as DNA and RNA nor does it take account of the 
ability of the cell to synthesise replacements rapidly for damaged macro­
molecules and it is therefore hardly surprising that the correlation between 
covalent binding and hepatotoxicity is poor. An investigation of the exact 
nature of this binding and the extent to which it affects DNA and RNA 
might be useful in the evaluation of the physiological significance of 
this covalent binding data.
CHAPTER 3
FINAL DISCUSSION
The work presented in this thesis has demonstrated the formation of 
methylenedioxyphenyi metabolite-cytochrome P-450 complexes in vivo and 
in vitro and has attempted to investigate further the nature of the complex 
and the consequences of complex formation.
The MDP metabolite-cytochrome P-450 complexes exhibit absorp- 
tion maxima at 427 nm and 455 nm in the reduced (Fe ) state and at 438 nm 
in the oxidized (Fe ) state. The metabolite complex formed in vivo is 
stable enough to survive the preparation of hepatic microsomes and is 
present in the oxidized state in isolated microsomes. However, the addition 
of certain Type I binding substrates to microsomes containing the in vivo 
complex in the oxidized, but not reduced, state results in a time dependent 
decrease in the amount of complex and an increase in the cytochrome P-450 
concentration of the microsomes. The cytochrome P-450 released from the 
in vivo complex was shown to be metabolically competent (Chapter 3). The 
released haemoprotein exhibited substrate specificities which were similar 
to those generally associated with cytochrome P-448.
Administration of isosafrole to phenobarbitone- and 3-methylchoian- 
threne-induced rats resulted in the formation of a larger amount of the 
metabolite complex in the,3-methylcholanthrene-induced rats and therefore 
metabolism of the isosafrole by cytochrome P-448 may result in an 
increased metabolism to the reactive species responsible for the formation 
of the complex or a modified form of cytochrome P-450 may be involved in 
binding the reactive metabolite.
Displacement of the MDP metabolite complex was only observed in 
microsomes containing the in vivo generated complex which was slow to 
form in vivo, taking 8-12 hrs to appear which is compatible with the 
hypothesis that the displacement process is a property of a novel haemo-
protein induced by isosafrole in the rat as demonstrated by Dickins et al
(1978). Isosafrole and the insecticide synergist piperonyl but oxide were 
both found to cause induction of hepatic monooxygenase activity in two 
different strains of mouse (Chapter 4). The two strains of mouse were 
chosen to test the hypothesis that the isosafrole-induced haemoprotein may 
be identical to the haemoprotein induced by 3-methylcholanthrene since the 
induced monooxygenase activities were similar in the Tat. The strains of 
mouse chosen were the C57BL/10 strain and DBA/2 strain which are 
considered to be responsive and non-responsive, respectively, to the poly- 
cyclic aromatic hydrocarbon inducers such as 3-methylcholanthrene. This 
genetic difference is probably due to the presence of an aberrant receptor 
protein in the DBA/2 strain which results in a lack of induction by polycyclic 
aromatic hydrocarbons. Phenobarbitone, pregnenolone-16a-carbonitrile, 
isosafrole and piperonyl butoxide all induced the hepatic monooxygenase 
activities in both C57BL/10 and DBA/2 mice whilst 3-methylcholanthrene 
only induced them in the C57BL/10 mice. The pattern of monooxygenase 
activities induced by the MDP-compounds was similar to both the phenobar­
bitone- and 3-methylcholanthrene-induced patterns but following displace­
ment of the in vivo generated MDP-metabolite complex the monooxygenase 
activities were more similar to those induced by 3-methylcholanthrene. 
Comparison of the electrophoretic pattern of -ihe induced haemoproteins 
was carried out using SDS-polyacrylamide gel electrophoresis and demon­
strated that although one of the minor bands induced by isosafrole and 
piperonyl butoxide corresponded to a band induced by 3-methylcholanthrene, 
the major bands were of different molecular weights to those induced by 
this compound. Any similarity in the electrophoretic pattern of the 
microsomes induced by the MDP compounds to that of a classical inducer 
was with phenobarbitone-induced microsomes and yet the monooxygenase
activities showed similarities to those of 3-methylcholanthrene induced 
microsomes therefore the haemoprotein(s) induced in mice by the MDP 
compounds is probably different from those induced by the classical 
inducers. Certainly the induction of an haemoprotein by the MDP 
compounds in the DBA/2 mice implies that either it is different from that 
induced by 3-methylcholanthrene or that there is a receptor protein present 
in the hepatic cytosol which although unable to bind 3-methylcholanthrene is 
still reactive towards the MDP compounds. It is also possible that more 
than one receptor protein is involved in the induction of any one specific 
haemoprotein and that although the receptor for 3-methylcholanthrene is 
absent, a receptor is still present to bind the MDP compounds.
Investigations of the spectral interactions of various substrates with 
cytochrome P-450 in isolated rat hepatocytes demonstrated Type land Type II 
binding spectra but failed to demonstrate Type RI spectra (Chapter 5). 
The binding spectra were stable enough to permit calculation of the Kg 
values in the isolated hepatocytes and these were found to correspond quite 
well to those obtained in hepatic microsomes. Methylenedioxyphenyl 
compounds bound to the cytochrome P-450 in isolated hepatocytes to give 
Type I binding spectra which rapidly gave way to the appearance of 
absorption maxima at 427 nm with time. A small peak was apparent a t 460 nm 
but this did not produce any recognisable 455 nm peak characteristic of 
the metabolite complex, a situation similar to that found in vivo since the 
metabolite complex measured by the appearance of the 427/455 nm complex
was not observed until 8-12 hrs after a single dose of isosafrole (Chapter 3).
14The apparently irreversible binding of [to - C]isosafrole-related 
material to the proteins throughout the cell was demonstrated following 
incubation of isolated hepatocytes with the radiolabelied substrate (Chapter 7).
The degree of binding was more similar to that observed in vivo by 
Elcombe (1976) rather than that demonstrated by Dickins (1978) in vitro 
with hepatic microsomes. This is probably due to the protective effect of 
the active conjugative pathways which are present in the isolated hepato­
cytes and deactivate the reactive metabolites produced by the monooxy­
genase before there is considerable binding. Covalent binding was also 
measured in phenobarbitone-, 3-methylcholanthrene- and isosafrole-induced 
hepatocytes and found to be increased in all cases. However, the extent to 
which the covalent binding increased following isosafrole induction was less 
than expected perhaps indicating the presence of an isosafrole metabolite- 
cytochrome P-450 complex in the hepatocytes which did not displace during 
the incubation and therefore prevented metabolism of the isosafrole sub­
strate.
Investigation of the in vitro formation of the isosafrole metabolite- 
cytochrome P-450 spectrum showed the 427/455 nm ratio to be pH dependent 
(Chapter 6) and to be dependent upon the state of induction of the 
haemoprotein. The two peaks of the reduced spectrum were separated by 
Protease VII treatment of the microsomes from safrole-induced rats which 
may indicate that the in vivo complex is the result of two separate 
cytochrome P-450 pools one located on the surface of the microsomal 
membrane and the other located within the membrane.
The significance of the results presented in this thesis in relation­
ship to the hepatotoxic effects of the MDP compounds is difficult to assess 
but the individual results should fit in with an hypothesis of the effects of 
methylenedioxyphenyl compounds on the metabolic activity of the hepatic 
monooxygenase system. The basic problem is in the extrapolation of in 
vitro results to the in vivo situation but the isolated hepatocyte system may 
be helpful in bridging this gap as explained in the following hypothesis.
On entering the liver MDP compounds are very rapidly taken up by 
the hepatocytes and bind to cytochrome P-450, since they elicit Type I 
binding spectra almost immediately when added to isolated hepatocytes 
(Chapter 5). The binding to cytochrome P-450 results in metabolism since 
the initial Type I spectrum gives way to an absorption maximum at 427 nm 
and possibly a t 460 nm (Chapter 5). The general lack of a 455 nm maximum 
could be due to a low intracellular pH (6.5-7.0) which would encourage the 
formation of the 427 nm species at the expense of the 455 nm species 
(Chapter 6). It could also be due to the activity of enzymes such as the 
glutathione-S-epoxide transferases or epoxide hydratases which could be 
responsible for inactivating the reactive metabolites before they were able 
to bind to the haemoprotein. The lack of 455 nm formation in vitro in 
hepatocytes is in agreement with the lack of a 455 nm species in the 
microsomes isolated from rats treated with isosafrole at times up to about 
8-12 hrs post dose (Chapter 3). The appearance of a 455 nm maximum was 
assumed to be the point at which the MDP-metaboiite complex was first 
formed, an assumption which may be false since the presence of a 427 nm 
maximum was indicated in the "off-balance" spectrum of isosafrole-micro- 
somes (isolated at 2 hrs and 4 hrs post dose) versus control microsomes but 
this was considered to be interference from cytochrome b^ (Chapter 3). The 
formation of the 427 nm species in isolated hepatocytes was accompanied by 
an apparent decrease in the amount of cytochrome P-450 within the cell 
(Chapter 5) which possibly indicates a decrease in carbon monoxide binding 
due to the presence of a MDP metabolite-cytochrome P-450 complex or 
destruction of a portion of the cytochrome P-450. The metabolite may 
cause destruction of cytochrome P-450 in vitro since atypical spectra were 
observed during the metabolism of methyienedioxynaphthalene (Chapter 6) 
and several other MDP compounds (Dickins, 1978; Mayer and Burke, 1976) by
hepatic microsomes, which may be attributed to the production of carbon 
monoxide during haem catabolism. Safrole and isosafrole have been 
demonstrated to cause the destruction of about 596 of the haem in a 
phenobarbitone-induced rat liver 11,000 g supernatant fortified with 
NADPH (Dickins, 1978), although under similar conditions the porphyrogenic 
agent 2-allyl-2-isopropylacetamide (AIA) caused the destruction of about 
30% of the haem (De Matteis, 1970) due to the formation of a covalent 
haem-AIA adduct (Oritz de Montellano et al, 1978). However, neither 
safrole nor isosafrole appear to have any effect on the activity of 6 -amino 
laevulinic acid (ALA) synthetase (Ioannides and Parke, 1976), the enzyme 
which is induced following destruction of the phenobarbitone-induced haem 
by AIA or allyl-substituted barbiturates. The formation of a metabolite 
complex which causes irreversible inhibition of the haemoprotein may 
possibly account for the fact that the in vitro generated MDP metabolite 
complex does not dissociate in the presence of a displacing substrate 
(Elcombe, 1976; Dickins, 1978). In fact, the displacement of the in vitro 
generated complex reported by Elcombe et al (1975a), using phenobarbitone- 
induced microsomes, may represent destruction of damaged cytochrome 
P-450 to yield carbon monoxide which subsequently bound to the undamaged 
cytochrome P-450 and gave the characteristic 450 nm peak in the reduced 
minus oxidized spectrum instead of the metabolite complex. Following 
irreversible inhibition of a portion of the cytochrome P-450 either the build 
up of endogenous substrates or the products of haem catabolism may initiate 
the process of enzyme induction (Granick, 1966), which results in the 
formation of an haemoprotein which more readily binds the MDP 
compounds. The increased binding of the MDP compounds results in the 
generation of a greater proportion of the metabolite complex with a large 
increase in the rate of formation of the 455 nm species which may be
formed by an haemoprotein which is buried deeper within the microsomal 
membrane (Chapter 6) and which may produce a different metabolite 
pattern. Enzyme induction results in the formation of a MDP metabolite- 
cytochrome P-450 complex which is readily dissociated in vitro in the 
oxidized state by certain Type I binding compounds and the released 
haemoprotein is metabolically competent (Chapter 3). The haemoprotein is 
induced by a mechanism different from that of 3-methylcholanthrene 
induction (Chapter 4) but has broadly similar monooxygenase activities to 
those of the 3-methylcholanthrene-induced haemoprotein. However, in 
isolated hepatocytes prepared from isosafrole-induced rats, the presence of 
the in vivo generated metabolite complex is observed as the 427 nm and 
455 nm absorption maxima of the reduced spectrum (Chapter 5) and 
therefore the complex may not be displaceable in vivo since it may not be 
converted to the oxidized, displaceable, complex. Further evidence for this 
effect was possibly demonstrated in the study of the covalent binding of 
[a)-^-C]-isosafrole-related material to the subcellular fractions of isolated 
hepatocytes incubated in vitro with this substrate. Although there is no 
evidence that formation of the metabolite complex and covalent binding are 
related, the degree of covalent binding was increased in hepatocytes 
prepared from rats previously induced with phenobarbitone, 3-methylcholan­
threne and isosafrole (Chapter 7), but in the latter case the binding was less
than expected from similar studies in microsomes (Dickins, 1978). This may
14perhaps reflect the inability of the C-isosafrole substrate to displace the 
in vivo generated isosafrole metabolite-cytochrome P-450 complex in the 
intact cell, which resulted in a decreased formation of the reactive species 
responsible for the covalent binding compared with the in vitro situation 
where the metabolite complex rapidly dissociates (Chapter 3). Although 
endogenous steroids have been shown to be good displacers of the MDP
metabolite-cytochrome P-450 complex (Dickins, 1978) the physiological 
significance of the displacement phenomenon is questionable in the light of 
the results in isolated hepatocytes.
The relationship of covalent binding observed in isolated hepato­
cytes (Chapter 7) to the hepatotoxicity of isosafrole is difficult to assess 
since the nature of the macromolecules involved in the binding, with regard 
to their involvement in essential metabolic processes, was not determined. 
Many other factors also require consideration, such as the turnover of these 
macromolecules and the activity of any repair processes which could 
decrease the consequences of the covalent binding of xenobiotics to 
essential macromolecules like DNA and RNA. Clearly, the damage caused 
by the covalent binding of isosafrole-related material to the cell nucleus is 
not irreparable since this compound is only a weak hepatocarcinogen. 
However, in the shorter term isosafrole produces hepatotoxic effects, 
possibly an isosafrole-induced necrosis of a proportion of the hepatocytes 
and the consequent regeneration of the liver to produce the regenerative 
nodules observed in the toxicity studies (Hagan et al, 1965; Taylor et al, 
1964). It is possible that the necrosis is a direct result of the effects of 
isosafrole in the mitochondria, since in vitro isosafrole uncouples oxidative 
phosphorylation in isolated mitochondria (Nelson et al, 1971), although the 
covalent binding of isosafrole-related material throughout the cell may be 
responsible for a general disruptive effect on the metabolic pathways by 
inactivation of essential enzymes. At the same time, induction of the 
hepatic monooxygenase results in the production of an haemoprotein with a 
greater affinity for the isosafrole and probably results in the formation of 
metabolites which are less toxic to the cell.
Enzyme-induction by isosafrole is not restricted to the hepatic 
monooxygenase since Lake et al (1973) have demonstrated induction in’ 
extra-hepatic tissues. This represents an area where further research is 
required since induction of the monooxygenase in extra-hepatic tissues is 
also observed with the polycyclic aromatic hydrocarbons such as 3-methyl­
cholanthrene but not with phenobarbitone, another similarity between 
isosafrole and potent carcinogens. There are several other areas where 
further studies are necessary and which should give more insight into the 
action of the MDP compounds on the hepatic monooxygenase system. 
Isolation of the isosafrole-induced haemoprotein in the purified form would 
give information as to the metabolic capabilities, substrate specificities and 
nature of the haemoprotein compared with those induced by phenobarbitone 
and 3-methylcholanthrene. The formation of the metabolite complex, its 
nature and stability would be more easily studied with the purified haemo­
protein and also the in vivo significance of the metabolite complex 
formation since the specificity of this haemoprotein for various endogenous 
substrates could be determined. Further work on the metabolic profile of 
the haemoprotein could identify the nature of the metabolite which is
displaced from the metabolite complex. This might be accomplished by the
3
use of very high specific activity H-labelled isosafrole and the identifi­
cation of the metabolite by radio-gas chromatography and mass spectro­
metry since only very small amounts of complex are formed thereby 
requiring an isolation and identification system capable of dealing with 
small quantities of unknown material. It would also be of interest to study 
the short term effect of the MDP compounds on the histology of the liver at 
times up to about 24 hrs to see if the initial result of the covalent binding to 
cellular macromolecules has any dramatic effect such as necrosis of any 
particular area of the liver. Identification of the nature of the covalently
bound metabolites might also give some indication as to why the degree of 
covalent binding is so high for safrole and isosafrole which are only weak 
hepatocarcinogens.
Finally, few investigators have considered the existence of two 
isomers of isosafrole and it would be interesting to separate the cis and 
trans stereo-isomers in order to compare their properties with respect to 
toxicology, metabolism and formation of the metabolite-cytochrome P-450 
complexes. These two isomers, which occur naturally in the ratio of 
approximately 4% cis:96% trans, may differ in both steric and £i-acceptor 
properties since the w-methyl group of the trans isomer is co-planar with 
the, aromatic ring whilst in the cis isomer it is situated above the plane of 
the ring due to steric hindrance. These differences in sterp-chemistry may 
possibly alter the rate and extent of metabolism and hence formation of the 
metabolite-cytochrome P-450 complex or covalent binding. Since isosa­
frole is only a weak hepatocarcinogen it is of interest to speculate that 
although only a small proportion of the covalent binding observed with 
isosafrole is derived from the cis isomer, it may be this isomer which is 
responsible for the carcinogenic potential of isosafrole.
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